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Chapter 1
Introduction
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Stem Cells- Application for 
Solid Organ Transplantation
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Current opinion in organ transplantation. 2012 Feb;17(1):55-62.

General introduction and outline 11
Body homeostasis is maintained by vital organs such as the heart, lungs, kidney and liver. Or-
gan failure due to injury or disease will ultimately result in a life threatening situation. Heart 
and lung function can be supported and even temporarily replaced by artificial heart and 
or lung machines. In case of failure of the kidneys, kidney function can partially be replaced 
by renal replacement therapy in the form of dialysis. In case of failure of many other organs, 
no replacement therapy is available. The only curative treatment of end stage organ failure 
is solid organ transplantation (SOT). An organ can either be transplanted from a deceased 
(post mortal) donor or, in case of living kidney or liver transplantation, from a living donor. 
If an organ is transplanted from an identical twin, the organ will not be recognized by the 
recipient’s immune system and will thus be accepted. In any other situation, the transplanted 
organ (allograft) will be recognized as foreign and will induce alloreactivity resulting in rejec-
tion of the organ. Therefore, to maintain their allograft, transplant recipients will in general 
depend on lifelong use of immunosuppressive medication. Improvements in the immuno-
suppressive regimen in the last decades have resulted in significant improvements of the 
short term outcome after transplantation while progress in the long term outcome lagged 
behind. Nevertheless, immunosuppressive drugs have several unwanted side effects such 
as the development of diabetes, hypertension, malignancies and nephrotoxicity. In order to 
optimize long term transplantation outcome, there is a need for new treatment regimens in 
the field of SOT.
A new therapeutic approach in the field of SOT could be provided by cell therapy. Cell 
therapy involves administration of a distinct population of cells with a therapeutic potential. 
Mesenchymal Stem or Stromal Cells (MSC) are one of the cell therapeutic options in SOT 
that have arisen in the last decades. These multipotent adult stem cells can be isolated from 
various types of tissues such as bone marrow, adipose tissue and multiple others. In absence 
of a specific marker, MSC are defined according to the criteria set by the International Society 
for Cell Therapy (ISCT) [1]. These criteria describe MSC as adherent cells with a CD73+, CD90+, 
CD105+, HLA-I+, CD14-, CD34-, CD45- and HLA-DR- immunophenotype and the capacity to 
differentiate into osteoblasts, adipocytes and chondrocytes. Interestingly, MSC have immu-
nomodulatory and regenerative capacities.
MSC are capable of inhibiting activated T cell proliferation in vitro[2, 3] and can induce regu-
latory T cells [4] . They decrease the T cell stimulatory capacity of dendritic cells [5] and are 
reported to differentiate macrophages into a more regulatory phenotype and function [6]. 
Although it was previously assumed that MSC act by differentiating into functional cells [7], 
evidence suggests that MSC are more likely to act in a paracrine manner [8] by which they 
target resident cells (figure 1). MSC secrete a range of anti-inflammatory factors, including 
IL-10, TGF-β, hepatocyte growth factor (HGF), nitric oxide (NO), HLA-G, and PGE2, that are all 
indicated to play some role in their immunomodulatory effect [9-11]. In particular the expres-
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sion of IDO by MSC is important for their inhibitory effect on T lymphocyte proliferation. In 
addition to their anti-inflammatory effects, paracrine mechanisms may mediate a beneficial 
effect of MSC on organ function in SOT by inhibition of fibrosis. HGF secreted by MSC may 
be one of the factors involved[11]. MSC may also exhibit a regenerative function via direct 
targeting of resident progenitor cells via the secretion of bFGF, BMP-7 and VEGF [11, 12].
As a result of their immunomodulatory and reparative properties, MSC have been used as 
an experimental cell therapeutic agent in immunological diseases such as Graft Versus Host 
Disease (GVHD) [13] and Crohn’s disease[14]. Their properties make MSC also appealing as a 
cell therapeutic agent in the field of SOT (figure 2). The potential of MSC to prolong allograft 
survival has been investigated in a number of transplant models. These studies demonstrated 
that skin and heart transplant survival can be prolonged by intravenous infusion of MSC [2, 
15, 16]. Administration of MSC resulted in allograft tolerance as a result of regulatory T cell 
generation in a mouse kidney transplant model [9]. In a rat kidney transplant model, it was 
shown that MSC reduce the inflammatory infiltrate, suggesting that MSC could be used to 
treat cellular rejection [17, 18]. Together, these data support clinical potential of MSC in SOT.
Figure 1. Proposed functionality of MSC. Immune activation as a result of ischemia-reperfusion-injury 
or alloreactivity results in an inflammatory environment characterized by elevated levels of the pro-
inflammatory cytokines IL-2, IFNγ and TNFα produced by immune cells such as T cells and macrophages, 
causing tissue damage and transplant rejection. As a consequence of the inflammatory environment, 
MSC will be activated. Upon activation, MSC express a variety of factors such as IDO and PD-L1 which can 
inhibit the immune response. Finally, when the immune response is dampened, growth factors secreted 
by MSC such as HGF, PDGF and VEGF support regeneration, until quiescence is re-achieved. 
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In order to develop MSC into effective therapy in SOT, several issues need to be addressed 
involving the culture expansion process, source and origin of MSC preparation, timing, ef-
ficacy and safety of MSC therapy.
 
When applying MSC therapy, choices should be made considering MSC preparation. As 
mentioned before, MSC can be isolated from numerous, if not all, different tissues of which 
bone marrow is the most commonly used, especially in clinical studies. Adipose tissue is 
gaining interest as an alternative as it has several benefits above bone marrow. For instance, 
adipose tissue has a higher yield of MSC and is obtainable in a less invasive manner com-
pared to bone marrow[19]. Yet, functional studies are required to reveal the properties of 
bone marrow derived MSC (BM-MSC) and adipose tissue derived MSC (ASC) in the field of 
transplantation.
Before clinical application, MSC are typically culture expanded. During this expansion, MSC 
could be at risk for genetic alterations. The fear for such alterations was fed by papers report-
Figure 2. Challenges in SOT and possible applicability of MSC. The immunomodulatory and regenerative 
capacities of MSC are suggested to ameliorate transplantation related ischemia reperfusion injury, 
prevent or treat rejection and target allograft pathology by immunomodulation and decreasing the need 
for immunosuppressive medication.
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ing spontaneous malignant transformation of human MSC in culture [20, 21]. However, these 
papers were retracted because of evidence of contamination of the MSC culture by tumor 
cell lines [22-24]. Nevertheless, it is evident that genetic stability deserves proper attention, 
that senescence of MSC cultures should be avoided and that more comprehensive stability 
testing than karyotyping might be necessary [25]. It has been reported that aneuploidy can 
occur in culture expanded MSC[26]. The implication of aneuploidy in MSC is currently not 
clear. 
Besides a potential risk of culture expansion, the culturing period might also provide a win-
dow of opportunity to optimize the MSC product.  Patient derived MSC might recover during 
this period before they are administered back into the patients and pre-treatment of MSC in 
culture with inflammatory cytokines such as IFNg might increase their immunosuppressive 
potential[27]. Hypoxic culture conditions are suggested to increase MSC proliferation rate 
which might result in a shorter laboratory-to-bedside period. However, although low-oxygen 
conditions are probably more physiological for MSC, whether hypoxia maintain the immuno-
suppressive property of MSC remains to be determined.  
Next, for clinical application, MSC can of autologous or allogeneic origin. Allogeneic MSC 
might be most convenient as they can be isolated from healthy individuals, culture ex-
panded, tested and cryopreserved prior to using them as a readily available cell product. 
The choice for allogeneic MSC therapy is supported by the paradigm that states that MSC 
are low immunogenic as they do not evoke immune cell responses [2, 28]. However, there is 
now accumulating evidence that MSC are recognized by the adaptive immune system [29-
31]. Therefore, repeated allogeneic MSC therapy could potentially lead to reduced efficacy 
due to rapid clearance of MSC [32], or potentially, anti-HLA sensitization. Autologous MSC 
therapy on the other hand does not harbour any risk for sensitization but does require time 
to culture-expand the cells prior to usage, which makes autologous MSC therapy unsuit-
able for acute indications. In order to choose between the more convenient and potentially 
commercially interesting allogeneic MSC and non-immunogenic autologous MSC, more 
knowledge is desired on the potential of MSC to induce an anti-HLA response.
While autologous MSC therapy is possible desirable in order to prevent immunization, it 
might not be feasible as it implies using MSC derived from patients. In kidney transplanta-
tion, patients have renal or even end stage renal disease. End stage renal disease is charac-
terized by retention of uremic toxins,  an increase in oxidative stress and an inflammatory 
environment which affects the function of immune cells[33]. MSC might as well be affected 
by uremic conditions. Patient derived MSC have shown to be unaffected by Crohn’s disease 
and multiple sclerosis [14, 34] but were functionally affected by systemic lupus erythemato-
sus and immune thrombocytopenic purpura [35, 36]. To assess feasibility of autologous MSC 
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treatment in kidney transplant recipients, the effects of renal disease on the proliferation 
capacity and immunosuppressive function of MSC needs to be evaluated.
Taken together, the properties of MSC and the safety and preliminary efficacy data from clini-
cal trials have initiated interest in MSC therapy in the field of SOT. In SOT, and more particu-
larly in kidney transplantation, MSC could potentially be used to treat transplantation related 
ischemia reperfusion injury, acute rejection and perhaps most of all, long term allograft 
pathology (figure 2). Nevertheless, while current data underline the potential of MSC therapy 
in SOT, at the same time, it stresses the lack of understanding of the biological mechanisms 
that are initiated after administration of MSC. Therefore, aspects such as MSC efficacy, culture 
expansion, immunogenicity and source and origin of MSC need to be elucidated.
OUTLINE OF THE THESIS
MSC have immunomodulatory and regenerative properties which make them attractive as 
a cell therapeutic agent in the field of solid organ transplantation (chapter 1). To study the 
potential of bone marrow (BM-MSC) and adipose tissue derived MSC (ASC) in the field of 
transplantation, the inhibitory effect of BM-MSC and ASC in vitro was evaluated and their po-
tential to inhibit alloreactivity in a humanized skin transplant model was studied (chapter 2). 
Before applying MSC in a clinical setting, MSC are typically culture expanded. During culture 
expansion, MSC may acquire genetic alterations. The occurrence and relevance of aneuploidy 
in culture expanded ASC was investigated (chapter 3). Next, as hypoxic conditions might be 
more physiological and potentially result in a higher yield of MSC, the effect of hypoxia on 
the immune modulatory capacities of ASC was evaluated (chapter 4). For clinical purposes, 
the use of allogeneic MSC is the most convenient. However, allogeneic MSC may induce al-
loreactivity.  As this is unwanted in the field of transplantation, the current thesis describes 
the potential of allogeneic BM-MSC and ASC to induce anti-HLA immune responses (chapter 
5).  While allogeneic MSC therapy might provide an immunological risk, it is questionable 
whether autologous MSC therapy in kidney transplantation is feasible as it involves the use 
of cells from patients with (end stage) renal disease that may not show the same functionality 
as cells from healthy individuals. As renal disease can affect several other cells, the current 
thesis describes the effect of renal disease on ASC (chapter 6) and BM-MSC (chapter 7) 
and thus whether autologous MSC therapy is feasible in kidney transplant recipients. Then, 
after studying the efficacy, source, origin, culture expansion and immunogenicity of MSC, 
the mechanism of action of MSC in vivo was investigated. The immunological effect of MSC 
infusion in mice was assessed in search for clues on the optimal timing and mechanism of 
MSC therapy (chapter 8). Finally, we summarized and discussed our results in chapter 9 and 
described future perspectives.
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ABSTRACT
Background
Recent studies with bone marrow (BM)-derived Mesenchymal Stromal Cells (MSC) in trans-
plant recipients demonstrate that treatment with MSC is safe and clinically feasible. While 
BM is currently the preferred source of MSC, adipose tissue is emerging as an alternative. To 
develop efficient therapies, there is a need for preclinical efficacy studies in transplantation. 
We used a unique humanized transplantation model to study the in vivo immunosuppressive 
effect of human BM-MSC and adipose tissue-derived MSC (ASC).
Methods
Gene expression of BM-MSC and ASC and their capacity to inhibit activated PBMC prolifera-
tion was evaluated. The in vivo immunosuppressive effect of BM-MSC and ASC was studied 
in a humanized mouse model. SCID mice were transplanted with human skin grafts and 
injected with human allogeneic PBMC with or without administration of BM-MSC or ASC. The 
effect of MSC on skin graft rejection was studied by immunohistochemistry and PCR.
Results
BM-MSC and ASC expressed TGFβ, CXCL-10 and IDO.  IDO expression and acitivity increased 
significantly in BM-MSC and ASC upon IFN-γ stimulation. IFN-γ stimulated BM-MSC and ASC 
inhibited the proliferation of activated PBMC in a significant and dose dependent manner. 
In our humanized mouse model, alloreactivity was marked by pronounced CD45+ T-cell 
infiltrates consisting of CD4+ and CD8+ T cells and increased IFN-γ expression in the skin 
grafts which were all significantly inhibited by both BM-MSC and ASC. 
Conclusion
BM-MSC and ASC are immunosuppressive in vitro and suppress alloreactivity in a preclinical 
humanized transplantation model.
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INTRODUCTION
In the last decades, the interest in Mesenchymal Stromal Cells (MSC) as a cell therapeutic 
agent has grown substantially[1-5]. These fibroblast-like, plastic adherent cells have multipo-
tent differentiation capacity and while they were originally isolated from bone marrow (BM), 
they can be isolated from virtually all tissues, including adipose tissue[6-10]. In absence of 
a specific marker, MSC are commonly defined by a panel of cell surface markers; including 
CD73, CD90, CD105 and CD166; and their multilineage differentiation capacity[11].
MSC are immunosuppressive cells as indicated by their capacity to inhibit activated T cell 
proliferation in vitro[12, 13]. This immunosuppressive potential is enhanced under inflamma-
tory conditions in which IFNγ plays an important role[14, 15]. In animal studies, the potential 
of MSC  has been confirmed  in multiple disease models for conditions including Graft versus 
Host Disease (GvHD)[16, 17];  ischemia-reperfusion-induced renal injury[18, 19]; and liver 
failure[20, 21]. Subsequently,  several clinical studies have been conducted evaluating  MSC 
therapy in amongst others GvHD[22]; end stage liver disease[23] and Crohn’s disease[24]. 
In the field of transplantation, MSC are of great interest due to their potential to inhibit 
the alloimmune response as well as to contribute to tissue repair. Animal transplant stud-
ies  showed that MSC are capable to inhibit acute rejection and or to prolong allograft 
survival[25-28]. As a result, MSC have been applied in kidney transplant recipients[29-31] 
and a study with MSC in liver transplantation has been initiated[32]. Recent studies, including 
ours, showed the safety and feasibility of autologous MSC treatment in kidney transplant re-
cipients when using bone marrow derived MSC (BM-MSC) in renal transplant recipients with 
subclinical rejection or as induction therapy [29-31, 33]. While these studies are indicative 
of an immunomodulatory effect of MSC in human, efficacy of MSC therapy in clinical trans-
plantation remains to be determined. Currently, BM is the most commonly used source of 
MSC. However, BM aspiration is an invasive procedure accompanied with donor morbidity. In 
contrast, adipose tissue can be obtained in a minimal invasive way via lipectomy or liposuc-
tion and is therefore emerging as an alternative[34]. Bone marrow has a lower yield of MSC 
compared to adipose tissue, and adipose tissue derived MSC (ASC) have a higher proliferation 
capacity than BM-MSC[35-37]. Considering their basic features, BM-MSC and ASC show many 
resemblances. Both BM-MSC and ASC express the classical MSC markers CD73, CD90, CD105 
and CD166[36, 37] although some differences in immunophenotype between BM-MSC and 
ASC have been reported[34, 38, 39]. BM-MSC and ASC both display the spindle shape MSC 
morphology and they are both capable of multilineage differentiation. Immunosuppressive 
capacities in vitro have been acknowledged for BM-MSC[12, 40, 41] and ASC[6, 42-44]. In 
animals transplant models, both BM-MSC[12, 25-27, 45, 46] and ASC[28] have shown to be 
beneficial in inhibiting acute rejection and or increasing allograft survival. The efficacy of 
BM-MSC and ASC in humanized transplant models has however never been investigated. In 
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the present study we focus on the immunomodulatory effects of BM-MSC and ASC in vitro 
and in a humanized skin allograft rejection model.
MATERIALS AND METHODS
Bone marrow and adipose tissue donors
MSC were isolated from either BM or adipose tissue from healthy controls. BM was obtained 
from 5 hematopoietic stem cell donors after written informed consent as approved by the 
Medical Ethical Committee of Leiden University Medical Centre as described before[47]. 
Adipose tissue was obtained from 9 live kidney donors after written informed consent as 
approved by the Medical Ethical Committee of the Erasmus MC (protocol no. MEC-2006- 190). 
BM-MSC isolation and culture
BM was aspirated under general anesthesia. The mononucleated cell (MNC) fraction was 
isolated by Ficoll density gradient separation and plated in tissue culture flasks at a density 
of 160 x 103 MNC/cm2 in low-glucose Dulbecco’s modified Eagle medium DMEM (Invitrogen, 
Paisley, UK) supplemented with penicillin/streptomycin (Lonza, Verviers, Belgium) and 10% 
fetal calf serum (FCS, Thermo Scientific HyClone)). The cultures were maintained at 370C, 5% 
CO2. The medium was refreshed twice a week. When the MSC cultures became confluent, 
cells were collected using trypsin (Lonza) and re-plated at a density of 4 x 103 cells/ cm2 or 
frozen until further usage.  
ASC isolation and culture
Abdominal subcutaneous adipose tissue was surgically removed under general anaesthesia 
during donor nephrectomy.  Adipose tissue was mechanically disrupted and enzymatically 
digested with sterile 0.5mg/ml collagenase type IV (Sigma-Aldrich, St Louis, MO) in RPMI-
1640 þ glutaMAX (Invitrogen) and p/s for 30min at 37 1C. Cell pellets were resuspended 
in MSC culture medium, consisting of MEM-α (Sigma-Aldrich(St. Louis, MO, USA) with 1% 
p/s and 15% fetal bovine serum (BioWhittaker, Verviers, Belgium), transferred to a 175- cm2 
culture flask (Greiner Bio-one, Essen, Germany) and kept at 370C and 5% CO2. Medium was 
refreshed twice a week. When ASC cultures became 90% confluent, cells were detached using 
0.05% trypsin–EDTA and frozen until further usage. 
For experiments, only passage 1-5 BM-MSC and ASC were used. Prior to usage for experi-
ments BM-MSC and ASC were cultured in parallel under the same culture conditions.
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Isolation of peripheral blood mononuclear cells (PBMCs)
PBMCs were collected from buffy coats of healthy blood bank donors (different than the 
MSC donors). PBMCs were isolated by density gradient centrifugation using Ficoll Isopaque 
(Pharmacia Amersham, Uppsala, Sweden) and used directly or frozen at -135˚C until use.
Real-time RT-PCR 
For evaluation of mRNA gene-expression by BM-MSC and ASC, 100,000 MSC were seeded per 
well in a 6 well plate in either normal MSC culture medium or MSC culture medium supple-
mented with 100ng/ml IFNγ. After 24 hours, MSC cell pellets were harvested. 
RNA was isolated and cDNA synthesized as described previously[48]. Quantitative expres-
sion was determined by real-time RT-PCR using universal PCR mix (Invitrogen) and Assays- 
on-demand for IDO (Hs00158627.m1), TGF-β (Hs00171257.m1) and CXCL-10 ( Hs 00171042.
m1) on an StepOnePlus real time PCR system (Applied Biosystems). Gene-expression was 
depicted as ratio with GAPDH.
IDO activity measurements
BM-MSC and ASC were cultured in standard MSC culture medium or culture medium supple-
mented with 100ng/ml IFNγ. After 1 week, medium was removed and BM-MSC and ASC 
were washed twice with 1X PBS. Next, BM-MSC and ASC were cultured for 24 hours in serum 
free MEM-α (+ 1% p/s) before medium was harvested. The tryptophan metabolic activity of 
IDO was determined by measurement of L-kynurenine in the conditioned medium of four 
unstimulated and four stimulated BM-MSC and ASC cultures. 30% trichloroacetic acid was 
added to the samples at a 1:3 ratio and after 30min incubation at 50°C the samples were 
centrifuged at 12,000 rpm for 5min. Supernatants were then diluted 1:1 in Ehrlich reagent 
(200mg 4-dimethylaminobenzaldehyde (Sigma, St. Louis, MO, USA) in 10ml of glacial acetic 
acid) in duplicate in a 96-wells flat bottom plate and absorbance was determined at 490nm 
using a multilabel plate reader (VersaMaxTM, Molecular Devices, Sunnyvale, CA, USA). L-kyn-
urenine (Sigma, St. Louis, MO, USA) diluted in unconditioned medium was used as standard.
   
Anti-CD3/CD28 lymphocyte stimulation assay 
MSC were seeded in round bottom 96-wells plates in MEMα with 10% heat inactivated hu-
man serum at 0.125 x 104; 0.25 x 104; 0.5 x 104; 1 x 104 or 2 x 104  cells per well. PBMCs were 
stimulated with anti-human-CD3 (0.5ug/5 x 105 cells), anti-human-CD28 (0.5ug/5 x 105 cells), 
and goat-anti-mouse antibody (0.5ug/5 x 105 cells) for cross-linking (all BD Pharmingen).
PBMCs were added to the round-bottom 96-well plates at 5 x 104 cells per well. Prolifera-
tion was measured by incorporation of 3H- thymidine (0.5μCi) during 8h using a beta-plate 
reader (LKB) on day 3. All experiments were performed in triplicate and medians were used 
for further analysis.
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Humanized SCID mouse allograft model
Animals
CB-17 SCID/ mice were obtained from Charles River Laboratories (Wilmington, Massachu-
setts, USA) and were used at age 8-10 weeks. The Animal Care and Use Committee of the 
Leiden University Medical Center approved all experiments. Animals were housed under 
specific pathogen free conditions in individually ventilated cages and allowed free access to 
food and water throughout the experiments.
Humanized SCID model
The humanized skin allograft model was approved by local medical ethical committee and 
local animal ethical committee. The study is based on the model described by Moulton et al. 
with slight adaptations[49]. In summary, human abdominal skin was obtained from healthy 
individuals who underwent elective plastic surgery procedures. Eight-mm punch biopsies 
were harvested and kept in culture medium and transplanted onto the back of CB-17 SCID 
mice within 12 hours. The mouse skin was shaved and skin grafts were fixed with a transpar-
ent adhesive film (Smith and Nephew, Hoofddorp, Netherlands) and allowed to heal for 4-6 
weeks. For humanization, third party peripheral blood mononuclear cells (PBMCs) were iso-
lated from fresh buffy coats, obtained from healthy controls, as described before. All animals 
received 100 μl of anti–asialo GM1 by intraperitoneal injection to deplete host NK cells at 
day-1 (Wako Chemicals USA,  Richmond, VA, USA).  At day 0, 24 hours after administration of 
anti-asialo, 3 × 108 PBMCs were transferred by intraperitoneal injection.
MSC were cultured for 1 week in the presence of 100ng/ml IFNγ (PeproTech EC Ltd, London, 
UK) before injection into SCID mice. BM-MSC (0.5 *106 per infusion, n=8 mice) or ASC (0.5 *106 
per infusion, n=7 mice) were injected under the skin graft at day 0 and 4. Control mice (n=9) 
received 100 μl saline at the same time points. Animals were sacrificed at day 14 days and skin 
grafts were harvested. The humanized SCID model is depicted in figure 3a.
Immunohistochemistry  
Immunohistochemical staining was performed as described previously [50]. Skin sections 
(4 μm) of snap-frozen skins grafts were air dried and acetone fixed. Slides were incubated 
overnight with mouse monoclonal IgG against human leukocytes (CD45; BD Pharminghen, 
Breda Netherlands) or cytotoxic T-lymphocytes (CD8; Millipore, Amsterdam Netherlands) 
and rabbit polyclonal anti-CD3 (NeoMarkers, Fremont, California, USA). Antibody binding 
was detected with horseradish peroxidase (HRP)-labeled goat anti-mouse IgG and goat anti-
rabbit IgG (both DAKO, Glostrum, Germany). After washing, sections were incubated with 
tyramide-fluorescein itransplantationhiocyanate in tyramide buffer (NENTM Life Science 
Products, Boston, MA, USA), washed and incubated with HRP-labeled rabbit anti-fluorescein 
itransplantationhiocyanate (DAKO, Glostrum, Germany) and developed with 3,3’-Diamino-
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benzidine (DAB) (Sigma, St Louis, MO, USA). Sections were counterstained with haematoxylin 
(Merck, Darmstadt, Germany) and mounted with imsol (Klinipath, Duiven, the Netherlands). 
Quantification of immunohistochemistry was performed in a blinded manner by assessing 10 
consecutive high power fields (magnification, ×200) on each section. Using Image J software, 
the percentage positive area in each image was determined.
Real-time RT-PCR 
RNA was isolated from explanted skingrafts using TRIzol Reagent (Life technologies) and 
RNeasy minikit (Qiagen, Venlo, The Netherlands) according to manufacturer’s recommenda-
tions. Quantitative expression was determined by real-time RT-PCR as described above using 
Assays- on-demand for IFNγ (Hs 00174086.m1), TNF-α (Hs99999043.m1), IL1-β (Hs00174097.
m1), IL-6 (Hs 00174131.m1 ) and GAPDH (Hs 99999905.m1) (all Applied Biosystems, Foster 
City, CA). Gene-expression was depicted as ratio with GAPDH.
STATISTICAL ANALYSES 
Mann Whitney statistical test was used to test for statistical significance, p value < 0.05 was 
considered statistical significant.
RESULTS
Bone marrow and adipose tissue donors
Study tissues were collected from healthy BM donors (n=5, mean age 15 years,  range 7-31 
years) and healthy adipose tissue donors (n=5, mean age 54 years,  range 32-67 years). The 
expanded MSC from healthy BM and adipose tissue  donors all expressed the common MSC 
markers CD73, CD90, CD105 and CD166 (data not shown). 
BM-MSC and ASC express immunomodulatory genes 
Both BM-MSC and ASC expressed TGF-β, CXCL-10, and IDO mRNA (figure 1A). Since MSC are 
activated under inflammatory conditions, we investigated the effect of the pro-inflammatory 
cytokine IFNγ on BM-MSC and ASC gene expression. Expression of TGFβ and CXCL-10 mRNA 
was not affected by 1 week of  IFNγ stimulation. However, IDO mRNA expression was in-
creased both in BM-MSC and ASC after IFNγ stimulation.
IDO activity increases after IFNγ stimulation in BM-MSC and ASC
To evaluate whether increased IDO mRNA expression was translated in enhanced IDO activity 
upon IFNγ stimulation of BM-MSC and ASC, we studied the concentrations of L-kynurenine 
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in BM-MSC and ASC conditioned medium.  In medium conditioned with IFNγ stimulated 
BM-MSC and ASC, levels of L-kynurenine were significantly higher compared to medium 
conditioned with unstimulated BM-MSC and ASC (figure 1B). As L-kynurine is the breakdown 
product of tryptophan, this indicates an increase of the tryptophan depleting activity of IDO 
in BM-MSC and ASC after IFNγ stimulation, which is suggestive for immunosuppressive activ-
ity of BM-MSC and ASC.
BM-MSC and ASC have immunosuppressive properties in vitro
We then compared the immunosuppressive capacity of IFNγ stimulated BM-MSC and ASC. 
The capacity of these stimulated MSC to inhibit the proliferation of αCD3ααCD28 activated 
PBMCs was evaluated. Both IFNγ stimulated BM-MSC and ASC were capable of significant and 
dose dependent inhibition of αCD3ααCD28 activated PBMC proliferation. The BM-MSC group 
showed significant inhibition until a MSC:PBMC ratio of 1:10, ASC until a MSC:PBMC ratio of 
1:20. No significant difference was detected between BM-MSC and ASC in the percentage 
inhibition (figure 2). 
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Figure 1: (A) mRNA gene expression of immunomodulatory genes of BM-MSC and ASC with or without 
IFNγ stimulation, n=5 for BM-MSC and n=5 for ASC. Ratio gene/GAPDH x1000 is shown. Means (SD) 
are depicted, *represents P<0.05. (B) Effect of IFNγ stimulation on IDO activity in BM-MSC and ASC 
determined by measurement of L-kynurenine in medium conditioned with unstimulated or IFNγ 
stimulated BM-MSC and ASC, n=4 for BM-MSC and n=4 for ASC, means (SD) are depicted, *represents 
P<0.05.
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BM-MSC and ASC downregulate alloreactivity in vivo
After confirmation of immunosuppressive capability in vitro, we investigated the effect of 
IFN-γ-stimulated BM-MSC and ASC on leukocyte recruitment into human skin in a huSCID 
mouse model (figure 3A). Human skin was transplanted and engrafted well within 6 weeks 
(figure 3B). After adoptive transfer of human PBMCs into the mouse by intraperitoneal injec-
tion, there was a marked infiltration of CD45+ leukocytes in the skin graft at day 14 (figure 
3C, figure 3D). Despite this marked leukocyte infiltration in the graft, skin integrity of the 
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Figure 2: Inhibition of aCD3CD28 stimulated PBMC by INFγ stimulated BM-MSC (n=4) and ASC (n=4). 
Means (SD) are depicted, *represents P<0.05.
Human skin 
transplant
PBMC injection IP (Day 0)
MSC injection SC (Day 0 and 4)
4-6 weeks 14 days
Anti-asialo 
injection IP
(Day -1)
Termination and harvest
of skin graft (Day 14)
Figure 3A HuSCID mouse model: human skin is transplanted; mouse NK cells are depleted using anti-
asialo GM1 injection at day-1; allogeneic PBMC are injected intraperitoneal at day 0; MSC are injected on 
day 0 and day 4; and after 14 days, mice are sacrificed and skin grafts are harvested.
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Figure 3B Representative example of engraftment process of skin graft, pictures taken at 12 and 16 days 
after skin graft transplantation.
Figure 3C Immunohistological evaluation of explanted skin grafts. Staining for CD45+, CD4+ and CD8+ T 
cells of skin grafts explanted from mice receiving only a skin transplant (SHAM group); mice receiving skin 
graft and PBMC; mice receiving skin graft, PBMC and BM-MSC; and mice receiving skin graft, PBMC and 
ASC. Representative biopsies are shown.
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huSCID mice remained intact and did not slough. This is probably due to the maintenance 
of blood flow by the murine vasculature as also described previously[49, 50]. The infiltrat-
ing CD45+ cells consisted of both CD4+ and CD8+ T cells (figure 3C, figure 3D). Mice not 
receiving an adoptive transfer of human PBMCs did not demonstrate leukocyte infiltration 
(SHAM group, figure 3C, figure 3D).  Administration of BM-MSC or ASC at day 0 and day 4 after 
allogeneic PBMC injection resulted in a significant reduction of CD45+, CD4+ and CD8+ T cell 
infiltration (figure 3C, figure 3D). RT-PCR analysis for expression of various pro-inflammatory 
human cytokines was performed on the explanted skin grafts of the mice. The mice that had 
received PBMC revealed a significant increase in mRNA expression of IFNγ, TNFα, IL-6 and 
IL1-β indicating inflammation compared to mice with skin grafts only (figure 3E). When mice 
with engrafted skin grafts were treated with BM-MSC or ASC after  PBMC injection, expres-
sion of IFNγ significantly decreased (figure 3E). Expression of  TNFα, IL-1β and IL-6 was also 
reduced  after BM-MSC or ASC treatment, although these differences did not reach statistical 
significance. 
DISCUSSION
We found that MSC derived from bone marrow and adipose tissue were capable of immune 
suppression in vitro and inhibition of T cell mediated alloreactivity in vivo. These results are 
important for future clinical application of MSC.  MSC are emerging as a cell therapeutic agent 
in the field of transplantation with now four completed trails in kidney transplant recipients 
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Figure 3D Quantitative evaluation of CD45+, CD4+ and CD8+ cells in biopsies of study groups. Data 
represent mean (SD), *indicates P<0.05. (E) mRNA gene expression in explanted skin grafts of IFNγ, TNFα, 
IL-6 and IL-1β of study groups. Ratio gene/GAPDH x1000 is shown. Data represent mean (SD), *indicates 
P<0.05.
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and multiple trails in preparation[29-31, 33, 51]. However, currently, there is no consensus 
considering the optimal source for the isolation of MSC for clinical application.
Our finding that BM-MSC and ASC are both effective indicates that the choice between 
BM-MSC and ASC for clinical application can be made upon practical considerations. This is 
important as, despite the numerous studies published on MSC and immune modulation, only 
a few compared their immunosuppressive capacity. Moreover, in the field of transplantation, 
no humanized mouse models have been used to evaluate the effect of MSC. In the present 
study, we first evaluated the in vitro immunosuppressive capacities of the MSC. We found that 
BM-MSC and ASC both express CXCL-10, TGFβ and IDO. The chemoattractive CXCL-10, the im-
mune regulatory TGFβ and antiproliferative IDO are known factors via which MSC excert their 
immune modulating properties [13, 52, 53]. Thus, our results confirm the immunosuppressive 
potential of both types of MSC. Further, as it is known that an inflammatory environment can 
stimulate the immunosuppressive MSC function [54], we evaluated their response to  IFNγ 
stimulation. Upon IFNγ stimulation, we found that IDO expression and activity was increased 
in both BM-MSC and ASC. This is in line with the notion that an inflammatory environment, in 
this study simulated with IFNγ, can potentiate MSC efficacy in both BM-MSC and ASC. 
In αCD3αCD28-induced PBMC proliferation assays we found BM-MSC and ASC both capable 
of dose dependent inhibition. These results confirm previous data showing that BM-MSC and 
ASC have the capacity to inhibit proliferation of alloantigen and mitogen activated PBMC [17, 
39, 55] and justifies examination of these cell populations in a preclinical transplant model.
Multiple animal studies have shown the potential of BM-MSC [12, 25-27, 45, 46] and ASC 
[28] to ameliorate ischemia reperfusion injury or alloreactivity. Yet, as mentioned before, 
human BM-MSC and human ASC have not been evaluated in a humanized transplant model. 
Issa et al. used such a humanized model for evaluation of regulatory T cell (Tregs) therapy. 
This model enabled the authors to study the effect of ex vivo-expanded Tregs and found 
them capable of inhibition of skin graft rejection[56]. Here, for the first time, we used such 
a unique humanized mouse model for evaluation of MSC treatment in allograft rejection. 
We found that BM-MSC and ASC were effective in inhibiting  alloreactivity.  Alloreactivity 
was marked by recruitment of CD45+ cells which consisted of CD4+ and CD8+ T cells and 
IFNγ, TNFα, IL-1β and Il-6 mRNA expression was increased in the explanted skin grafts. Local 
administration of BM-MSC as well as ASC reduced inflammation by inhibiting the recruitment 
of T cells and decreasing IFNγ, TNFα, IL-6 and IL-1β expression in the skin grafts. These results 
support the use of BM-MSC and ASC to treat transplant rejection.
In conclusion, the immunosuppressive potential of BM-MSC and ASC has been highlighted 
in the present study. Our experiments confirm the immunosuppressive capacities of BM-MSC 
and ASC in vitro. By extending our investigations to a humanised transplant model our data 
underscore the potential of BM-MSC and ASC therapy in clinical transplantation.  
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ABSTRACT
Background aims
Adipose tissue-derived mesenchymal stromal cells (ASCs) are of interest as a cell therapeutic 
agent for immunologic and degenerative diseases. During in vitro expansion, ASCs may be 
at risk for genetic alterations, and genetic screening is a prerequisite. We examined the pres-
ence of aneuploidy in ASCs and its origin and development during culture and evaluated the 
implications of aneuploidy for therapeutic use of ASCs.
Methods
Adipose tissue of healthy individuals was used for isolation and expansion of ASCs. Chro-
mosome copy numbers were studied using fluorescence in situ hybridization analysis. 
Aneuploidy was studied in freshly isolated ASCs, in ASCs cultured for 0–16 passages and in 
senescent cultures. To evaluate the plasticity of ploidy, ASCs were cloned, and the variation 
of ploidy in the clones was examined. Tumorigenicity was studied by subcutaneous injection 
of aneuploid ASCs in immunodeficient NOD/SCID mice.
Results
No aneuploidy was detected in freshly isolated ASCs. In low passages (passages 0–4), 
aneuploidy was detected in 3.4% of ASCs. Prolonged culture expansion of ASCs (passages 
5–16) resulted in a significant increase of aneuploidy to 7.1%. With senescence, aneuploidy 
increased further to 19.8%. Aneuploidy was observed in clones of diploid ASCs, demonstrat-
ing the de novo development of aneuploidy. No transformation of ASCs was observed, and 
in contrast to cancer cell lines, aneuploid ASCs were incapable of tumor formation in im-
munodeficient mice.
Conclusions
ASC cultures contain a stable percentage of aneuploid cells. Aneuploidy was not a predeces-
sor of transformation or tumor formation. This finding indicates that aneuploidy is culture-
induced but unlikely to compromise clinical application of ASCs.
INTRODUCTION
Mesenchymal stromal cells (MSCs) have immunomodulatory and regenerative capacities 
[1-4]. They are of interest as a cell therapeutic agent for various medical conditions, includ-
ing Crohn disease, graft-versus-host disease, and solid-organ transplantation [1, 5, 6]. At 
the present time, >300 clinical trials are registered to study the applicability and effects of 
MSC administration (April 2013, http://clinicaltrials.gov). In the absence of a specific marker, 
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MSCs are defined by the criteria set by the International Society for Cellular Therapy as plastic 
adherent cells with a CD73+, CD90+, CD105+, CD14−, CD34−, CD45− and human leukocyte 
antigen (HLA)-DR− immunophenotype and the capacity to differentiate into osteoblasts, 
adipocytes and chondrocytes [7]. The primary source of MSCs is bone marrow; however, 
MSCs reside in virtually all tissues [8], of which adipose tissue is the most accessible and 
most suitable for the isolation of cells for research and therapeutic purposes. Adipose tissue-
derived mesenchymal stromal cells (ASCs) are very similar to bone marrow-derived MSCs [9, 
10], although un-cultured ASCs express CD34 [11, 12].
For most clinical applications, ASC are culture-expanded to obtain sufficient numbers of 
cells. During expansion, ASCs may be at risk for transformation. To ensure patient safety, 
ASCs should be subjected to strict release criteria, similar to MSCs. [13]. However, until now, 
genetic screening of clinical-grade MSCs has been limited to karyotyping of a small number 
of cells [1, 2, 13, 14].
Preclinical research evaluating the genetic stability of MSC has resulted in contradicting 
outcomes. Studies reporting spontaneous transformation of MSC in culture [15, 16] were 
retracted when cell cultures appeared to be contaminated with tumor cell lines [17, 18]. Nev-
ertheless, there is evidence that aneuploidy occurs in cultured MSC derived from both bone 
marrow and adipose tissue [19-22]. These chromosomal aberrations have also been detected 
in MSC used in clinical trials [23]. Because aneuploidy has been suggested to be associated 
with cancer [24], aneuploidy in MSC cultures may be a worrisome finding and its detection in 
MSC cultures warrants thorough investigation. 
To date, it is unknown whether aneuploidy in ASCs is already present in vivo or whether 
it is induced during the culture process. How aneuploidy evolves during further extensive 
culture expansion is also unknown. Additionally, it is unknown whether aneuploidy is as-
sociated with transformation or tumor formation and whether it compromises the safety of 
clinical application of ASCs. The aim of this study is to examine the occurrence and functional 
implications of aneuploidy in ASCs.
METHODS
Sources of adipose tissue
Subcutaneous abdominal adipose tissue was surgically removed from healthy living kidney 
donors during donor nephrectomy after receiving written informed consent, as approved 
by the Medical Ethical Committee of Erasmus Medical Center (protocol no. MEC-2006-190). 
Adipose tissue was collected in minimal essential medium alpha (MEM-α) (Invitrogen, Paisley, 
UK) supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin (Invitrogen).
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ASC isolation, culture and differentiation
ASCs were isolated from adipose tissue as described previously [9, 12, 25]. Briefly, adipose 
tissue was mechanically disrupted and enzymatically digested with sterile 0.5 mg/mL col-
lagenase type IV (Sigma-Aldrich, St Louis, MO, USA) in RPMI-1640 Medium with GlutaMAX 
(Invitrogen) and penicillin/streptomycin for 30 min at 37°C. The cell suspension was seeded 
in culture flasks in ASC culture medium consisting of MEM-α with 1% penicillin/streptomycin 
and 15% fetal bovine serum (Lonza, Verviers, Belgium). Cultures were kept at 37°C, 5% CO2 
and 95% humidity. Medium was changed every 3–4 days. Upon 90% confluency, ASC were 
detached using 0.05% trypsin-EDTA at 37°C. ASC were counted in order to calculate the 
population doublings and reseeded at a density of 1000 cells per cm2. On average, each 
passage represented 3.3 population doublings. ASC immunophenotype and osteogenic and 
adipogenic differentiation capacity were evaluated as described previously to confirm ASC 
identity [12, 25]
Fluorescence-activated cell sorting of un-cultured ASCs
For fluorescence-activated cell sorting (FACS) of un-cultured ASCs from the freshly isolated 
cell suspension, cells were washed with FACSFlow (BD Biosciences, San Jose, CA, USA) and 
incubated with mouse anti-human monoclonal antibodies against HLA-ABC-PE-Cy7, 
CD34-APC, CD45-PERCP (all BD Biosciences), CD31-APC-Cy7 (BioLegend, San Diego, CA, 
USA) and CD73-PE (BD Pharma, San Jose, CA, USA). To obtain ASCs, HLA-ABC+CD45−CD31−
CD34+CD73+ cells were gated and sorted (BD FACSAria II SORP; BD Biosciences). Purified ASCs 
were immediately fixed in 3:1 methanol acetic acid and kept at −20°C for fluorescence in situ 
hybridization (FISH) analysis.
FISH analysis
Dual-color FISH analysis was performed using the bacterial artificial chromosome (BAC) 
clones RP11-121E15 (chromosome 15q25.2) and RP11-411B10 (chromosome 18p11.21). 
Initially, the centromere probes Pα3.5 (chromosome 3) and D8Z2 (centromere 8) were used, 
but the more confined signal of the BAC clones facilitated the counting. Mbo1-digested 
BAC DNA or plasmid DNA was labeled with Bio-16-dUTP or Dig-11-dUTP (Roche Applied 
Science, Indianapolis, IN, USA) using the random prime labeling system BioPrime (Invitrogen 
Corporation, Carlsbad, CA, USA). Microscope chamber slides with fixed ASCs were hybrid-
ized overnight at 37°C with 10–20 ng labeled centromere probe or 40–50 ng labeled BAC 
probe. The following day, the slides were washed (2× saline sodium citrate [SSC] and 0.1× 
SSC, 0.1% Tween) at 55°C and incubated with Alexa Fluor 594 Streptavidin (Life Technologies, 
Bleiswijk, the Netherlands) and anti-digoxigenin-fluorescein isothiocyanate (Roche, Almere, 
the Netherlands) for 2 h. After washing (2× SSC, 0.1× SSC), the slides were counter-stained 
with 4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, Zwijndrecht, Netherlands) and 
mounted in anti-fade solution (DABCO-Vectashield 1:1; Vector Laboratories, Burlingame, CA, 
Aneuploidy in ASCs 39
USA). For each hybridization, a minimum of 300 nuclei were scored with an Axioplan 2 imag-
ing microscope (Carl Zeiss; Sliedrecht, the Netherlands) using a chroma-sp-100 DAPI and a 
chroma-sp-103v1 red filter (Chroma Technology, Bellows Falls, VT, USA), and the images were 
captured with ISIS software (Metasystems, Altlussheim, Germany) [26, 27].
Cloning ASCs
Sub-confluent ASC cultures were trypsinized, and single cells were seeded in 96-well flat 
bottom plates using FACS (BD FACSAria II SORP). After 1 day of culture, wells containing more 
than one cell were discarded. Other cells were cultured until colony formation occurred. 
Sub-confluent clones were transferred to chamber slides for FISH analysis. FISH analysis of 
primary cultures and clones was performed using the BAC clones RP11-121E15 (chromosome 
15q25.2) and RP11-411B10 (chromosome 18p11.21).
Senescence-associated β-galactosidase staining
Two ASC cultures that were non-proliferative for a minimal period of 4 weeks despite 
media refreshments and passaging were seeded in six-well flat bottom plates. Staining for 
β-galactosidase activity at pH 6, which is a known characteristic of senescent cells [28], was 
performed using a Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, 
Danvers, MA, USA) according to the manufacturer’s protocol. Sub-confluent proliferating 
low-passage ASCs were used as a control. Representative examples and the percentage of 
cells positive for β-galactosidase activity at pH 6 were depicted.
Analysis of tumorigenicity of ASCs in immunodeficient mice
As described previously [29], immunodeficient NOD/SCID mice (Erasmus MC institutional 
breeding) 6–8 weeks old were subcutaneously injected with 6x106 ASCs (N=4) using 29-gauge 
needles. Control mice received 1x106 cells of the human hepatoma cell line Huh7. The mice 
were macroscopically screened for tumor formation for 2 months. After 2 months, mice were 
sacrificed and the injection area was studied histologically for abnormalities. In addition, fat 
tissue at the injection site was removed and ASC isolated and brought into culture. ASC were 
then stained with antibodies against mouse CD44 and human HLA class I and analyzed by 
flow cytometry to confirm their ASC phenotype and to detect whether the cultures contained 
human ASC. 
Statistical analysis
Data were analyzed using the Student t test. Statistical significance was defined as P < 0.05.
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RESULTS
Characterization of ASCs
ASCs were successfully isolated from adipose tissue of all donors (n = 17). After culture expan-
sion, ASCs were characterized by flow cytometry and demonstrated a CD73+, CD90+, CD105+, 
CD166+, HLA-ABC+ and CD45− immunophenotype (Figure 1). Multi-lineage differentiation 
capacity was confirmed by adipogenic and osteogenic differentiation visualized by oil red O 
and von Kossa staining, respectively (data not shown).
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Figure 1. Immunophenotype of ASCs. Gray histograms represent unstained cells, and open histograms 
represent stained cells. Representative culture is shown.
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Aneuploidy in ASCs
We performed FISH analysis on cultured ASCs to detect the presence of aneuploid cells 
(Figure 2). Because there is a general consensus to use low-passage ASCs for clinical studies, 
we performed FISH analysis on 12 different ASC cultures of low passage (0–4 passages, ap-
proximately 2–17 population doublings) to detect the presence of aneuploid cells in cultures 
of therapeutic potential. On average, 96.6% of ASCs were diploid, and 3.4% (range, 1.3–7; 
standard error of the mean [SEM] 0.4) were aneuploid (Table I, Figure 3). The occurrence of 
aneuploidy was not related to the age of the ASC donor and even occurred in ASCs that 
Figure 2. FISH analysis of ASCs. Representative example of FISH staining of three diploid ASCs and one 
tetraploid ASC (bottom cell) is shown. Colors indicate hybridized probes on chromosome 15q25.2 and 
chromosome 18p11.21.
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Table I. Overview of 12 ASC cultures between passages 0 and 4 analyzed for aneuploidy.
Culture number Sex Age Passage analysed Approx. population doublings Aneuploidy (%)
1 f 64 0 2-4 3.9
2 m 44 0 2-4 4.8
3 f 30 1 6-7 2.5
4 f 42 2 9-10 3.9
5 m 44 2 9-10 1.3
6 m 77 2 9-10 3.3
7 f 56 2 9-10 4.1
8 m 73 3 13-14 7.0
9 m 39 3 13-14 2.3
10 m 42 3 13-14 2.3
11 m 47 4 16-17 3.1
12 f 32 4 16-17 2.6
Approximate population doublings are indicated. F, female; M, male.
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Figure 3. Aneuploidy in ASC cultures of clinically relevant passages. Percentages of aneuploid ASCs in 
12 cultures of passages 0-4 (approximately 2-17 population doublings) (see Table II for details) were 
determined by FISH analysis.
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were cultured for only a few days (passage 0, approximately 2–4 population doublings). Most 
aneuploid ASCs were tetraploid (86.7% of aneuploid cells). Octaploidy and other forms of 
poliploidy were detected at low frequencies.
Aneuploidy in ASC clones
To determine whether aneuploidy can arise from diploid ancestor cells, ASC clones were 
generated from three cultures. The ancestor ASC populations consisted of 2.4% (passage 3), 
1.2% (passage 2) and 3.1% (passage 4) aneuploid cells; if diploid cells would give rise only to 
diploid cells, the large majority of clones would be expected to be fully diploid. On average, 
the possibility of cloning a diploid cell was 97.8%. FISH analysis on the generated clones 
showed that most clones contained a percentage of aneuploid cells, ranging from 0.3–6% 
(Figure 4). These results indicate that aneuploid ASCs can arise from diploid ancestor 
Aneuploidy in non-cultured ASCs
To evaluate whether aneuploidy in ASCs is a culture-induced phenomenon, the occurrence 
of aneuploidy in non-cultured ASCs was evaluated. Using FACS, HLA-ABC+CD31−CD45−
CD34+CD73+ cells were isolated from the stromal vascular fraction. From this cell fraction, 
a population of cells with spindle-shaped morphology develops in culture within a few 
days (data not shown), demonstrating that these cells represent ASCs. The percentage of 
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Figure 4. Schedule of percentages of aneuploidy in ASC clones. Three ancestor cultures contained 2.4%, 
1.2% and 3.1% of aneuploid cells. Clones from ASCs of these cultures derive from diploid ancestor cells in 
97.6%, 98.8% and 96.9% of the cases. Of 24 analyzed clones, 22 contained aneuploid cells, indicating that 
aneuploidy arises de novo from diploid cells.
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aneuploidy in non-cultured ASCs of three donors was examined by direct fixation of the 
freshly isolated HLA-ABC+CD31−CD45−CD34+CD73+ cells and subsequent FISH analysis. In 
contrast to cultured ASCs, freshly isolated ASCs were 100% diploid. These results indicate that 
aneuploidy in ASCs is culture-induced.
Aneuploidy in high-passage and senescent ASCs
To study whether aneuploidy increased after prolonged culture expansion of ASCs, we 
analyzed the percentage of aneuploidy in five ASC cultures of passages ranging from 5–16 
(approximately 19–57 population doublings). These high-passage ASCs displayed normal 
ASC morphology and proliferation. The incidence of aneuploidy in these cultures was on 
average 7.1% (SEM 1.5), which was significantly higher than the 3.4% aneuploidy in passages 
0–4 ASCs (Table II, Figure 5A). 
We also studied aneuploidy in two senescent passage 15 ASC cultures (approximately 
49–50 population doublings). These cultures were non-proliferative for >4 weeks and dis-
played an altered morphology and increase in cell size (Figure 5B lower panel). Their state of 
senescence was confirmed by staining for β-galactosidase activity at pH 6, which is specific 
for senescent cells and indicated a mean percentage of senescent cells of 94% (SEM 0.6) 
(Figure 5B lower panel, C) compared with low-passage proliferating ASCs (Figure 5B upper 
panel, C). In these senescent cultures, the percentage of aneuploidy increased dramatically 
to 19.8% (SEM 6.1) (Table II, Figure 5D).
Table II. Overview of five ASC cultures between passages 5 and 16 analyzed for aneuploidy.
Culture number Sex Age Passage analysed Approx. population doublings Aneuploidy (%)
13 f 62 5 19-20 2.1
13 f 62 10 36-37 11.1
13 f 62 12 42-43 3.5
14 f 56 8 29-30 10.9
14 f 56 9 33-34 6.4
15 m 48 11 39-40 5
16 f 39 14 49-50 13.3
17 m 36 16 56-57 4.5
13 f 62 15 49-50 13.7
14 f 56 15 49-50 25.8
Table 2. Approximate population doublings are indicated. Bold items indicate senescent cultures.
 F, female; M, male.
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Figure 5. Aneuploidy in ASC cultures of high passages. (A) Percentages of aneuploid ASCs in eight 
cultures of passages 5-16 (see Table II for details) determined by FISH analsis. (B) Qualitative determination 
of senescence by staining for senescence-associated (SA) – β-galactosidase of low-passage proliferating 
ASCs (upper panel) and senescent ASCs (lower panel). Blue cells indicate cells positive for β-galactosidase 
activity at pH 6, a known marker for senescence. Representative examples are shown. (C) Quantitative 
measurement of senescence—percentage of cells positive for β -galactosidase at pH 6 in senescent 
cultures and controls. (D) Aneuploidy in non-cultured ASCs, ASCs of passages 0-4, ASCs of passages 5-16 
and senescent ASCs determined by FISH analysis. *P < 0.05.
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Tumorigenicity of aneuploid ASCs
Because aneuploidy is considered to be associated with tumor formation, we examined 
whether aneuploid ASCs had tumorigenic potential. In culture, no transformation of ASCs 
was observed in any of the cultures, including cells that were senescent and cultured for >6 
months.
The tumorigenicity of aneuploid ASCs was evaluated by subcutaneous injection of 6x106 
ASCs containing a known proportion of aneuploid cells in immunodeficient NOD/SCID mice. 
Four mice were injected with ASCs in the flank just above the hind limb. The first three mice 
received ASCs of three different ASC cultures of passages 2–4 (approximately 9–17 popula-
tion doublings), and the fourth received a mixture of the ASCs. Before injection, a sample of 
the ASCs was collected for FISH analysis. The ASC cultures consisted of 2.3%, 2.6% and 3.3% 
aneuploid cells; this implies that 140,000–200,000 aneuploid cells were injected in the mice. 
Mice receiving ASCs remained in good condition, and no tumor formation was macroscopi-
cally observed 2 months after injection. No cutaneous or subcutaneous tumor formation had 
occurred in any of the mice (Figure 6A–C). Mice injected with the hepatoma cell line Huh7 at 
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Figure 6. Tumorigenicity of ASCs. Immunodeficient NOD/SCID mice received subcutaneous injections of 
6 x 106 ASCs including 2.3-3.3% aneuploid cells. After 2 months, the mice were macroscopically examined 
for tumor formation. No cutaneous or subcutaneous tumor formation was found (A-C). Injection of 1 x 106 
Huh7 human hepatoma cells induced tumor formation (D). ASCs were isolated from the adipose tissue of 
the injection and contralateral site and characterized by flow cytometry (E). The cells stained positive for 
anti-mouse CD44 but were negative for anti-human HLA-ABC, indicating the mouse origin of the cells.
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these same locations formed tumors, confirming that the subcutaneous environment sup-
ports tumorigenesis (Figure 6D). The subcutaneous adipose tissue located at the site of injec-
tion and at the contralateral side was collected for ASC isolation and culture. After 1 week, 
spindle-shaped ASCs appeared in the cultures. Flow cytometry analysis of the ASCs revealed 
their mouse origin (Figure 6E). No human cells were detected in cultures from adipose tissue 
of the injection side, indicating that even in immunodeficient mice ASC injection harbors no 
threat despite the presence of aneuploid cells.
DISCUSSION
In this study, we show that ASC cultures contain a fraction of aneuploid cells. The finding of 
aneuploid cells in ASC cultures is in accordance with earlier studies that reported aneuploidy 
in bone marrow-derived MSC [20] and ASC [19, 21] cultures. This phenomenon has also been 
described in clinical-grade MSCs [23].
Aneuploidy refers to a state in which cells possess an abnormal number of chromosomes 
and is suggested to be associated with cancer[24]. Because safety is crucial for MSC therapy, 
it is surprising that little is known about the clinical implications of aneuploidy in culture-
expanded ASCs. In the present study, we examined the occurrence of aneuploidy during 
short-term and long-term culture of ASCs. The absence of aneuploidy in freshly isolated ASCs 
indicates that aneuploidy in ASCs is induced by culture expansion. To avoid the risk of inject-
ing aneuploid ASCs, the possibility of using freshly isolated ASCs, as studied by others [30], 
could be considered. However, efficacy studies are needed to determine whether the thera-
peutic potential of fresh ASCs is comparable to culture-expanded ASCs. The percentage of 
aneuploidy remained stable in clinically relevant passage numbers (passages 0–4). In higher 
passage numbers, the percentage of aneuploidy significantly increased. Aneuploid ASCs did 
not transform in vitro and did not form tumors in vivo. Senescent ASC cultures had a high 
percentage of aneuploid cells, suggesting aneuploidy may occur in particular in old ASCs.
At the present time, MSC therapy is the subject of extensive basic research and is under 
clinical evaluation in many medical fields [31-34]. Safety is a main theme of these studies. 
Results from first clinical trials using human MSCs have not provided evidence for tumor 
formation, although longer follow-up is needed. A few articles were published in recent 
years reporting the alarming finding of transformation of MSCs [15, 35, 36]. Although some 
of these reports were retracted when cultures appeared to be contaminated with tumor cell 
lines 17 and 18,[17, 18], transformation has been proven to occur in murine MSCs and to 
cause sarcoma formation [37, 38]. Similar results were obtained with macaque MSCs [39]. 
These findings suggest that murine and macaque MSCs are susceptible to transformation 
and capable of tumor formation, whereas human MSCs are not [40, 41]. This suggestion indi-
cates an essential difference between MSCs of different species. However, there is still debate 
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concerning the genetic stability of MSCs and the implication for clinical safety [42, 43]. We 
recently carried out a single nucleotide polymorphism array-based whole-genome analysis 
of expanded MSCs and found no evidence for culture-obtained genomic translocations or 
deletions in MSCs [12]. Our analysis suggests that the occurrence of aneuploidy in MSCs is 
not associated with the development of other genetic abnormalities.
Nevertheless, the occurrence of aneuploidy in ASC cultures is an interesting biologic 
phenomenon. Cloning of low-passage ASCs resulted in clones that were predominantly 
diploid but contained low percentages of aneuploid ASCs. These results indicate that there is 
plasticity in the ploidy of ASCs. The fact that the percentage of aneuploidy remained stable 
in these clones for several passages suggests that some form of autoregulation of ploidy in 
ASCs exists. It is possible that this autoregulatory capacity is lost when ASC cultures age and 
become senescent and show elevated frequencies of aneuploidy.
In conclusion, we found aneuploidy in ASCs to be a culture-induced phenomenon, which 
is stable during culture and increased in senescent cultures. We demonstrated plasticity of 
ploidy in ASCs and found no transformation or tumor formation by aneuploid ASCs. Aneu-
ploidy in low-passage ASCs is unlikely to compromise clinical application of ASCs.
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ABSTRACT
Adipose tissue-derived mesenchymal stem cells (ASC) are of great interest as a cellular 
therapeutic agent for regenerative and immunomodulatory purposes. The function of ASC 
adapts to environmental conditions, such as oxygen tension. Oxygen levels within tissues 
are typically much lower than under standard culture conditions and ASC used for therapy 
therefore encounter a change from normoxic to hypoxic conditions. The effect of hypoxia on 
the regenerative potential of ASC has been investigated in a number of studies. The effect 
of hypoxia on the immunomodulatory function of ASC, however, remains to be determined. 
In the present study the effect of hypoxic (1% oxygen) culture conditions on human ASC 
was examined. ASC showed no signs of toxicity under low oxygen levels and no major im-
munophenotypical changes were observed, apart from a down regulation of the marker 
CD105. Oxygen tension had no effect on the proliferation of ASC and colony forming unit 
(CFU) efficiency remained the same under 1% and 20% oxygen. Under both oxygen levels 
ASC were capable of strong upregulation of the immunomodulatory molecules indolamine 
2,3-dioxygenase (IDO) and programmed death ligand-1 (PD-L1)  upon stimulation with IFN-γ 
and TNF-α, and, in addition, IDO activity as measured by the accumulation of L-kynurenine 
was not affected under hypoxia. The ability of ASC to inhibit anti-CD3/CD28 stimulated CD4+ 
and CD8+ T cell proliferation was not hampered by hypoxia. The results of the present study 
demonstrate that the immunosuppressive capacity of ASC is maintained under hypoxic 
conditions. These findings are important for the therapeutic use of ASC and may be applied 
for the in vitro generation of ASC with improved functionality for therapeutic use.
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INTRODUCTION
Mesenchymal stem cells (MSC) have emerged as cells with great clinical potential. In vitro 
studies have demonstrated the immunosuppressive and regenerative capacities of MSC. 
Currently, MSC have been evaluated as a cell therapeutic agent in many medical fields 
including graft versus host disease, solid organ transplantation and Crohn’s disease [1-3]. 
MSC can be isolated from a wide range of tissues [4, 5], of which bone marrow is the clas-
sical, and most frequently used source. However, bone marrow aspiration is invasive and is 
accompanied with donor morbidity [6]. In contrast, adipose tissue is more accessible, has 
a higher yield of MSC, and adipose tissue-derived MSC (ASC) share many properties with 
their bone marrow derived counterparts [7, 8]. Adipose tissue is therefore the favored source 
of MSC in an increasing number of studies [9-11]. To obtain sufficient numbers of MSC for 
research and certainly clinical application the cells are culture expanded. Culture conditions, 
however, have striking effects on the phenotype and function of MSC. Advantage of this can 
be taken by modulating culture conditions in such a way that cells with superior functionality 
are obtained.
Oxygen concentration is an important environmental factor that affects MSC. While MSC 
are normally cultured under 20% oxygen tension, tissue-resident MSC face much lower 
oxygen concentrations. Oxygen tension in adipose tissue, for instance, fluctuates depending 
on blood flow, but varies typically between 3 and 11% [12]. Lower oxygen concentrations can 
occur in the incidence of injury. It has been demonstrated that hypoxic conditions affect the 
function of bone marrow derived MSC. Culturing under 1% oxygen reduces MSC senescence 
while it increases proliferation and maintains the differentiation properties of the cells [13]. 
Similar results have been obtained for MSC derived from adipose tissue and Wharton’s jelly 
[14-16]. This suggests that MSC are triggered by injury-induced hypoxic conditions to expand 
and eventually differentiate. MSC have also been shown to enhance their angiogenic poten-
tial under hypoxia by increasing their secretion of vascular endothelial growth factor (VEGF) 
and bFGF [17].
Tissue trauma is almost without exception followed by inflammation. Inflammation in its 
turn is a major activator of the immunosuppressive capacity of MSC [18], which thereby al-
lows regeneration by inhibiting immune activity. It is however unknown whether hypoxia, 
occurring before the initiation of inflammation, alters the immunosuppressive capacities of 
MSC. As these capacities are essential for MSC therapy, it is important to evaluate the effect 
of hypoxia on MSC. Therefore, in the present study we examined the effect of low oxygen 
concentrations on the phenotype and immunomodulatory properties of human ASC.
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MATERIALS AND METHODS
Adipose tissue
Subcutaneous adipose tissue was surgically removed from healthy live kidney donors during 
the kidney donation procedure after written informed consent, as approved by the Medical 
Ethical Committee of the Erasmus MC (protocol no. MEC-2006-190). Adipose tissue was col-
lected in essential medium alpha (MEM-α) (Life Technologies, Paisley, UK) supplemented with 
100U/ml penicillin and 10.000U/ml streptomycin (p/s) and 2mM L-glutamine (Lonza, Verviers, 
Belgium).
ASC isolation
Adipose tissue-derived mesenchymal stem cells were isolated from adipose tissue of five 
donors as described previously [5, 19]. In brief, adipose tissue was mechanically disrupted, 
enzymatically digested with sterile 0.5mg/mL collagenase type IV (Sigma-Aldrich, St. Louis, 
MO, USA) in RPMI-1640 + glutaMAX (Life Technologies) and p/s for 30 min at 37°C. Cells were 
resuspended in ASC culture medium, consisting of MEM-α with 15% fetal bovine serum (FBS) 
(Lonza), transferred to a 175cm2 culture flask (Greiner Bio-one, Essen, Germany) and kept at 
37°C, 5% CO2, 20% O2 and 95% humidity. Medium was changed every 3-4 days. When >90% 
confluent, ASC were detached using 0.05% trypsin-EDTA at 37°C and either directly used for 
experiments or frozen until usage. ASC were used for experiments between passages 1 and 5. 
Immunophenotyping by flow cytometry
Adipose tissue-derived mesenchymal stem cells were immunophenotyped by flow cytometry 
after standard culture expansion and after one week exposure to hypoxic culture conditions. 
Subconfluent ASC were trypsinized and washed with FACSFlow (BD Biosciences, San Jose, 
CA, USA). Cell suspensions were incubated with mouse-anti-human monocolonal antibodies 
against CD45-PerCP, CD73-PE, CD166-PE, HLA-ABC-APC, HLA-DR-APC-Cy7 (all BD Biosciences) 
and CD105-FITC (R&D Systems, Abingdon, UK) at room temperature in the absence of light 
for 15 min. After two washes with FACSFlow, flow cytometric analysis was performed using 
an eight color FACSCANTO-II with FACSDIVA Software (BD Biosciences) and FlowJo Software 
(Tree Star, Palo Alto, CA). 
Hypoxic culture conditions
Hypoxic conditions were induced by culture of ASC in 1% O2, 5% CO2 and 94% N2 in a 95% 
humidified atmosphere. Control cells were kept under normoxic conditions (20% O2).
Lactate measurements
Adipose tissue-derived mesenchymal stem cells were seeded in six-well plates at a concen-
tration of 200,000 cells per well in ASC culture medium and kept under either normoxic or 
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hypoxic conditions. After 3 days, the conditioned medium was collected and frozen at -80°C 
until usage. A lactate assay kit (BioVision, Milpitas, CA, USA) was used for measurement of 
lactate levels. In brief, samples were incubated with 50μl of the Reaction Mix for 30 min at 
room temperature in the dark. The formed product was measured spectrophotometrically 
at 570nm on a Victor2 1420 multilabel plate reader (PerkinElmer, Santa Clara, MA, USA) and 
corrected for background.
Measurement of metabolic activity by MTT assay
Adipose tissue-derived mesenchymal stem cells were seeded in 96-well flat bottom plates at 
a concentration of 3000 cells per well in 200μl ASC culture medium and kept for 24h, 48h or 
72h under normoxic or hypoxic conditions. Five hours prior to the end of the incubation, 20μl 
sterile MTT (Sigma-Aldrich) (5mg MTT/ml disolved in 1x PBS) was added to the wells. Culture 
medium was then removed and 100μl DMSO added to the cells to dissolve formed crystals. 
Mitochondrial conversion of MTT was determined by absorbance measurements at 550nm 
wavelength on a Victor2 1420 multilabel plate reader.
Colony forming unit (CFU) assay
Adipose tissue-derived mesenchymal stem cells were seeded at 50 cells per 6 cm diameter 
culture dishes in quintuple (3.0 cells/cm²). After 2 weeks of culture under normoxic or hypoxic 
conditions, medium was removed, the dishes washed with PBS and fixed in 70% ethanol. 
Colonies were stained with 2.3% crystal violet solution (Sigma-Aldrich) for 30 min. Dishes 
were then washed with tap water and colonies with a diameter of more than 1mm counted. 
Colony forming unit (CFU) efficiency was expressed as the percentage of cells capable of 
forming colonies.
Proliferation assay 
Adipose tissue-derived mesenchymal stem cells were seeded at a density of 1000 cells/cm2 
in 75cm2 culture flasks and kept under normoxic or hypoxic conditions for 1 week without 
medium changes. Cells were then detached by trypsinization, counted, and re-seeded. Popu-
lation doublings were calculated using the formula 2LOG(number of cells at td7/number of 
cells at td0). Cumulative population doublings during 5 consecutive weeks of culture were 
plotted.
Quantitative mRNA expression
Adipose tissue-derived mesenchymal stem cells were seeded in six-well plates at a concen-
tration of 1×105 per well in the presence or absence of 20ng/ml TNFα and 50ng/ml IFNγ and 
kept under normoxic or hypoxic conditions. After 6h, 24h or 72h, RNAlater (Life Technologies) 
was added to the cells. RNA was isolated and 500ng used for cDNA synthesis as described 
previously [20]. Gene expression was determined by real-time RT-PCR using universal PCR 
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master mix (Life Technologies) and Assays-on-demand for hypoxia induced factor 1α (HIF1-α) 
(Hs00153153.m1), HIF2-α (Hs1026149.m1), VEGF (Hs00173626.m1), IDO (Hs00158627.m1), 
PDL-1 (Hs00204257.m1), TGFβ1 (Hs00171257.m1), IL10 (Hs00174086.m1), IL6 (Hs00174131.
m1) and CXCL10 (Hs00171042.m1) (all Applied Biosciences, Foster City, CA, USA) on an ABI 
PRISM 7700 sequence detector (Applied Biosystems).  As housekeeping gene expression 
fluctuates under hypoxia, data was expressed as relative copy number of the PCR products 
per 500ng RNA. Relative copy number was calculated using the formula 2(40-Ct value).
IDO activity measurements
Adipose tissue-derived mesenchymal stem cells were cultured for 24h or 72h with or without 
20ng/ml TNF-α and 50ng/ml IFN-γ under normoxic or hypoxic conditions. The tryptophan 
metabolic activity of IDO was determined by measurement of L-kynurenine in the condi-
tioned medium of five ASC cultures. Thirty percent of trichloroacetic acid was added to the 
samples at a 1:3 ratio and after 30 min incubation at 50°C the samples were centrifuged 
at 12,000 rpm for 5 min. Supernatants were then diluted 1:1 in Ehrlich reagent (200mg 
4-dimethylaminobenzaldehyde (Sigma, St. Louis, MO, USA) in 10ml of glacial acetic acid) in 
duplicate in a 96-wells flat bottom plate and absorbance was determined at 490nm using a 
multilabel plate reader (VersaMaxTM, Molecular Devices, Sunnyvale, CA, USA). L-kynurenine 
(Sigma, St. Louis, MO, USA) diluted in unconditioned medium was used as standard.   
PBMC isolation
Peripheral Blood Mononuclear Cells (PBMC) were collected from buffy coats of healthy blood 
bank donors. PBMC were isolated by density gradient centrifugation using Ficoll Isopaque 
(δ=1.077, Amersham, Uppsala, Sweden) and frozen -135°C until use .
Anti-CD3/CD28 lymphocyte stimulation assay
Peripheral blood mononuclear cells (PBMC) were labeled using the PKH26 Red Fluorescent 
Cell Linker Kit (Sigma-Aldrich) and stimulated with anti-CD3 antibody (0.5μl/5×105 cells), 
anti-CD28 antibody (0.5μl/5×105 cells) and a goat-anti-mouse antibody  (1μl/5×105 cells) 
for cross-linking (all BD Biosciences).  PBMC were seeded in round-bottom 96-well plates 
at 5×104 cells per well and ASC added at 1:2.5, 1:5, 1:10 and 1:20 ratios in MEM-α with p/s 
and 10% heat inactivated (HI)-human serum. After 3 days of incubation under normoxic or 
hypoxic conditions, PBMC were collected, washed twice with FACSFlow (BD Biosciences) and 
incubated with monoclonal antibodies against TCR-FITC (Serotec, Oxford, UK), CD3-AmCyan, 
CD4-Pacific Blue, CD8-PerCP (all BD Biosciences) for 15 minutes at room temperature in the 
absence of light. After two washes with FACSFlow, flow cytometric analysis was performed 
using an 8 color FACSCANTO-II with FACSDIVA Software (BD Biosciences). 
Effect of hypoxia on ASC 59
Statistical analysis
Data were statistically analyzed using Mann Whitney, and Kruskal-Wallis statistical tests. P < 
0.05 was considered significant.
RESULTS
ASC identity
In several previous studies we have demonstrated that the adherent cells of the stromal vas-
cular fraction of human adipose tissue are ASC with properties similar to bone marrow MSC 
[5, 19, 21]. Thus ASC have a spindle-shaped fibroblastic morphology in culture, have a CD45-
CD73+CD105+CD166+HLAclass I+ immunophenotype and can differentiate in adipogenic and 
osteogenic lineages  [19] (data not shown).
Culture of ASC under hypoxic conditions
Under hypoxic conditions, cells are forced to switch to anaerobic metabolism and will pro-
duce lactate. In our model, ASC significantly increased lactate concentrations in the culture 
medium after 3 days of culture under hypoxic conditions (28.3mM, range 25-31, versus 
12mM, range 10-14, under normoxic conditions) (Figure 1A).Culture of ASC under hypoxic 
conditions (1% O2) for 24 h had no effect on mRNA expression levels of hypoxia-inducible 
factor 1-α (HIF1-α) and HIF2-α (Figure 1B). As hypoxia stabilizes HIF protein, we examined 
whether gene expression downstream of HIF was affected by hypoxia in ASC. Expression of 
(VEGF) downstream of HIF1-α was significantly increased under hypoxia by nearly a factor 
two (Figure 1C).
Effect of hypoxia on ASC characteristics
To study the effect of hypoxia on ASC characteristics; metabolic activity, survival, growth, and 
proliferation of ASC was examined. Culture of ASC under 1% O2 for 24 h up to 72h had no ef-
fect on ASC metabolic activity and there was no evidence for loss of cell viability, as measured 
by the mitochondrial reduction of MTT to formazan (Figure 2A). There was a similar increase 
in the conversion of MTT under normoxic and hypoxic conditions at 24 h up to 72 h, which re-
flects the similar increase in cellular metabolic activity under both conditions. Parallel culture 
of ASC under normoxic and hypoxic conditions for five consecutive weeks demonstrated no 
difference in population doubling times, which were 2.6 days (range 1.9-3.1), under normoxia 
and 2.5 days (range 1.9-5.0) under hypoxia. Therefore, cumulative population doublings were 
the same under both oxygen tensions (Figure 2B). Furthermore, there was no difference in 
the colony forming unit (CFU) capacity of ASC cultured under 20 and 1% O2 (Figure 2C), sug-
gesting oxygen tension does not affect the stemness of ASC. Finally, the immunophenotype 
of ASC was determined after 10 days of culture under normoxic or hypoxic conditions. Under 
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Figure 1. (A) Lactate production by ASC. ASC were cultured under 20 or 1% O2 for 3 days and medium 
collected for lactate measurements. Mean with SEM of three experiments is shown. (B) Effect of hypoxia 
on gene expression of hypoxia-inducible genes; mRNA expression of HIF1-α and HIF2-α by ASC after 
24h culture under normoxic (20% O2) and hypoxic (1% O2) conditions. Mean with SD of four different 
experiments is shown. (C) mRNA expression of VEGF, downstream of HIF1-α under normoxia and hypoxia. 
Mean with SD of four different ASC cultures, *Indicates p <0.05.
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Figure 2. Effect of hypoxia on ASC characteristics. (A) ASC metabolic activity measured by MTT assay. 
Mean with SEM of three different ASC cultures shown. (B) Cumulative population doublings of ASC 
cultured under normoxic and hypoxic conditions. (C) CFU efficiency of ASC. Mean with SEM of four 
different ASC cultures shown. (D) Immunophenotype of ASC after culturing for 10 days under normoxic 
and hypoxic conditions. Filled histogram; unstained ASC, solid line; ASC cultured under 20% O2, dotted 
line; ASC cultured under 1% O2. *Indicates p <0.05.
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both conditions, the ASC immunophenotype was CD45-CD73+CD105+CD166+HLA-I+HLA-II- 
(Figure 2D). The expression of CD105 was, however, significantly lower in ASC cultured under 
hypoxic conditions (MFI 2530) than in ASC cultured under normoxia (MFI 4215). 
Effect of hypoxia on the expression of immunomodulatory genes by ASC and IDO activity
It is known that the immunomodulatory capacity of ASC is induced under inflammatory 
conditions. This was confirmed in the present study by showing that treatment of ASC with 
IFN-γ and TNF-α for 6, 24 and 72 h induced a strong increase in the mRNA expression of 
immunomodulatory programmed death ligand 1 (PD-L1) (102-fold), CXCL10 (106-fold)  and 
IDO (105-fold). Under hypoxic conditions, ASC maintained the capacity to induce the expres-
sion of IDO, PD-L1 and CXCL10 in response to IFN-γ and TNF-α to a similar extent as under 
normoxic concentrations (Figure 3A-C). 
To determine whether hypoxia affected the tryptophan depleting activity of IDO in ASC we 
measured concentrations of L-kynurenine, the breakdown product of tryptophan, in condi-
tioned medium of ASC cultured for 24h or 72h with or without TNF-α and IFN-γ under 20 or 
1% oxygen. Culture with TNF-α and IFN-γ strongly increased L-kynurenine levels at 24 and 72 
h (Figure 3D and Figure 3E). Hypoxia did not affect L-kynurenine levels indicating preserved 
IDO activity under hypoxic conditions.
Furthermore, TGF-β, associated with the immunomodulatory capacity of ASC, was ex-
pressed by ASC under resting conditions and at similar levels upon stimulation with IFN-γ 
and TNF-α. Hypoxia did not affect TGF-β expression (data not shown). IL10 was not expressed 
by ASC under any of the conditions tested (data not shown). Pro-inflammatory IL6 was ex-
pressed by ASC, and its expression did not change under low oxygen conditions (data not 
shown). These data suggest that ASC maintain their capacity to express immunomodulatory 
factors and respond to inflammatory conditions by activating their immunomodulatory ap-
paratus under hypoxic conditions. 
Immunosuppressive capacities of ASC under hypoxia
To study whether hypoxia influences the in vitro immunosuppressive capacities of ASC, 
ASC were added to anti-CD3 and anti-CD28 stimulated PKH-labeled allogeneic PBMC. The 
proliferation of CD4+ and CD8+ T cells tended to be lower under hypoxia than under nor-
moxia, although the difference was not significant. Under normoxia, there was a significant 
inhibition of CD4+ and CD8+ T cell proliferation at ASC:PBMC ratios of 1:2.5 (Figure 4A-B). 
Under hypoxia, inhibition of T cell proliferation was more profound as T cell proliferation was 
significantly inhibited till ASC:PBMC ratios up to 1:5 (Figure 4A-B). Direct comparison of the T 
cell inhibition by ASC under normoxia and hypoxia demonstrated that inhibition of CD4+ and 
CD8+ T cell proliferation was significantly higher at a  1:5 under 1% oxygen level (Figure 4C-D). 
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Figure 3. Effect of hypoxia on the induction of PD-L1 (A), CXCL-10 (B), and IDO (C); mRNA expression in 
ASC after IFN-γ/TNF-α stimulation. ASC were cultured under 20 or 1% O2 for 6, 24, or 72h with or without 
50ng/ml IFN-γ and 20ng/mlTNF-α. Every data point represents a distinct ASC culture (n =4 different ASC 
cultures). (D,E) IDO activity determined by accumulation of L-kynurenine in ASC conditioned medium in 
the absence and presence of TNF-α and IFN-γ [24h (D) and 72h (E)]. Means of five ASC cultures with SEM 
shown.
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DISCUSSION
Adipose tissue-derived mesenchymal stem cells possess an assortment of properties that 
make them suitable for regenerative and immunomodulatory applications. The properties of 
ASC are affected by changing environmental conditions that induce ASC to adapt a particular 
function. Oxygen tension is one of these environmental factors. Oxygen tension in tissue 
fluctuates between 3% and 11% [22] and may be lower in case of trauma, and such changes 
may affect the function of ASC. In the present study, we cultured ASC under 20% and 1% 
oxygen to examine whether oxygen tension would affect the in vitro properties of ASC. 
In the present study we found that ASC were resistant to hypoxic conditions and detected 
no signs of toxicity or decreased CFU efficiency under low oxygen concentrations. There is 
some controversy on the effect of hypoxia on the proliferation of bone marrow and adipose 
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Figure 4. (A–D) PBMC were labeled with PKH and stimulated with anti-CD3/CD28 antibodies. On day 3, 
the proliferation of CD4+ and CD8+ T cells was analyzed by flow cytometry. (A,B) percentage proliferating 
cells shown. (C,D) percentage inhibition of proliferation shown, compared to the condition without ASC. 
Mean with SEM of three experiments with different ASC cultures shown, *p-value<0.05.
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tissue-derived MSC, with some studies reporting an inhibitory effect of low oxygen levels on 
proliferation [23-25], others reporting increased proliferation [26], while we found that ASC 
proliferation was not affected over at least five passages. There are a number of factors that 
may influence the outcome of studies, such as the percentage of oxygen used to generate 
hypoxic conditions with some studies using 1% oxygen and others up to 5%. Furthermore, 
the composition of the cell culture medium, in particular the use of serum, and the species of 
ASC used will affect outcomes. In the present study, the immunophenotype of ASC was only 
moderately affected by hypoxia, which is in line with earlier studies [24, 25]. In our hands, 
only the expression of CD105 (endoglin) was consistently down regulated under low oxygen 
tension. This is quite surprisingly, as CD105 is known to be up regulated under hypoxia in en-
dothelial cells [27]. The consequence of the down regulation of CD105, which is an adhesive 
molecule and part of the TGFβ receptor complex remains to be determined.
In the current study, we further found that a hypoxic pre-conditioning regimen does not 
hamper the immunosuppressive properties of ASC. The immunosuppressive function of 
ASC is induced by inflammatory cytokines such as IFN-γ and TNF-α [18, 28]. These cytokines 
stimulate the expression of anti-proliferative IDO and of the inhibitory co-stimulatory mol-
ecule PD-L1. The induction of these proteins and the activity of IDO were not affected by 
hypoxic conditions, indicating that the immunosuppressive machinery of ASC is maintained 
at low oxygen concentrations. In addition, the strongly enhanced expression of the chemo-
kine CXCL10 under inflammatory conditions was not affected by hypoxia, suggesting that 
the chemoattractive properties of ASC for immune cells are preserved under low oxygen 
concentrations. 
Subsequently, we found that culture under 1% O2 did not hinder the suppressive effects of 
ASC on T cell proliferation. The percentage of inhibition of t cells by ASC was even increased 
under hypoxia. Thus although ASC under hypoxia were phenotypically indifferent from ASC 
under normoxic conditions, they had a more profound effect on T cell proliferation. One ex-
planation could be that hypoxic conditions shift the balance between T cell proliferation and 
the inhibitory effect of ASC. Thus while T cells are affected in their proliferation by hypoxia, 
as demonstrated earlier [29] and shown in the present study, ASC maintain their suppres-
sive capacity. It is possible that under hypoxic conditions, T cells are more sensitive to low 
tryptophan concentrations induced by IDO expression in ASC or by PD-L1 induced inhibition 
of proliferation. ASC therefore have a relatively larger impact on inflammatory conditions 
and are more effective in inhibiting immune responses under hypoxic conditions, such as in 
case of trauma, than under normoxic conditions. Alternatively, the enhanced efficacy of ASC 
to inhibit T cell proliferation under hypoxia may be explained by the fact that ASC employ 
additional mechanisms of immunomodulation under hypoxic conditions that were not 
analyzed in the present study. 
In summary, our data indicates that a reduction of oxygen tension up to at least 1% does 
not hamper the immunomodulatory therapeutic efficiency of ASC. This is of relevance as for 
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most clinical purposes, the immunosuppressive capacities of ASC are essential. Assertion 
of these capacities under hypoxia is crucial as ASC will encounter hypoxic conditions when 
administered for most, if not all, immunomodulatory applications. Subsequently, as there 
is evidence that hypoxic pre-conditioning enhances the regenerative potential of ASC [30, 
31], maintenance of immunosuppressive capacities under hypoxia is needed when hypoxia 
pre-conditioning will be used for regenerative application. The present study shows that in 
these situations, the immunomodulatory capacity of ASC is preserved.
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ABSTRACT
Introduction
For clinical applications, Mesenchymal Stromal Cells (MSC) can be isolated from bone marrow 
and adipose tissue of autologous or allogeneic origin. Allogeneic cell usage has advantages 
but may harbor the risk of sensitization against foreign HLA. Therefore, we evaluated whether 
bone marrow and adipose tissue-derived MSC are capable of inducing HLA-specific alloreac-
tivity. 
Methods
MSC were isolated from healthy human Bone Marrow (BM-MSC) and adipose tissue (ASC) 
donors. Peripheral Blood Mononuclear Cells (PBMC) were co-cultured with HLA-AB mis-
matched BM-MSC or ASC pre-cultured with or without IFNy. After isolation via FACS sorting, 
the educated CD8+ T effector populations were exposed for 4 hours to Europium labeled 
MSC of the same HLA make up as in the co-cultures or with different HLA. Lysis of MSC was 
determined by spectrophotometric measurement of Europium release.
Result
CD8+ T cells educated with BM-MSC were capable of HLA specific lysis of BM-MSC. The 
maximum lysis was 24% in an effector: target (E:T) ratio of 40:1.  Exposure to IFNγ increased 
HLA-I expression on BM-MSC and increased lysis to 48%. Co-culturing of PBMC with IFNγ-
stimulated BM-MSC further increased lysis to 76%. Surprisingly, lysis induced by ASC was 
significantly lower. CD8+ T cells educated with ASC induced a maximum lysis of 13% and 
CD8+ T cells educated with IFNγ-stimulated ASC of only 31%. 
Conclusion
Allogeneic BM-MSC, and to a lesser extend ASC, are capable of inducing HLA specific re-
activity. Our results suggest that clinical therapy with allogeneic MSC should be carefully 
considered.
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INTRODUCTION
Mesenchymal stromal cells (MSC) are adult stem or progenitor cells which can be isolated 
from virtually all postnatal tissues including bone marrow and adipose tissue[1-3]. MSC are 
defined by their capacity to adhere to plastic, their multilineage differentiation capacity and 
a panel of cell surface markers including CD13, CD73, CD90 , CD105, CD166 and HLA-class I 
[1, 4]. HLA-class-II expression on MSC is low or absent. MSC have immune modulatory and 
reparative properties which makes them appealing as a cell therapeutic agent for degenera-
tive disease and immune disorders. When exposed to inflammatory conditions such as IFNγ 
stimulation, MSC increase their immunosuppressive properties but also their expression of 
HLA-class I and II[5, 6].  
In the last decades, multiple clinical trials evaluating the potential of MSC for a wide 
spectrum of medical conditions have been conducted. Next to safety and feasibility of MSC 
therapy, preliminary efficacy results were obtained in some of these studies evaluating MSC 
amongst others in rheumatoid arthritis[7, 8]; Crohn’s disease[9, 10]; liver cirrhosis[11] and 
solid organ transplantation[12-15]. 
For clinical application, the choice of MSC is likely to affect the outcome of the therapy.
MSC are typically isolated from bone marrow and culture expanded. As donor age might 
be of influence for bone marrow derived MSC (BM-MSC) composition and function[16-18], 
use of MSC derived from young bone marrow donors might be preferable. Yet, this choice has 
some drawbacks as bone marrow aspiration is an invasive procedure and the use of BM from 
young individuals involves ethical dilemmas. Adipose tissue derived MSC (ASC) might serve 
as an alternative with several advantages: adipose tissue can be obtained in a minimal inva-
sive manner via lipectomy or mini liposuction; adipose tissue has a higher yield of MSC[19]; 
and finally, ASC are at least as immunosuppressive as BM-MSC in vitro[20, 21].
Next, there is a choice of using MSC of autologous or allogeneic origin. Allogeneic cells 
provide a practical ‘off the shelf’ cell therapeutic agent as they can be isolated and cultured 
in advance. Recent studies suggest that allogeneic MSC have comparable efficacy compared 
to autologous MSC [22, 23]. However, allogeneic MSC might possibly elicit an anti-HLA im-
mune response [24]. In contrast, autologous MSC avoid potential immunogenic responses, 
but need to be prepared per individual and are unsuitable for acute indications. Furthermore, 
although suitable in some situations[25, 26], patient MSC can be affected by the disease 
rendering them unfit for clinical application[27, 28]. In contrast, allogeneic cells provide a 
practical ‘off the shelf’ cell therapeutic agent as they can be isolated from healthy donors 
and cultured in advance. Recent studies further suggest efficacy of allogeneic MSC therapy 
[22, 23]. However, allogeneic MSC might elicit a HLA-specific immune response [24]. The risk 
of anti-HLA sensitization by allogeneic MSC has been considered insignificant in the past as 
MSC were suggested to be low-immunogeneic[29-32]. However, we have shown that alloge-
neic MSC are susceptible for lysis by pre-activated CD8+ T cells[33] in an HLA-specific fashion, 
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which challenges this old paradigm. It is however unknown whether MSC themselves are 
capable of inducing HLA-specific CD8+ cytotoxicity. This would signify a risk of sensitization 
by allogeneic MSC therapy and could potentially affect the efficacy of repeated MSC adminis-
trations or even future organs transplantations. The development of anti-MSC donor immune 
responses should therefore be studied before new studies are planned with allogeneic MSC. 
Thus, in the present study we evaluated whether repeated exposure to BM-MSC and/or ASC 
induced HLA-class-I specific lysis by CD8+ T cells.
METHODS
Isolation of ASC
During live donor kidney transplantation, abdominal subcutaneous adipose tissue was surgi-
cally removed from 5 healthy kidney donors after written informed consent as approved by 
the medical ethical committee of the Erasmus Medical Center Rotterdam (protocol no. MEC-
2006-190). Adipose tissue was collected in MEM-α medium (Sigma-Aldrich(St. Louis, MO, 
USA) supplemented with 100IU/ml penicillin and 100μg/ml streptomycin (p/s, Gibco BRL, 
Paisley UK) and 2mM L-glutamine (Lonza, Verviers, Belgium),. ASC were isolated as described 
previously[1]: adipose tissue was mechanically disrupted with a scalpel knife, and then enzy-
matically digested with 0.5mg/ml collagenase type IV (Sigma-Aldrich, St Louis, MO) in RPMI-
1640 glutaMAX (Invitrogen) and p/s for 30 minutes at 37°C under continuous shaking. The 
obtained cell suspension was transferred to a T175 cm2 culture flask (Greiner Bio-one, Essen, 
Germany) and cultures were kept at 37°C, 5% CO2 and 95% humidity. MSC culture medium 
which consisted of MEM-α (Sigma-Aldrich, St. Louis, MO, USA) with 1% p/s, 2nM L-glutamine 
and 15% fetal bovine serum (BioWhittaker, Verviers, Belgium) was refreshed twice a week.
When ASC cultures reached >90% confluency, MSC were detached with 0.5% trypsin-EDTA 
(Lonza, Verviers, Belgium) and used for experiments or frozen at -150°C until usage
Isolation of BM-MSC
BM was obtained from 5 hematopoietic stem cell donors after written informed consent as 
approved by the Medical Ethical Committee of Leiden University Medical Centre as described 
before[34]. In brief, BM was aspirated under general anesthesia. The mononucleated cell 
(MNC) fraction was isolated by Ficoll density gradient separation (Ficoll Isopaque, δ=1.077, 
Amersham, Uppsala, Sweden) and plated in tissue culture flasks at a density of 160 x 103 
MNC/cm2 in low-glucose Dulbecco’s modified Eagle medium DMEM (Invitrogen, Paisley, 
UK) supplemented with 1% p/s (Lonza) and 10% fetal calf serum (FCS, Thermo Scientific 
HyClone,). The cultures were maintained at 37°C, 5% CO2. The medium was refreshed twice 
a week. When the MSC cultures became confluent, cells were collected using trypsin (Lonza) 
and re-plated at a density of 4 x 103 cells/ cm2 or frozen until further usage.
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BM-MSC and ASC donor characteristics
MSC isolated from 5 healthy HLA-AB mismatched bone marrow (mean age 15.4 years, range 
7-31) and adipose tissue donors (mean age 50.7 years, range 27-67) (table 1) were used for 
experiments. Prior to using them in experiments, BM-MSC and ASC were cultured in parallel 
in MEM- with 1% p/s and 15% fetal bovine serum under standard culture conditions. When 
indicated, MSC were then stimulated with 100 ng/ml IFNγ for 1 week. Passage 2-6 MSC were 
used. 
Isolation of peripheral blood mononuclear cells (PBMC)
Peripheral blood was collected from healthy blood bank donors. Donors with 4 mismatches 
for HLA-A and HLA-B with the BM-MSC and ASC were selected (table 1). PBMC were isolated 
by density gradient centrifugation using Ficoll Isopaque and frozen at -150°C until usage. 
Immunophenotypic characterization of BM-MSC and ASC
Unstimulated and 1 week 100ng/ml IFNγ-stimulated BM-MSC and ASC were trypsinized 
and washed with FACSFlow (BD Biosciences, San Jose, CA). Cell suspensions were incubated 
with mouse-anti-human monoclonal antibodies against CD13-PECy7; CD45-PERCP; HLA-DR-
FITC; HLA-ABC-PE-Cy7; CD31-FITC; CD73-PE; CD166-PE (all BD Biosciences); CD90-APC and 
CD105-FITC (R&D Systems, Abingdon, UK) at room temperature in the absence of light for 15 
Table 1: HLA typing of BM-MSC, ASC and PBMC used in the 5 experiments.
No BM-MSC/ASC HLA-I HLA-I
A A B B
1 BM-MSC 1 1 3 7 35
ASC 1 24 15 51
PBMC 1 32(19) 44(12) 18
2 BM-MSC 2 3 24(9) 35 38(16)
ASC 2 1 30(19) 8 41
PBMC 2 68(28) 51 (5) 53
3 BM-MSC 3 24(9) 62(15) 55(22)
ASC 3 11 30(19) 52(5) 35
PBMC 3 1 3 8 64(40)
4 BM-MSC 4 2 29(19) 7 44(12)
ASC 4 1 26(10) 38(16) 51(5)
PBMC 4 3 23 49 61
5 BM-MSC 5 2 24(9) 35 58(17)
ASC 5 3 7 13
PBMC 2 68(28) 51 (5) 53
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Figure 1: Experimental design of study. Five HLA-class I mismatched BM- MSC and ASC pairs were used. 
BM-MSC and ASC were either unstimulated or pre-stimulated for 1 week with IFNγ. To obtain educated 
CD8+ T cells, a co-culture was established with BM-MSC or ASC and HLA-class I mismatched PBMC in the 
presence of 200 U/ml IL-2. CD3+CD8+ effectors (BM-MSC educated CD8+ T cells; IFNγ-BM-MSC educated 
CD8+ T cells; ASC educated CD8+ T cells and IFNγ-ASC educated CD8+ T cells) were selected via FACS 
sorting. CD3+CD8- cells were isolated from all co-cultures as a negative control. After Europium labeling, 
target cells, either IFNγ-stimulated or unstimulated BM-MSC and ASC, were exposed to the effector cells 
as depicted here for BM-MSC educated CD8+ T cells. Europium release was assessed as a measure of CD8+ 
T cell mediated lysis.
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minutes. After two washes with FACSFlow, flow cytometric analysis was performed using an 
8 color FACSCANTO-II with FACSDIVA Software (BD Biosciences) and FlowJo Software (Tree 
Star Inc. Palo Alto, CA). For analysis, background MFI was substracted and the mean MFI of 4 
experiments were calculated.
Generation of BM-MSC and ASC educated CD8+ effector populations
Five BM-MSC and ASC cultures with different HLA-A and HLA-B subtypes were selected (table 
1). These BM-MSC and ASC were cultured in parallel under the same conditions for 1 week 
with or without 100ng/ml IFNγ before they were seeded in 24-well flat bottom plates. PBMC 
with a 2-2 mismatch for HLA-A and HLA-B with both the BM-MSC and the ASC were then 
selected. To generate effector cells, 5 x 105 PBMC were co-cultured with 1,2 x 10 6 BM-MSC 
or, in parallel, with the ASC in MEMα containing 10% of human heat inactivated serum and 
200IU/mL IL-2 (Chiron, Amsterdam, The Netherlands). After 1 week of co-culture, the PBMC 
were removed from the co-cultures, washed with 1X PBS and incubated with mononuclear 
antibodies against CD3-Amcyan, CD8-PE-Cy7 and 7AAD-viaprobe (all BD Biosciences) for 
15 minutes in the dark. The cells were washed and the BM-MSC and ASC educated effector 
CD3+CD8+ cell populations were isolated by FACS sorting (FACS-ARIA Cell-sorter, BD Biosci-
ences). 
This procedure resulted in the isolation of the following effector populations: CD3+CD8+ 
cells educated by BM-MSC (BM-MSC educated CD8+ T cells); CD3+CD8+ cells educated by 
IFNγ-stimulated BM-MSC (IFNγ-BM-MSC educated CD8+ T cells); CD3+CD8+ cells educated 
by ASC (ASC educated CD8+ T cells) and CD3+CD8+ cells educated by IFNγ-stimulated ASC 
(IFNγ-ASC educated CD8+ T cells); as a control, the CD3+CD8- populations were isolated from 
all four co-cultures. Our experimental design is depicted in figure 1.
Evaluation of cytotoxicity mediated lysis of BM-MSC and ASC by Europium release assay
To examine the cytotoxic capacity of the CD3+CD8+ effector T cells, BM-MSC and ASC identi-
cal to those used in the co-cultures were cultured for 1 week in the presence or absence 
of 100ng/ml IFNγ and labeled with Europium–diethylenetriaminepentaacetate (DTPA) 
(Sigma-Aldrich, St. Louis, MO) (figure 1). These target MSC were used in the Europium release 
cytotoxicity assay as described previously[33]. In brief, the different effector populations 
were exposed for 4 hours to each of the different Europium labeled targets cells; unstimu-
lated BM-MSC; IFNγ-stimulated BM-MSC; unstimulated ASC and IFNγ-stimulated ASC. The 
effectors were incubated with 2500 target cells at effector: target (E:T) ratios of 40:1 to 
0.3:1 in round-bottom 96-well plates (Nunc, Roskilde, Denmark) at 37°C. The plates were 
then centrifuged and 20μl of the supernatant was transferred to 96-well plates with low 
background fluorescence (fluoroimmunoplates [FluoroNunc plates]; Nunc). Subsequently, 
100μl of enhancement solution (PerkinElmer, Groningen, the Netherlands) was added to 
each well and release of Europium was measured in a time-resolved fluorometer (Victor 
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1420 multilabel counter; LKB-Wallac, Turku, Finland). Maximal release of Europium by target 
cells was measured by incubation of 2500 labeled target cells with 1% Triton (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) for 4hr. Spontaneous release of Europium was measured by 
incubation of labeled target cells without effector cells for 4hr; the percentage leakage was 
calculated as (spontaneous release/maximal release)x100%. The percentage cytotoxicity 
mediated lysis was calculated as %lysis = (measured lysis-spontaneous release)/(maximal 
release- spontaneous release)x100%.
Statistical analysis
Paired t-test was used to test for statistical significance in MFI of the staining for cell surface 
markers on BM-MSC and ASC. Two-way ANOVA was used to evaluate statistical significance of 
differences in lysis of different target populations and by the CD8+ T effector cells and CD8- T 
cell control populations. Significant lysis was defined as lysis of a target cell by a certain CD8+ 
T effector population which was significantly higher than the background lysis of the CD8- 
negative control T cell population.
RESULTS
BM-MSC and ASC immunophenotype
Cell surface marker expression was analyzed by flow cytometry using a characterization panel 
for MSC. Both BM-MSC and ASC expressed CD13; CD73; CD90; CD105; CD166 and HLA-ABC 
and were negative for HLA-DR; CD31 and CD45, confirming their MSC immunophenotype 
(figure 2A). 
Expression of HLA-class I was upregulated in BM-MSC and ASC after IFNγ stimulation (figure 
2B). IFNγ stimulation did not affect MSC cell surface marker expression on ASC. In BM-MSC, 
only CD13 was slightly upregulated after IFNγ stimulation (data not shown). 
BM-MSC induce HLA-class I specific lysis by CD8+ T cells
To evaluate the capacity of BM-MSC to induce CD8+ T cell mediated lysis, CD8+ T effector cells 
were isolated via FACS sorting after one week of co-culture of PBMC with HLA-AB mismatched 
BM-MSC. BM-MSC educated CD8+ T effector cells were capable of lysing Europium labeled 
BM-MSC identical to the one used in the co-culture (figure 3A). Lysis was dose dependent and 
reached a maximum of 24% (mean, range 13-37%) at a 40:1 effector: target (E:T) ratio, which 
was significantly higher than lysis by CD8- T cells (figure 3B). IFNγ stimulation of BM-MSC 
targets further increased lysis to 48% (mean, range 25-80%, figure 3A). In contrast, when 
BM-MSC-educated CD8+ T cells were exposed to IFNγ-stimulated or unstimulated ASC with a 
different HLA make-up, no lysis was detected (figure 3A) indicating that the BM-MSC induced 
lysis was HLA-class I specific. 
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Figure 2A: Flow cytometric immunophenotyping of BM-MSC and ASC. BM-MSC (black solid lines) 
and ASC (black dotted lines) expressed MSC markers CD13, CD73, CD90, CD105, CD166 and HLA-ABC 
and were negative for HLA-DR, CD31 and CD45. No significant differences were detected. Grey solid 
histograms represent unstained control, n=4, representative examples are shown. 
Figure 2B: IFNγ stimulation resulted in upregulation of 
HLA-class I expression on BM-MSC and ASC, mean MFI 
of n=5, * indicates p<0.05. 
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IFNγ stimulation increases BM-MSC induced lysis 
CD8+ T effector cells were educated with IFNγ-stimulated BM-MSC to study the effect 
of inflammatory conditions on the induction of CD8+ T cell mediated lysis. IFNγ-BM-MSC 
educated CD8+ T cells induced 76% lysis of IFNγ-stimulated target BM-MSC (mean, range 
58-91%) (figure 3C3c), which was significantly higher than the lysis induced by unstimulated 
BM-MSC (figure 3a). No lysis of ASC with different HLA was observed (figure 3C) confirming 
the HLA-class I specific character of the lysis.
ASC induce less lysis compared to BM-MSC 
Next, we studied the capacity of ASC to induce CD8+ T cell mediated lysis. Educated CD8+ 
T effector cells were generated by co-culturing ASC and mismatched PBMC. In contrast to 
BM-MSC educated CD8+ T cells, which significantly lysed BM-MSC, ASC- educated CD8+ T 
cells were only capable of lysing ASC when target ASC were pre-stimulated with IFNγ (mean 
13%, range 4-21, figure 4A). This lysis of IFNγ-stimulated ASC target cells was significantly 
lower than the lysis of IFNγ-stimulated BM-MSC targets (fig 3Aby BM-MSC-educated CD8+ T 
cells (figure 3a).
IFNγ stimulation increases ASC induced lysis
Finally, to evaluate the influence of inflammatory conditions on  ASC on their capacity to 
induce CD8+ cytotoxicity, PBMC were co-cultured with IFNγ-stimulated mismatched ASC. 
The IFNγ-ASC educated CD8+ T cells were capable of significant lysis of IFNγ-stimulated 
ASC targets (mean lysis of 31%, range 19-51%, figure 4C) and not of the mismatched IFNγ-
stimulated BM-MSC (figure 4C). These data confirm the HLA-class I specificity of ASC induced 
lysis and further denote an effect of IFNγ stimulation on the ASC induced CD8+ mediated 
lysis, as also seen in the experiments performed with BM-MSC. However, the maximum lysis 
of 31% IFNγ stimulated ASC by IFNγ-ASC educated CD8+ T cells was substantially lower than 
the maximum lysis of 76% of IFNγ-stimulated BM-MSC by IFNγ-BM-MSC educated CD8+ T 
cells. Therefore, these results indicate a lower capacity of IFNγ-stimulated ASC to induce 
CD8+ cytotoxity compared to IFNγ-stimulated BM-MSC. 
DISCUSSION
Currently, MSC have been applied in several clinical studies. Some of these studies indicated 
a clinical effect of MSC while others could not confirm MSC efficacy [12, 35-37]. These contra-
dicting outcomes might be explained by a great variety in MSC preparations. MSC of bone 
marrow or adipose tissue and of autologous as well as allogeneic origin have been used. The 
effect of these differences in MSC preparation on study outcome is currently unknown. To 
decide on the use of allogeneic or autologous MSC, more knowledge on immunogenicity 
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of allogeneic MSC is required and potential differences between bone marrow and adipose 
tissue derived MSC need to be evaluated. 
The use of allogeneic MSC has several benefits. It can be used as an ‘off the shelf’ therapy 
and recent studies suggest that allogeneic MSC can provide an effective treatment[22, 23] 
And, as several preclinical studies found MSC to be low immunogeneic [29-32], it has been 
suggested that allogeneic MSC can be used without risk for sensitization. However, other 
studies showed that allogeneic MSC are susceptible for lysis by CD8+ T cells[38] and NK cells 
[38, 39] and can induce memory T cells [40-42] and the production of IgG antibodies[43], 
which argues against a low-immunogeneic profile of MSC. In the current study we investi-
gated whether MSC are capable of inducing HLA-class I specific CD8+ T cell cytotoxicity. We 
tested this for the most commonly used bone marrow derived MSC as well as adipose derived 
MSC, which are an important alternative. 
In this study, we generated educated CD8+ T cells by co-culturing BM-MSC with HLA-AB 
mismatched PBMC, simulating the first exposure of allogeneic MSC to the recipient immune 
system. Next, we challenged those educated CD8+ effector T cells with MSC from the same 
donor that were used in the co-culture, to mimic a second exposure to MSC, or with MSC from 
an allogeneic HLA-AB mismatched donor. In this system, we found BM-MSC capable of induc-
ing of HLA-class I specific lysis of allogeneic BM-MSC. This indicates that though allogeneic 
BM-MSC can be immunosuppressive in vitro [29], activation of the adaptive immune system 
by BM-MSC is not prevented by this anti-proliferative effect. 
When used for treatment of inflammatory disease, MSC might face an inflammatory 
environment. Inflammatory conditions, which can be simulated with IFNγ, increase the im-
munosuppressive potential of MSC [6, 44]. However, in accordance with others [5], we found 
that BM-MSC and ASC also increase their expression of HLA-class I upon IFNγ stimulation. 
This upregulation could influence the induction of CD8 cytotoxicity as this is a HLA-class I 
restricted process. Thus, we used CD8+ T cells educated with IFNγ-stimulated BM-MSC and 
found that the lysis of IFNγ-stimulated BM-MSC was increased. This implies that inflammatory 
conditions in vivo might increase the immunogenicity of BM-MSC.
Next, we evaluated the immunogenicity of ASC. ASC are arising as an alternative for BM-
MSC as they have several favorable characteristics: adipose tissue is easy to obtain and has 
a high yield of MSC; further, ASC are at least as immunosuppressive in vitro as BM-MSC[20, 
21]. Surprisingly, we found that ASC were not capable of inducing CD8+ T cell mediated lysis. 
Significant lysis was only detected when ASC targets were IFNγ-stimulated. This indicates a 
less immunogeneic profile of ASC compared to BM-MSC as BM-MSC did induce significant 
CD8+ T cell mediated lysis. When using IFNγ-stimulated ASC to educate the CD8+ T cells, 
an increase in lysis of ASC was observed. However, this lysis was again markedly lower than 
the lysis induced by IFNγ-stimulated BM-MSC, confirming the less immunogeneic profile of 
ASC. We hypothesized that this difference in immunogenicity could be the result of levels 
of HLA-class I expression. Yet, although BM-MSC showed a higher fold increase in HLA-class 
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I expression upon IFNγ stimulation, HLA-class I levels were lower in unstimulated BM-MSC 
compared to ASC. Another potential explanation for the difference in lysis induced by BM-
MSC and ASC might be found in the differences in age of BM-MSC and ASC donors used 
in this study. Age has been suggested to be of relevance for the differentiation capacity 
and composition of BM-MSC [16, 17]. However the proliferation rate of ASC was found to 
be unaffected by age [45] and the effect of age on other properties of BM-MSC and ASC 
such as the immunosuppressive capacity  as well as their immunogeneic potential remains 
to be determined. Finally, the difference in immunogenicity between BM-MSC and ASC can 
be explained by for instance a difference in the expression of lysis inhibiting proteins such as 
serpins remains to be determined. 
Taken together, our results indicate that BM-MSC and ASC can induce anti HLA sensitiza-
tion. Whether this property will translate into sensitization when MSC are infused in vivo is 
unknown. It can be questioned whether MSC reside long enough after infusion to initiate 
this immune response [46]. Yet, the potential of MSC to induce anti HLA sensitization as 
described in this study plea for the use of autologous MSC treatment if possible and a careful 
consideration when applying allogeneic MSC. In particular situations, the use of allogeneic 
MSC is preferable such as in situations of acute organ failure or in cases when the patients’ 
disease affect MSC functionality. In those situations, the risk of allogeneic MSC therapy can 
possibly be reduced by choosing a low risk study design e.g. using allogeneic MSC which are 
mismatched with the organ donor and screening of MSC recipients for absence of anti-donor 
reactivity prior to MSC treatment and monitoring for the development of anti-MSC donor 
immune responses after MSC treatment.
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ABSTRACT
Mesenchymal stem cells are a potential therapeutic agent in renal disease and kidney 
transplantation. Autologous cell use in kidney transplantation is preferred to avoid anti-HLA 
reactivity; however, the influence of renal disease on mesenchymal stem cells is unknown. 
To investigate the feasibility of autologous cell therapy in patients with renal disease, we 
isolated these cells from subcutaneous adipose tissue of healthy controls and patients with 
renal disease and compared them phenotypically and functionally. The mesenchymal stem 
cells from both groups showed similar morphology and differentiation capacity, and were 
both over 90% positive for CD73, CD105, and CD166, and negative for CD31 and CD45. 
They demonstrated comparable population doubling times, rates of apoptosis, and were 
both capable of inhibiting allo-antigen- and anti-CD3/CD28-activated peripheral blood 
mononuclear cell proliferation. In response to immune activation they both increased the 
expression of pro-inflammatory and anti-inflammatory factors. These mesenchymal stem 
cells were genetically stable after extensive expansion and, importantly, were not affected 
by uremic serum. Thus, mesenchymal stem cells of patients with renal disease have similar 
characteristics and functionality as those from healthy controls. Hence, our results indicate 
the feasibility of their use in autologous cell therapy in patients with renal disease.
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INTRODUCTION
Mesenchymal stem or stromal cells (MSC) are multipotent fibroblastic cells that can be de-
rived from bone marrow and many other tissues including adipose tissue [1-3]. In culture, 
MSC are rapidly proliferating, adherent cells, showing a spindle-shaped morphology. They 
have colony forming capacity and the ability to differentiate into osteoblasts, chondrocytes 
and adipocytes [4]. There is no specific MSC marker and according to the criteria of the 
International Society of Cellular Therapy (ISCT), cultured MSC are characterized by a CD14-, 
CD45-, HLA-DR-, CD73+, CD90+, CD105+ phenotype[5]. In addition, they express CD13, CD166, 
HLA class I and lack the endothelial marker CD31. Recently, it is reported that freshly isolated 
adipose tissue derived MSC are initially CD34+ and increasingly express ISCT MSC markers 
after culture expansion [6].
MSC can modulate the immune system by inhibition of mitogen and allo-activated lym-
phocyte proliferation [7-9]. This effect is to a large extent dependent on soluble factors. MSC 
inhibit lymphocyte proliferation via the secretion of TGF-β, IL-10, nitric oxide (NO), HLA-G and 
hepatocyte growth factor (HGF) [7, 10-12] and the expression of indoleamine 2,3-dioxygen-
ase (IDO) [13]. MSC furthermore secrete trophic factors that stimulate vasculogenesis and 
angiogenesis and aid tissue regeneration [14]. 
As a result, MSC receive a lot of interest in many medical fields as a cellular therapy. Cur-
rently, MSC therapy is subject of 216 registered clinical trials (http://clinicaltrials.gov, Febru-
ary, 2012). 
In renal disease, patients may profit from the repair capacity and immunomodulatory 
potential of MSC [15]. In kidney transplantation, MSC therapy could find use as an induction/
immunosuppressive therapy [16-19] and for repair of ischemia reperfusion injury.
There is a choice of MSC tissue source for therapeutic applications. While most studies have 
used MSC from bone marrow origin, adipose tissue has an advantage above bone marrow 
as it is obtainable in a less invasive manner and large numbers of cells can be cultured in less 
time. Another critical choice is whether to use MSC of autologous or allogeneic origin. In a 
(pre-) transplant setting it is crucial to avoid induction of HLA reactivity against a potential 
future donor and therefore exposure to allogeneic MSC is to be avoided. Autologous adipose 
tissue-derived MSC are thus the preferred choice of cells for use in renal disease and (pre-) 
transplant patients.
Although RD is known to affect the immune system [20], it is reported that functional regu-
latory T cells can be obtained from uremic patients [21]. However, it is unknown whether re-
nal impairment affects the functionality of MSC. In patients with immune thrombocytopenic 
purpura, systemic lupus erythematosus, rheumatoid arthritis and aplastic anemia, numbers 
and/or functionality of MSC were reported to be impaired [22-25], whereas no influence of 
disease on MSC was found in multiple sclerosis and Crohn’s disease [26-28]. 
There is a need to clarify whether MSC derived from RD patients are of the same quality as 
those obtained from healthy controls in order to determine whether it is safe and feasible to 
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use autologous MSC for RD and kidney transplant patients. Besides the influence of RD on the 
intrinsic properties of MSC, uremic conditions found in these patients may have an impact 
on MSC functionality as well. There is evidence that uremia affects endothelial progenitor cell 
differentiation and number [29, 30], but it is unknown whether uremia affects MSC function-
ality. Analysis of the effect of uremic conditions on MSC may predict the efficacy of MSC after 
administration to renal disease patients.
This is the first study reporting the effect of uremic conditions on human MSC functionality. 
Furthermore, we isolated adipose tissue-derived MSC from RD patients and healthy controls 
and compared their expansion potential and differentiation and immunomodulatory 
capacity. In addition, the genetic stability of MSC of renal disease patients in culture was 
investigated. 
RESULTS
MSC isolation
Cultures of MSC were established by plating adipose tissue derived cell suspension in culture 
flasks. After 3 days, non-adherent cells were removed. MSC were successfully isolated from all 
16 healthy controls (MSC-HC) and 16 renal disease patients (MSC-RD). MSC donor character-
istics are depicted in table 1. Renal disease patients received standard of care medication for 
renal insufficiency. Additionally used medications are listed in the table. 
Phenotypical characteristics of MSC
Morphology
MSC-HC and MSC-RD cultured in standard culture medium showed a similar spindle shaped 
morphology (Figure 1a).  
Immunophenotype
The immunophenotype of MSC-HC and MSC-RD was characterized by flow cytometric analy-
sis. In the freshly isolated cell fraction, we selected the HLA-ABC+CD45-CD31- fraction to ob-
tain the non-hematopoietic, non-endothelial cell fraction and the CD34+CD73+ population 
to study the MSC. These fresh MSC further showed CD90 expression and CD105 and CD166 
were expressed at low levels. There was no difference between the immunophenotype of 
freshly isolated MSC-HC and MSC-RD (figure 1b). 
After culture expansion, MSC cell surface markers CD13, CD73, CD105, CD90 and CD166 
were expressed in over 95% of MSC-HC and MSC-RD (figure 1c). CD31, CD34 and CD45 were 
absent, while HLA-DR was expressed at a low level. No differences between the immunophe-
notypes of cultured MSC-HC and MSC-RD were detected.
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Table 1 Characteristics of mesenchymal stem cell donors (healthy controls and renal disease patients) at 
time of sampling the adipose tissue
Healthy controls
n=16
Renal Disease patients
n=16
Gender (f/m) 10/6 6/10
Age, year (mean, range) 54.5 (25-73) 56.2 (26-72)
BMI  (mean, range) 29.8 (22-38) 27.1 (20-31)
Creatinine, μmol/L  (mean, range) 76 (65-95) 757 (240-1536)
GFR, mL/min/1.73 m2 (mean, range)a 76.8 (63->90) 10.3 (8-17)b
Renal replacement therapy (RRT) (ND/PD/HD) (16/0/0) (6/8/2)
Duration of RRT (months, range)c NA 16.2 (8.4-30.3)
Diabetes Mellitusd 0/16 4/16
Hypertensione 3/16 16/16
Medication usef
anti-hypertentive drugs 3/16 16/16
erythropoiesis-stimulating agents 0/16 9/16
antiplatelet drugs 1/16 5/16
cholesterol lowering drugs 0/16 4/16
prednisone 0/16 2/16
insuline 0/16 2/16
KTx indication NA
Nephrosclerosis 6
Focal segmental glomerulosclerosis 2
Medullary cystic kidney disease 1
Adult-onset polycystic kidney disease 1
Rapidly progressive glomerulonephritis 1
Henoch-Schonlein purpura 1
IgA nephropathy 1
Membranous glomerulopathy 1
Diabetic nephropathy 1
Renal insufficiency e.c.i. 1
Abbreviations: BMI, body mass index; GFR, glomerular filtration rate; HD, hemodialysis; KTx, kidney 
transplantation indication; NA, not applicable; ND, no dialysis; PD, peritoneal dialysis; RRT, renal 
replacement therapy. aGFR was calculated with the Modification of Diet in Renal Disease Study (MDRD) 
calculation. bIn the renal disease patient group, only pre-emptive patients are included. cDuration of RRT: 
NA for healthy controls. dNumber of subjects with diabetes mellitus.eNumber of subject with therapy 
requiring hypertension. fMost commonly used drugs (besides standard of care medication for renal 
insufficiency).
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Serum analysis
To investigate the influence of uremia, MSC were studied after exposure to media contain-
ing  10% pooled human serum derived from healthy controls (human healthy serum H-HS) 
or pre-emptive (GFR 15-25) (human pre-emptive serum, H-PS) or dialysis patients (human 
dialysis serum, H-DS). The sera were tested for levels of creatinine, urea, C-Reactive Protein 
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Figure 1. Characteristics of mesenchymal stem or stromal cell healthy control (MSC-HC) and 
mesenchymal stem or stromal cell renal disease (MSC-RD). (a) Microscopic image of representative 
example of MSC-HC (left) and MSC-RD (right; original magnification x 100; n=16 for MSC-HC and MSC-
RD). (b) Representative example of flow cytometric analysis of cell surface marker expression on freshly 
isolated MSC-HC (solid lines) and MSC-RD (dashed lines; n=3 for patients and controls). Isotype IgG 
controls are represented by the solid histograms. For human leukocyte antigen (HLA) class I and CD45 
no isotypes could be used, as these markers were used for gating of MSC from the cell suspension. (c) 
Representative example of flow cytometric analysis of cell surface marker expression on cultured MSC-HC 
(solid lines) and MSC-RD (dashed lines). Solid histograms represent unstained controls (n=4 for patients 
and controls). (d) Comparison of cell surface marker expression in MSC-RD cultured for 1 week in serum 
of healthy individuals (H-HS, white bars), pre-emptive renal disease patients (H-PS, gray bars), and dialysis 
patients (H-DS, black bars; n=4).
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(CRP), IL-1β and IL-6. Creatinine, urea and CRP levels were significantly increased in serum 
of pre-emptive renal disease patients compared to healthy individuals (respectively 86.7 
versus 424.7 μmol/L, 6.25 versus 24.1 mmol/L and 1.55 versus 10.9 mg/L). Creatinine was 
further increased in serum of dialysis patients (920.8 μmol/L) while urea was still elevated 
compared to healthy serum but lower than in pre-emptive serum (15.9 mg/L). IL-1β and IL-6 
were increased in dialysis serum only (Figure 2). 
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Figure 2. Characteristics of the different pooled human sera used to evaluate the influence of uremia 
on mesenchymal stem or stromal cell (MSC). Levels of (a) creatinine, (b) urea, (c) C-reactive protein, (d) 
interleukin (IL)-1β, and (e) IL-6 in pooled heat-inactivated human serum of healthy male individuals (H-HS, 
white bars), pre-emptive male RD patients (H-PS, gray bars), and male dialysis patients (H-DS, black bars). 
For the experiments, minimum essential medium-a (MEM-a) with 10% serum was used.
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Phenotypical characteristics of MSC exposed to uremic conditions
Morphology 
MSC-RD were cultured for 1 week in medium containing 10% H-HS, H-PS or H-DS. No mor-
phological changes were detected.
Immunophenotype 
Immunophenotypical analysis of MSC-RD was performed by flow cytometry after exposure 
for 1 week to medium containing 10% H-HS, H-PS or H-DS.  No effects of the various sera on 
the immunophenotype of MSC-RD were detected (Figure 1d).
Proliferation potential of MSC
Population doubling time
The proliferation potential of MSC of healthy controls and renal disease patients was evalu-
ated over 4 passages. MSC-RD demonstrated a mean population doubling time of 2.7 days 
(range 2.2-4.0), not significantly different from MSC-HC (2.8 days, range 2.2-4.3) (figure 3a). 
The population doubling times of MSC-HC and MSC-RD furthermore remained stable for at 
least 70 days of culture (figure 3b). Exposure of MSC-RD to human serum led to a decrease in 
population doubling time to 1.9 days (range 1.5-2.9). Culture in medium containing serum of 
pre-emptive and ESRD patients had no effect on the proliferation rate of MSC-RD (population 
doubling time 1.7, range 1.5-2.0 and 1.9, range 1.7-2.3 respectively)(Figure 3a). 
Colony Forming Unit Efficiency
For comparison of the colony forming unit (CFU) efficiency of MSC-HC and MSC-RD, MSC 
were seeded at 3.0 cells/cm² and cultured for two weeks before colonies were counted. 28% 
of MSC-HC showed CFU capacity (range 19.2-48%) versus 21% of MSC-RD (range 14.0-30.4%), 
which was not significantly different (Figure 3c).
Apoptosis analysis
Apoptosis detection was performed using flow cytometric analysis of Annexin V staining in 
combination with 7-AAD viability staining. The experiment was performed with 3 MSC-HC 
and 3 MSC-RD cultures. A representative example is shown in Figure 3d.  On average, viable 
cells represented 94.6% and apoptotic cells 4.1% of the expanded MSC-HC compared to 95% 
and 3.7% respectively of the MSC-RD, indicating there was no difference in apoptosis rate 
between MSC-HC and MSC-RD. 
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Figure 3. Proliferation, colony-forming unit (CFU) capacity, and apoptosis of mesenchymal stem or 
stromal cell healthy control (MSC-HC) and mesenchymal stem or stromal cell renal disease (MSC-RD). (a) 
Comparison of population doubling times of MSC-HC and MSC-RD cultured in 15% fetal bovine serum 
(FBS), of MSC-RD in 10% healthy human serum (H-HS), pre-emptive RD patients (H-PS), and of dialysis 
patients (H-DS; n=6). (b) Population doubling times of MSC-HC (left) and MSC-RD (right) remained stable 
for at least 70 days of culture (n=3). (c) CFU efficiency of MSC-HC and MSC-RD (n=5). (d) Representative 
example of apoptosis analysis in MSC-HC (left) and MSC-RD (right) under standard culture conditions 
(n=3).
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Functional characteristics of MSC
Differentiation
When exposed to differentiation medium, both MSC-HC and MSC-RD showed osteogenic 
and adipogenic differentiation capacity as demonstrated by histological detection of calcium 
depositions with von Kossa staining for osteogenic differentiation and staining of lipid drop-
lets with oil red O for adipogenic differentiation (Figure 4). Differentiation capacity was not 
affected by exposure to uremic conditions (data not shown). 
Immunosuppressive capacities
The immunomodulatory capacities of MSC-HC and MSC-RD were examined by analysis of 
their ability to inhibit the proliferation of allo-antigen and anti-CD3/CD28 activated periph-
eral blood mononuclear cells (PBMC). The effect of MSC on allo-antigen activated PBMC was 
evaluated in Mixed Lymphocyte Reaction (MLR) assays (n=16) using 5 different MSC-HC, 5 
Figure 4. Differentiation capacity of mesenchymal stem or stromal cell healthy control (MSC-HC) and 
mesenchymal stem or stromal cell renal disease (MSC-RD). (a) Osteogenic differentiation of MSC-HC (left) 
and MSC-RD (right) was determined after culturing for 3 weeks under osteogenic conditions by von Kossa 
staining (original magnification x100; n=3). (b) Adipogenic differentiation of MSC-HC (left) and MSC-RD 
(right) was determined after culturing for 2 weeks under adipogenic conditions by oil red O staining 
(original magnification x100; n=3).
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different MSC-RD and minimal 1-2-2 HLA-A, -B, and -DR mismatched PBMC. In all experiments 
both MSC-HC and MSC-RD were capable of a significant and dose-dependent suppression of 
PBMC proliferation up to a 1:20 dilution. No significant difference was detected between the 
suppressive function of MSC-HC and MSC-RD (Figure 5a). 
The ability of MSC-HC and MSC-RD to inhibit the proliferation of activated PBMC was 
confirmed by adding MSC to anti-CD3/CD28 activated PBMC. MSC-HC and MSC-RD showed 
a significant and similar inhibition of anti-CD3/CD28 activated PBMC at ratios of 1:2.5 to 1:40 
(Figure 5b). 
We next examined whether uremic serum containing medium affected the immunosup-
pressive effect of MSC. While MSC survival and proliferation was unaffected by uremia, PBMC 
showed a severely reduced proliferation capacity after stimulation with allogeneic PBMC 
in medium containing serum from dialysis patients. Therefore no inhibitory effect of MSC 
could be determined (Figure 5c). Proliferation of PBMC was preserved after stimulation with 
anti-CD3/CD28 in medium containing serum of pre-emptive RD patients, while prolifera-
tion was reduced but detectable when exposed to 10% dialysis serum. MSC were capable 
of further inhibiting the proliferation of anti-CD3/CD28 stimulated PBMC proliferation in 
10% pre-emptive and dialysis serum, demonstrating that PBMC functionality was, but MSC 
functionality was not affected by uremic conditions.  To summarize, MSC maintained their 
inhibitory effect on PBMC proliferation under uremic conditions (Figure 5d). 
Expression of pro-inflammatory and anti-inflammatory gene products
MSC respond to inflammatory conditions with an increase in the expression of both pro- and 
anti-inflammatory factors. To compare the capacity of MSC-HC and MCS-RD to respond to 
inflammatory stimuli, MSC were cultured with allo-antigen activated PBMC (MLR) in a tran-
swell system. MSC-RD were furthermore cultured in serum of pre-emptive renal disease and 
dialysis patients. After 1 and 3 days MSC were harvested and mRNA isolated. MSC-HC and 
MSC-RD cultured in the different sera showed a similar response to the pro-inflammatory 
conditions. They increased expression of anti-inflammatory indoleamine 2,3-dioxygenase 
(IDO) and programmed death ligand 1 (PD-L1), while the expression of transforming growth 
factor beta TGF-β was mildly reduced (Figure 5e). The expression of the pro-inflammatory 
cytokines IL-1β, IL-6 and IL-8 was increased in all MSC tested, demonstrating that MSC-HC 
and MSC-RD follow the same trend in gene expression in response to inflammatory stimuli 
(figure 5e). MSC-RD exposed to 10% uremic sera showed the same gene expression profile as 
MSC-RD in healthy serum, except for IL-1β, which was induced at lower levels after 1 day of 
culture with MLR (figure 5f ). 
Cytogenetic and molecular genetic analysis of expanded MSC-RD
As genomic stability of MSC is crucial for their use in future clinical trials, SNP array based 
whole genome analysis of 3 expanded MSC-RD was performed. As a control the non-cultured 
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Figure 5. Immunomodulatory effect of mesenchymal stem or stromal cell healthy control (MSC-HC; n=5) 
and mesenchymal stem or stromal cell renal disease (MSC-RD; n=5). (a) Inhibition of the proliferation of 
allo-activated PBMCs (mixed lymphocyte reaction (MLR), minimal 1-2-2 human leukocyte antigen (HLA)-A, 
-B, and -DR mismatched) by MSC-HC and MSC-RD (n=16). (b) Inhibition of the proliferation of anti-CD3/
CD28 stimulated PBMCs by MSC-HC and MSC-RD (n=12). (c) Inhibition of the proliferation of allo-activated 
PBMCs (MLR, minimal 1-2-2 HLA-A, -B, and -DR mismatched) by MSC-RD in human serum of healthy 
individuals, pre-emptive RD patients and of patients on dialysis (n=6). (d) Inhibition of the proliferation 
of anti-CD3/CD28-stimulated PBMCs by MSC-RD in the three sera. *P<0.05, **P<0.01, compared with no 
MSCs in the corresponding serum (n=3). (e) mRNA expression of anti-inflammatory (indoleamine 2,3- 
dioxygenase (IDO), transforming growth factor-β (TGF-β), and programmed death ligand 1 (PD-L1)) and 
pro-inflammatory (interleukin (IL)-1β, IL- 6, and IL-8) genes by MSCs after stimulation with allo-activated 
PBMCs (MLR). Data shown represent the fold change in the expression compared with control MSCs 
cultured without MLR (MSC-HC n=5, MSC-RD n=4). (f ) mRNA expression of IDO, TGF-β, PD-L1, IL-1β, IL-6, 
and IL-8 genes by MSC-RD after 3-day stimulation with allo-activated PBMCs (MLR; mean fold change 
in expression compared with control MSCs cultured without MLR) in medium containing 10% human 
healthy serum (H-HS), human pre-emptive serum (H-PS), or human dialysis serum (H-DS; n=3). CPM, 
counts per minute.
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PBMC of the MSC donor were used. Using a window of 3 SNP or 50KB, we did not detect any 
Copy Number Variations (CNV) among the PBMC/MSC pairs. Even on the single SNP level we 
did not observed a significant change in SNP calling (less than 2 out of 317000) 
Karyotyping of cultured MSC-HC and MSC-RD revealed only normal karyotypes. 
In addition, fluorescence in situ hybridisation (FISH) was performed on 5 MSC cultures (3 
healthy controls (age 62, 64 and 56) controls and 3 renal disease patients (age 26, 37 and 
77)) which were all cultured for 10 population doublings. The results indicated karyotypic 
normal diploid cells in >95% of MSC of both healthy controls and RD patients (representative 
example of diploid cell in figure 6).  A small number of tetraploidic MSC was detected. This 
has been described previously [31].
Figure 6. Fluorescence in situ hybridization (FISH) analysis: representative example of three diploid cells. 
The 4,6–diamidino-2–phenylindole (DAPI) counterstained nuclei are visible. In each nucleus two green 
spots (centromere 3 signal) and two red spots (centromere 8) can be detected.
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DISCUSSION
In this study we investigated the effects of kidney disease on adipose tissue derived MSC. 
Kidney disease is characterised not only by a systemic accumulation of creatinine and urea 
but also by associated chronic inflammation, shown by high levels of C-reactive protein in 
patients with RD [32]. Uremic conditions and systemic inflammation have a clear impact on 
human health. On the cellular level, kidney disease impairs the functioning of immune cells, 
as we confirmed in the present study by showing a decreased proliferative response to allo-
activation of PBMC in uremic serum. In contrast, in vitro exposure of MSC to uremic conditions 
did not compromise the proliferation rate, differentiation or immunomodulatory capacity 
of MSC. This is the first study that indicates that MSC are resistant to high levels of uremia. 
Earlier we demonstrated that adipose tissue derived MSC increased their immunosuppres-
sive capacity when stimulated with the proinflammatory cytokines IFN-γ, TNF-α and IL-6 [33]. 
In the present study we found no effect of serum of RD patients on the immunosuppressive 
capacity of MSC. This suggests that the uremic and inflammatory conditions in RD patients 
do not compromise the immunosuppressive function of MSC. 
In addition, MSC of renal disease patients did not differ phenotypically and functionally 
from MSC of healthy individuals. Immediately after isolation from adipose tissue, the immu-
nophenotype of renal disease MSC was indistinguishable from MSC of healthy individuals. 
After culture expansion both MSC-HC and MSC-RD adapted to the ISCT immunophenotypes 
which remained stable in culture. Their proliferation rate was rapid and non-declining, which 
would guarantee that sufficient numbers of MSC of RD patients can be generated in short 
amount of time. Our results therefore indicate that renal disease has no intrinsic and extrinsic 
effect MSC. This is important for the feasibility of clinical application of autologous MSC in 
renal disease patients. 
An important matter of concern for cellular therapy is the genetic stability of the cells in 
culture. Studies reporting malignant transformation of MSC in culture [34, 35] have recently 
been retracted as the cultures investigated were contaminated with tumor cell lines [36]. This 
strengthens the hypothesis that MSC are genetically stable[37]. Nevertheless, screening for 
genetic stability remains important to ensure that healthy cells are put back into patients, 
particularly when the cells have been derived from a diseased milieu. The copy number varia-
tion analysis as carried out in the present study is very suitable for this purpose.
Whether MSC used for cell therapy should be of allogeneic or autologous origin is a deli-
cate question. It has been suggested that autologous cell usage harbours the risk for homing 
of malignant cells. However, we recently found that autologous MSC are susceptible to lysis 
by NK cells [38] and are therefore unlikely to be of greater risk for tumor formation than al-
logeneic cells. Although allogeneic MSC are more practical and cost effective, as they can be 
cultured in advance and used as an off-the-shelf product, their use may have some hazards. 
It has been demonstrated that allogeneic MSC can be immunogeneic [39]. Whether potential 
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immunogenicity of MSC would hamper their clinical effects is unknown. In clinical organ 
transplantation, however, the introduction of foreign HLA might trigger sensitisation against 
a potential future donor organ. At this point in time, therefore, MSC therapy with autologous 
cells is recommended in RD patients. When there is more known about the development of 
sensitisation against allogeneic MSC, therapy with allogeneic MSC may become preferable.
We have demonstrated that MSC can be successfully isolated and expanded from adipose 
tissue of RD patients and that these MSC are fully functional, even under uremic conditions. 
These results remove one of the barriers for developing therapies with autologous MSC in RD.
METHODS
Sources of adipose tissue
Pre kidney transplantation patients (renal disease patients) (n=16) and healthy live kidney 
donors (healthy controls) (n=16) were included after written informed consent as approved 
by the Medical Ethical Committee of the Erasmus MC (protocol no. MEC-2006-190). Their 
characteristics are shown in table 1. (GFR was calculated using the MDRD Study Equation). 
During the kidney donation and transplantation procedure, subcutaneous adipose tissue 
was surgically removed from the abdominal incision and collected in minimum essential 
medium alpha (MEM-α) (Invitrogen, Paisley, Scotland) with 100IU/ml penicillin and 100μg/ml 
streptomycin (p/s) (Invitrogen).
MSC isolation, culture and differentiation
MSC from renal disease patients (MSC-RD) and healthy controls (MSC-HC) were isolated from 
the adipose tissue as described previously [3, 40]. In brief, adipose tissue was mechanically 
disrupted, enzymatically digested with sterile 0.5mg/mL collagenase type IV (Sigma-Aldrich, 
St. Louis, MO) in RPMI-1640 + glutaMAX (Invitrogen) and p/s for 30 min at 37°C. For character-
ization of freshly isolated MSC, erythrocytes were lysed with RBC Lysis Buffer (eBioscience) ac-
cording to protocol. For culture expansion, cells were resuspended in MSC-culture medium, 
consisting of MEM-α with 1% p/s and 15% fetal bovine serum (FBS) (Biowithaker), transferred 
to a 175 cm2 culture flask (Greiner Bio-one, Essen, Germany) and kept at 37°C, 5% CO2, 95% 
humidity. Medium was changed every 3-4 days. When >90% confluent, MSC were detached 
using 0.05% trypsin-EDTA at 37°C. Different MSC cultures were used for experiments between 
passages 1 and 5. 
To confirm the differentiation capacity of MSC, osteogenic and adipogenic differentiation 
was induced as described previously [40].
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Proliferation
For calculation of population doubling time, MSC were seeded at a density of 1000 cells/
cm2 and cultured until 90% confluency was reached, after which the cells were detached by 
trypsinisation, counted and re-seeded. 
Colony forming unit (CFU) assay
MSC were seeded at 50 cells per 6 cm diameter culture dishes in quintuple (3.0 cells/cm²). 
After 2 weeks of culture, medium was removed, the dishes washed once with 1x PBS and 
fixed in 70% ethanol for 5 minutes. Colonies were stained with 2.3% crystal violet solution 
(Sigma-Aldrich) for 30 minutes. Dishes were then washed with tap water and colonies 
(>1mm) counted. CFU efficiency was expressed as the percentage of cells capable of forming 
colonies.
Flow Cytometric Characterization of MSC
MSC were immunophenotyped immediately after isolation or after culture expansion. 
Cultured cells were trypsinised and washed with FACSFlow (BD Biosciences, San Jose, CA). 
Cell suspensions were incubated with mouse-anti-human monocolonal antibodies against 
CD13-PECy7, CD45-PERCP, HLA-DR-FITC, HLA-ABC-APC (all BD Biosciences), CD14-PE (Sero-
tec), CD31-FITC, CD73-PE, CD166-PE (BD Pharma) CD90-APC, CD105-FITC (R&D Systems) at 
room temperature in the absence of light for 15 minutes. After two washes with FACSFlow, 
flow cytometric analysis was performed using an 8 color FACSCANTO-II with FACSDIVA Soft-
ware (BD Biosciences) and FlowJo Software (Tree Star Inc. Palo Alto, CA).   Appropriate IgG 
antibodies were used (BD Pharmingen) for isotype control. For apoptosis analysis, an Annexin 
V-PE apoptosis Detection Kit I (BD Pharmingen) was used according to the manufacturer’s 
description. 
PBMC isolation
Peripheral blood mononuclear cells (PBMC) were collected from buffy coats of healthy blood 
bank donors (different than the MSC donors). PBMC were isolated by density gradient cen-
trifugation using Ficoll Isopaque (δ=1.077, Amersham, Uppsala, Sweden) and frozen -135°C 
until use [41] .
Serum collection
Serum of pre-emptive male renal disease patients listed for kidney transplantation was 
collected and pooled from 10 individuals (Human Pre-emptive Serum H-PS). Furthermore, 
serum of male patients with terminal renal insufficiency who received renal replacement 
therapy by hemodialyis was collected just pre dialysis and pooled from 10 individuals (Hu-
man Dialysis Serum, H-DS). Control serum was collected from male healthy individuals (Blood 
Bank donors) and pooled from 7-10 individuals (Human Healthy Serum (H-HS). 
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All sera were heat inactivated and were tested for creatinine, CRP, urea and Il-1 β and IL-6 
levels. 
Mixed Lymphocyte Reactions 
In mixed lymphocyte reactions (MLR), 5×104 PBMC were seeded in round-bottom 96-well   
plates and stimulated with 5×104 γ-irradiated (40 Gy) HLA-A, -B and -DR mismatched PBMC 
in MEM-α with p/s and 10% heat-inactivated (HI)-human serum (pre-emptive, dialysis or 
healthy). MSC were added to the MLR at a 1:2.5, 1:5, 1:10, 1:20 and 1:40 ratio. On day 7, pro-
liferation was measured by incorporation of 3H-thymidine (0.5 μCi/well, 8-hour incubation) 
using a β-plate reader (LKB, Bromma, Sweden). 
To determine the proliferation capacity of the PBMC, 5×104 cells were stimulated with 1 
μg/mL phytohaemagglutinin (PHA; Murex Biotech Ltd, Kent, UK) for 3 days and 3H-thymidine 
incorporation measured. Only results of PBMC with sufficient proliferation capacity (>10,000 
cpm) were included. Experiments were performed in triplicate and medians were used for 
further analysis.
Anti-CD3 /CD28 lymphocyte stimulation assay
PBMC were stimulated with anti-human-CD3 (0.5 μl/5×105 cells), anti-human-CD28 (0.5 
μl/5×105 cells) and goat-anti-mouse antibody (1 μl/5×105 cells) for cross-linking (all BD 
Pharmingen). PBMC were seeded in round-bottom 96-well plates at 5×104 cells per well and 
MSC were added at 1:2.5, 1:5, 1:10, 1:20 and 1:40 ratios in MEM-α with p/s and 10% heat 
inactivated (HI)-human serum (pre-emptive, dialysis or healthy).
On day 3, proliferation was measured by incorporation of 3H-thymidine using a β-plate 
reader (LKB, Bromma, Sweden). Only results of PBMC with sufficient proliferation (>10,000 
cpm) were included. All experiments were performed in triplicate and medians were used for 
further analysis.
Real-time RT-PCR
MSC were seeded in 6 well plates at 2×105 per well in the presence or absence of an MLR 
separated from the MSC by a transwell system (1×106 responder x 1×106 stimulator PBMC, 
HLA-A, -B and -DR mismatched). At day 0, day 1 and day 3, MSC cell pellets were harvested. 
RNA was isolated and cDNA synthesized as described previously [42]. Quantitative expression 
was determined by real-time RT-PCR using universal PCR mix (Invitrogen) and Assays-on-
demand for IDO (Hs00158627.m1), PDL-1 (H200204257.m1), TGF-β (Hs00171257.m1), IL-1β 
(Hs01555410.m1), IL-6 (Hs00174131.m1), and IL-8 (Hs00174114.m1) (all Applied Biosystems, 
CA) on an ABI PRISM 7700 sequence detector (Applied Biosystems). Expression levels were 
calculated as ratio per 18S RNA or as copies mRNA per 500 ng of total RNA. 
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Screening genetic stability
Cytogenetic and molecular analysis
GTG banded chromosomes were prepared following standard procedures and karyotypes 
were described following the recommendations for cytogenetic nomenclature [43].
FISH analysis
From 5 control and 3 renal disease patients, part of the cultured MSC cells were used for 
dual-color FISH using centromeric chromosome 3 and 8 probes. DNA of the plasmids probes 
Pα3.5(centromere 3) and D8Z2 centromere 8) were labelled with the Random Prime labelling 
system (Invitrogen, Corporation, Carlsbad, California, USA) using Bio-16-dUTP or Dig-11-
dUTP (Roche Applied Science, Indianapolis, USA). Of each probe 5 ng labelled product was 
mixed denatured and hybridised overnight at 37ºC  Next day the slides were washed (2x SSC 
and 0.1x SSC, 0.1% Tween) at 55ºC and incubated with Streptadivine Alexa 594 and anti-
Digoxiginine FITC for 2 hours. After washing (2xSSC, 0.1xSSC, 55C) the slides were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, Zwijndrecht, Netherlands) 
and mounted in anti-fade solution (Dabco-Vectashield 1:1(Vector Laboratories, Burlingame, 
California, USA). 
For each hybridization, a minimum of 300 nuclei were scored with an Axioplan 2 Imag-
ing microscope (Carl Zeiss,Sliedrecht the Netherlands) using a chroma-sp-100 DAPI and a 
chroma-sp- 103v1 red filter(Chroma Technology, Bellows Falls, VT, USA) and the images were 
captured with the ISIS software (Metasystems, Altlussheim, Germany). 
[44, 45].
DNA isolation
DNA was isolated from frozen PBMC (10x106) and MSC (10x106) using the QIAamp DNA mini-
kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. DNA quantity 
was measured using the NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, Delaware USA).
High-density SNP-based oligonucleotide array analysis
Whole genome analysis using Illumina cyto-SNP bead chip version 12.2 (Illumina San Diego, 
CA, USA) array was performed on DNA derived from MSC-RD expanded roughly 1000-fold 
in culture. Genomic DNA (200ng) from the PBMC and MSC sample was processed using re-
agents and protocols as described by the supplier. The data were analyzed using Beadstudio 
software (Illumina), which allows for the visualization of several different variables relevant 
to the detection of copy number alterations (CNA), including the B-allele frequency (BAF) 
and log R ratio (LRR) [46]. The normalized intensity ratio for each SNP in the samples was 
compared with a 40 CEU HapMap reference set. The BAF and LRR output data were also 
analyzed and visualized for CNA’s by using the software program Nexus Copy Number (Nexus 
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BioDiscovery, El Segundo, CA, USA). Results were compared with an in-house database of 
known copy number variations, and the public available copy number variations dataset 
containing ~3500 healthy controls (DGV Dataset of Genomic Variants and CHOPS data base). 
In addition to the paired analysis for deletions and duplications in MSC versus PBMC DNA, 
we also looked for non concordance for each SNP marker present on the array using the 
Genomestudio GT® paired analysis settings.
STATISTICAL ANALYSIS
Data were analyzed using the (two-tailed) Wilcoxon signed-rank test. Statistical significance 
was defined as P less than 0.05.
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ABSTRACT 
Background aims. Mesenchymal stromal cells (MSCs) are pluripotent cells that have immuno-
suppressive and reparative properties in vitro and in vivo. Although autologous bone marrow 
(BM)-derived MSCs are already clinically tested in transplant recipients, it is unclear whether 
these BM cells are affected by renal disease. We assessed whether renal failure affected 
the function and therapeutic potential of BM-MSCs. Methods. MSCs from 10 adults with 
end-stage renal disease (ESRD) and 10 age-matched healthy controls were expanded from 
BM aspirates and tested for phenotype and functionality in vitro. Results. MSCs from ESRD 
patients were >90% positive for CD73, CD90 and CD105 and negative for CD34 and CD45 and 
showed a similar morphology and differentiation capacity as MSCs from healthy controls. Of 
importance for their clinical utility, growth characteristics were similar in both groups, and 
sufficient numbers of MSCs were obtained within 4 weeks. Messenger RNA expression levels 
of self-renewal genes and factors involved in repair and inflammation were also comparable 
between both groups. Likewise, microRNA expression profiling showed a broad overlap 
between ESRD and healthy donor MSCs. ESRD MSCs displayed the same immunosuppressive 
capacities as healthy control MSCs, demonstrated by a similar dose-dependent inhibition of 
peripheral blood mononuclear cell proliferation, similar inhibition of proinflammatory cyto-
kines tumor necrosis factor-a and interferon-g production and a concomitant increase in the 
production of interleukin-10. Conclusions. Expanded BM-MSCs procured from ESRD patients 
and healthy controls are both phenotypically and functionally similar. These findings are im-
portant for the potential autologous clinical application of BM-MSCs in transplant recipients.
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INTRODUCTION
It has been postulated in recent years that mesenchymal stromal cells (MSCs) may be useful 
in modifying and potentially reversing loss of function in kidney disease and in preventing 
allograft rejection in transplant recipients [1-6]. MSCs were first discovered in bone marrow 
(BM) aspirates but have also been isolated and expanded from various other adult tissues 
[7]. At the present time, no unique phenotype has been identified that allows the prospec-
tive isolation of MSCs. Their isolation and characterization relies primarily on their ability to 
adhere to plastic, their multi-lineage differentiation and their membrane antigen profile [8]. 
Pre-clinical studies indicate that administration of MSCs ameliorates renal injury and accel-
erates tissue repair, and numerous experimental studies have demonstrated beneficial effects 
after solid organ transplantation [2, 4, 5, 9-13]. The potential mechanism of MSC-induced kid-
ney repair has been addressed in numerous studies [10, 13-18]. There is increasing evidence 
that the process of trans-differentiation is rare and of limited biologic relevance [15]. It is cur-
rently believed that paracrine factors are responsible for the effects of MSCs, including their 
mitogenic, anti-apoptotic, angiogenic and various immune-modulating properties [19-25]. 
In human kidney transplantation, there is great interest in the therapeutic application of 
MSCs, and the first clinical trials using autologous BM-MSCs in kidney transplantation with 
the initial focus on their potential as induction therapy and to treat allograft rejection have 
started [20, 26, 27]. A concern for the use of allogeneic MSCs is the potential induction of 
an allo-response with negative consequences for MSC efficacy and potentially for graft 
survival in the case of transplantation. A concern for the use of autologous MSCs includes 
their potential dysfunction secondary to the underlying disease, as reported in systemic 
lupus erythematosus, immune thrombocytopenic purpura, rheumatoid arthritis, multiple 
myeloma and aplastic anemia [28-32], and a potential safety risk related to genetic stability. 
A few pre- clinical studies have reported on the impact of renal disease on the phenotype 
and function of MSCs. In mice, functional incompetence of MSCs was reported after exposure 
to uremic conditions [33]. In human BM-MSCs, uremic serum induced an osteoblast-like phe-
notype accompanied by matrix remodeling and calcification [34], whereas human adipose 
tissue- derived MSCs are not affected by renal disease [35]. None of these studies has studied 
human BM-MSCs isolated from patients with end-stage renal disease (ESRD); so far, BM-MSCs 
are the only cell product used in clinical trials with MSCs in nephrology. 
We performed a head-to-head comparison between BM-MSCs from patients with ESRD 
and from healthy controls regarding their phenotypic and functional characteristics. More 
recently, micro- RNAs (miRNAs) have been shown to play a critical role in differentiation and 
MSC functionality[36], and their dysregulation has been shown in various diseases includ-
ing kidney diseases [37, 38].Because miRNA expression in MSCs from patients with ESRD is 
completely unknown, we have included in this study comparison of miRNA expression in 
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MSCs from patients with ESRD and healthy controls. We believe our results to be important 
for clinical application in transplant recipients.
METHODS
Patients and controls
BM samples were collected from patients with ESRD and from healthy controls that were ei-
ther BM donors in a clinical renal transplantation setting or patients undergoing orthopedic 
surgery. Ethics committee approval was obtained for the aspiration
protocol, and individual written consents were obtained from all individuals. Two age-
matched groups of 10 individuals each were compiled for the analyses.
Isolation and culture of MSCs
Heparinized BM was aspirated under local or general anesthesia. The mononucleated cell 
fraction was isolated by Ficoll density gradient separation and plated in tissue culture flasks 
at a density of 16 x 103mononucleated cells/cm2in low-glucose Dulbecco’s modified Eagle 
medium (DMEM; Invitrogen, Breda, the Netherlands) supplemented with penicillin/ strep-
tomycin (Lonza) and 10% fetal calf serum (Thermo Scientific HyClone). The cultures were 
maintained at 37°C 5% carbon dioxide. The medium was refreshed twice a week. When the 
MSC colonies or cultures reached confluence, the cells were collected using trypsin (Lonza) 
and re-plated at 4 x 103 cells/cm2.
Characterization of MSCs
The expanded MSC populations were characterized by morphology (spindle-shaped cells) 
and by fluorescence-activated cell sorter analysis for expression of the following membrane 
markers: HLA class I (ABC), HLA class II (DR), CD31, CD34, CD 45, CD73, CD80, CD90 and CD105. 
All specific fluorochrome-labeled antibodies and isotype controls were purchased from BD 
Biosciences (BD Bioscience, Franklin Lakes, NJ, USA) except for CD105 (Ancell Corporation, 
Bayport, MN, USA).
Differentiation of MSCs
For adipogenic and osteogenic differentiation, 50 x 103 MSCs were plated in a 24-well plate in 
duplicate. Adipogenic and osteogenic differentiation medium consisted of basic medium 1 
(a-MEM/ 4 mmol/L L-glutamine/penicillin/streptomycin, 10% fetal calf serum) supplemented 
with insulin (10 μg/mL), 5 μmol/L 3-isobutyl-1-methylxanthine, 50 μmol/L indomethacin, 
100 nmol/L dexamethasone and 50 μg/mL vitamin C. The medium was refreshed weekly 
with adipogenic and osteogenic differentiation medium supplemented with 5 mmol/L 
β-glycerophosphate. After a culture time of 3 weeks, the cells were stained for alkaline 
Renal disease does not affect BM-MSCs 113
phosphatase expression using fast blue staining, for calcium deposition using alizarin red 
and for lipids using oil red O. For chondrogenic differentiation, 2 x 105 cells were pelleted 
by centrifugation (7 min at 350g) and maintained in basic medium 2 (high-glucose DMEM/4 
mmol/L L-gluta- mine/penicillin/streptomycin), supplemented with proline(40μg/mL), 
ITS(50mg/mL), sodiumpyruvate (100 μg/mL), ascorbate-2-phosphate (50 μg/mL), transform-
ing growth factor (TGF)-β3 (10 ng/mL) and 100 nmol/L dexamethasone. The medium was 
refreshed weekly. After a total culture time of 3 weeks, the pellets were formalin-fixed (o/n 4% 
formalin) and embedded in paraffin. Subsequently, 5-μm sections
were de-paraffinized, re-hydrated and stained (20 min) with 1% toluidine blue. 
The stained adipogenic and osteogenic differentiation cultures were subjected to semi-
quantitative visual scoring resulting in a number from 0 (no staining) to 4 (maximal staining 
of positive control). The stained paraffin sections from the chondrogenic differentiation were 
scored from 0 (no staining) to 2 (maximal staining of positive control).
Karyotype analysis
Karyotype analysis was performed by routine G-banding on sub-confluent, expanding MSC 
cultures. At least 20 metaphases were analyzed.
RNA isolation and real-time polymerase chain reaction
Total RNA from MSCs was extracted using TRIzol reagent (Invitrogen). Complementary DNA 
(cDNA) was synthesized from 1 μg total RNA, using an oligo dT primer, RNase out, M-MLV 
reverse transcriptase, M-DTT and buffers in a volume of 20 μL (Invitrogen). Quantitative real-
time polymerase chain reaction (PCR) was performed in duplicate by using iQ SYBR Green 
Supermix on iCycler real- time detection system (BioRad, Veenendaal, the Netherlands). The 
amplification reaction volume was 12.5 μL, consisting of 6.25 μL iQ SYBR Green PCR master 
mix, 0.5 μL primers, 2.5 μL cDNA and 3.25 μL water. The messenger RNA (mRNA) level was 
normalized by the housekeeping gene glycerin aldehyde-3-phosphate dehydrogenase 
(GAPDH).
Profiling miRNAs by TaqMan Array MicroRNA Cards
Total RNA from selected MSC samples was isolated using TRIzol reagent (Invitrogen) and 350 
ng of total RNA was reverse transcribed using the miRNA reverse transcription kit (Applied 
Biosystems, Carlsbad, CA, USA) in combination with the stemloop Megaplex Primer Pools, 
Human Pools A v2.1 (Applied Biosystems) according to the manufacturer’s instructions. For 
each cDNA sample, 384 microRNAs including 6 controls (RNU44, RNU48, 4*U6), were profiled 
using TaqMan Array Human MicroRNA Card A v2.0 (Applied Biosystems) according to the 
manufacturer’s instructions. All arrays were run on a 7900HT Fast Real-Time PCR System 
(Applied Biosystems) and default thermal-cycling conditions. For each array, the obtained 
CT-values were converted to relative quantities normalized to RNU48.
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Peripheral blood mononuclear cell isolation and fibroblast culture
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy blood 
donors (different from the MSC donors) by density gradient centrifugation using Ficoll-
isopaque and frozen until use (-80°C). The SV40-transformed human renal fibroblast cell 
line TK173 (from normal kidney) has been previously characterized [39] and was cultured as 
described [40].
In vitro MSC and PBMC proliferation assay
Cultured MSCs from patients with ESRD and healthy controls were plated in flat-bottom 
96-well plates (Costar; Sigma-Aldrich, Zwijndrecht, the Netherlands) and allowed to attach 
overnight. PBMCs were stimulated with anti-CD3/anti-CD28 Dynabeads (1 bead/5 cells; 
Invitrogen) and were seeded in DMEM with 5% human serum (Sanquin, Amsterdam, the 
Netherlands) and 10% fetal bovine serum. PBMCs were seeded in triplicate at a concentra-
tion of 1 x 105/well. MSCs were added to the PBMC proliferation assay at 1:1250, 1:250, 1:50; 
1:10 and 1:2 ratios. After 5 days, supernatants were assayed for cytokine production, and 
cells were cultured for an additional 16 h in presence of 3H-thymidine (0.5 μCi). 3H-Thymidine 
incorporation was determined as a measure for proliferation.
Determination of cytokine production
Production of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10 and interferon (IFN)-γ 
in supernatants from the PBMC proliferation assay was measured by immunoassays specific 
for human cytokines. Cytokine production was also measured in expanding MSC cultures 
without stimulation. At 70% confluence, the medium was refreshed and supernatants were 
collected 2 and 3 days later. Cytokines were simultaneously tested with the Bio-Plex Human 
Cytokine 17-Plex Panel following the manufacturer’s instructions (Bio-Rad Laboratories) 
[41]. Samples were analyzed using a Bio-Plex Array Reader with Bio-Plex software (Bio-Rad 
Laboratories) [41].
Statistical analysis
Continuous normally distributed data are presented as mean ± SD. Differences between two 
groups were analyzed using the unpaired two-sample t test. When criteria for parametric 
testing were not met, the Mann-Whitney test was used. Differences were considered statisti-
cally significant with P < 0.05. Data analysis was performed using SPSS version 17.0 (SPSS Inc, 
Chicago, IL, USA) and GraphPad Prism, version 5.0 (GraphPad Prism Software Inc, San Diego, 
CA, USA).
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RESULTS
Isolation, expansion and characterization of MSCs
Because differentiation potential and proliferation rate are reported to decline in aged hu-
man MSCs [39, 40], we selected two age-matched study populations and used expanded 
MSC populations at similar low passage numbers (P3-4). Healthy controls (five women and 
five men) had a median age of 64 years (±7.98), which was comparable to the patients with 
ESRD. Patient demographics are presented in Table I. The MSC cultures of patients with ESRD 
and healthy controls showed similar expansion kinetics and population doubling times 
(Figure1A,B) and were morphologically identical, showing the frequently described spindle 
shape (data not shown). In addition, the membrane marker profiles of the expanded MSCs 
from both groups were indistinguishable (Figure 1C). 
All MSC cultures showed the capacity to differentiate along at least one but typically two 
of the three lineages tested (Figure 1D). There are no significant differences in in vitro dif-
Table 1 Characteristics of ESRD patients
Patients characteristics  ESRD patients (N=10)
Mean age (years) 66 ± 4.78
Gender (male/female) 7/3
Mean Body Mass Index  (kg/m2) 22.16 ± 4.06
Initial Kidney Disease, N (%)
- ADPKD
- Hypertension
- Hypertension and Diabetes
- ATN
- IgA -nephropathy
- Granulomatosis with polyangiitis
- ECI
 
1 (10%)
2 (20%)
1 (10%)
1 (10%)
2 (20%)
1 (10%)
2 (20%)
Dialysis, N(%)
Non
Hemodialysis
Peritoneal ialysis
 
4 (40%)
2 (20%)
4 (40%)
Mean time on dialysis (months) 10.1± 3.65
Medication, N (%)
- EPO
- Insulin
- Oral anti-diabetic agent
 
7 (70%)
1 (10%)
1 (10%)
Anti-hypertensive agents, N (%)
- 0
- 1
- 2
>2
1 (10%)
3 (30%)
3 (30%)
3 (30%)
All values are mean± SD. ADPKD, autosomal dominant polycystic kidney disease. ATN, acute tubular 
necrosis. EPO, Erythropoïetine. ESRD, end stage renal disease.
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ferentiation capacities between the MSCs from both groups, although the differentiation 
capacities of the healthy controls seemed more variable. Quantitative PCR analysis showed 
that mRNA levels of the self-renewal genes c-myc, Sox-2 and Klf-4 were highly similar in both 
groups, with the exception of OCT4 mRNA levels, which were significantly higher in patients 
with ESRD (Figure 1E). 
MSC products expanded in parallel for potential clinical use were subjected to karyotype 
analysis. All four tested MSC cultures from the healthy donors showed a normal karyotype. Of 
the eight MSC cultures from patients with ESRD, one displayed a clonal karyotypic abnormal-
ity, 46,XY,del(3) (q11q21) (data not shown). This abnormality was not detected in a repeated 
karyotype analysis of the MSC culture or in the karyotype of the patient’s peripheral blood.

Figure 1. Isolation, expansion and characterization of MSCs. Expansion characteristics of MSC cultures 
from healthy controls (HC) and patients with ESRD for individual cultures (A) and expressed in population 
doubling time (PDT) per group (B). Immunophenotype of HC and ESRD patients (C). Differentiation 
capacity of BM-MSCs from HC and ESRD patients semi-quantitatively assessed by oil red O (ORO), 
toluidine blue, alkaline phosphatase (AP) and calcium (Ca) staining (D). Expression of mRNA for self-
renewal genes Oct-4, C-myc, Sox2 and KLF-4 was assessed by quantitative real-time PCR in BM-MSCs of 
HC and ESRD patients (E). GAPDH expression was used as a control.
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mRNA expression of cytokines and angiogenic factors and cytokine expression in supernatants of MSC cultures
We next focused our analysis on mRNA encoding cytokines and angiogenic factors in both 
groups. mRNA levels of indoleamine 2,3-dioxygenase and the cytokines IL-10, TNF-α and 
IFN-γ and of the angiogenic factor basic fibroblast growth factor were of very low abundance 
(data not shown). mRNA levels of Angiopoietin-1 (Ang-1), Tie-2, vascular endothelial growth 
factor (VEGF), IL-6 and TGF-β were highly similar in both groups (Figure 2A,B). Ang-2 was 
significantly higher and IL-8 significantly lower in patients with ESRD. 
Cytokine production was measured in expanding, non-stimulated MSC cultures. From the 
17 cytokines analyzed, only monocyte chemotactic protein-1 and IL-6 could be detected 
in the supernatants of MSC cultures. There was no difference in expression levels of both 
cytokines between BM-MSCs of patients with ESRD and healthy controls (Figure 2C,D).
Figure 2. Similar expression levels of cytokines and angiogenic factors between BM-MSCs of patients 
with ESRD and healthy controls (HC). Expression of mRNA of angiogenic factors Ang-1, Ang-2, Tie-2 and 
VEGF (A) and IL-6, IL-8, PDL-1 and TGF-β (B) in BM-MSCs of HC and ESRD patients. GAPDH expression was 
used as a control. Concentration of IL-6 (pg/mL) (C) and monocyte chemotactic protein-1 (MCP-1) (D) in 
supernatants of BM-MSCs of HC and ESRD patients after 2 days of culture.
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BM-MSC miRNA expression profiles of ESRD patients and healthy controls
Differential expression of miRNA is increasingly acknowledged as a determining factor in 
lineage differentiation[36].We performed miRNA profiling as a broad, non-biased measure 
of the differentiation status of our MSC cultures. When the normalized data are subjected to 
un-biased cluster analyses, the BM-MSCs from both patients with ESRD and controls grouped 
together and separated from the hematopoietic phenotypes CD4, CD8 and CD14 (Figure3). 
As predicted, the most related expression profile was from the human kidney fibroblast cell 
line TK173, confirming the phenotypic similarity between MSCs and fibroblasts. Based on the 
miRNA profiles, we conclude that the impact of ESRD on the BM-MSC phenotype is minimal. 
Only three miRNAs were differentially expressed between the two groups (hsa-miR-876-
5p, hsa-miR-146a and hsa- miR-517b; Mann Whitney P < 0.02, P < 0.04, P < 0.04). However, 
these were low abundant miRNAs, and the value of these differences is limited. A few more 
Figure 3. BM-MSCs miRNA expression profiles of patients with ESRD and healthy controls. miRNA 
signature of BM-MSCs of ESRD (P1-P6) compared with BM-MSCs from HC (C1-5) and compared with 
fibroblasts (TK173) and immune cells (CD4, CD8 and CD14; all two samples) as indicated.
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Figure 4. BM-MSCs from patients with ESRD suppress immune responses in vitro. BM-MSCs from ESRD 
patients (at different ratios of MSCs to PBMCs) have the same immunosuppressive capacities as BM-MSCs 
from HC in the mixed lymphocyte reaction. (A) MSCs from HC and ESRD patients were added at a ratio 
of 1:10 to stimulated PBMCs (left panel) and proliferation of 100,000 stimulated PBMCs with anti-CD3/
CD28 beads and different amounts of MSCs (right panel) (as indicated). Proliferation measured by 
3H-thymidine incorporation in counts is expressed as a percentage (%). Stimulated PBMCs with anti-CD3/
CD28 are depicted as 100%. (B) Cytokine production of IFN-γ, TNF-α, IL-6 and IL-10 in the supernatants of 
PBMC cultures, anti-CD3/CD28 stimulated PBMCs and 10,000 MSC/100,000 PBMC co- cultures. Cytokine 
production is depicted as a percentage compared with the cytokine production of anti-CD3/CD28 
stimulated PBMCs (depicted as 100%). Mean production of cytokines in the anti-CD3/CD28 stimulated 
PBMCs group are as follows: IFN-γ, 23.8 ng/mL (range, 10.7e40.4 ng/mL), TNF-α, 1.4 ng/mL (range, 0.4e2.8 
ng/mL), IL-10, 0.4 ng/mL (range, 0.2e0.6 ng/mL) and IL-6, 11.2 ng/mL (range, 0.1e17.4 ng/mL). Mean 
production of IFN-γ, TNF-α and IL-10 in the MSCs of the HC and ESRD groups were below the detection 
limit (see lines 1 ng/mL, 62.5 pg/mL and 18.8 pg/mL), and the mean IL-6 production in the MSCs of HC 
was 29.5 ng/mL. Bars represent the mean and SD of data from 10 patients in triplo. *P < 0.05, **P < 0.01 
and ***P < 0.001 compared with anti-CD3/CD28 stimulated PBMCs. (d.l., detection limit.)
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recent studies have reported miRNA expression profiles in differentiating MSCs [36]. These 
miRNAs include miR-143, miR-103 and miR-107 for adipocyte differentiation, miR-140 for 
cartilage development, miR-683, 663 in chondrocyte and miR-24, let7a, let7b, let7c, miR-138 
and miR-320 as osteocyte-specific miRNAs [44]. Although we did not test the expression of 
these miRNAs in differentiating cultures, at baseline none of these miRNAs were differentially 
expressed between the two groups. miR-143, miR-140-5b, miR-24, let7b, miR-138 and miRNA 
320 were included in the 30 most abundant miRNAs present in the MSCs.
BM-MSCs from ESRD patients suppress immune responses in vitro
An important characteristic of MSCs, especially in the context of potential use in renal trans-
plantation, is the anti-inflammatory and immunosuppressive function. Autologous PBMCs 
were activated by polyclonal CD3/CD28 activation in the absence or presence of MSCs. 
MSCs from both healthy controls and patients with ESRD inhibited this proliferation in a 
dose-dependent manner, reaching near to optimal inhibition at a 1:10 MSC-to-PBMC ratio 
(Figure 4A). The same cultures were analyzed for cytokine production by these polyclonal 
PBMCs. MSCs from both healthy controls and patients with ESRD showed a similar effect- no 
inhibition of IL-10 production but an inhibition for IFN-γ and TNF-α (Figure4B). MSC cultures 
alone did not show production of any of these cytokines. In contrast, MSCs produced IL-6 (as 
also described in Figure 2C), explaining the increased production in co-cultures (Figure 4B).
DISCUSSION
The great potential for MSCs as a therapeutic tool for allograft rejection after renal transplan-
tation is supported by positive results in different experimental models [5, 9, 11, 13, 41]. In 
these studies, recipient and donor-derived MSCs were shown to have better immunomodu-
latory properties than third-party MSCs [41-44]. However, donor- derived MSCs were also 
reported to cause sensitization, and application with autologous MSCs seems preferable 
[45-47].The first clinical trials using autologous BM-MSCs in kidney transplantation have 
started [26, 27, 48]. However, a premise in these studies is that BM-MSCs from patients with 
renal failure are not affected by the disease background. So far, no formal assessment of this 
assumption has been made. This assumption is very relevant because BM-MSCs from patients 
with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis were shown 
to be deficient in their ability to support hematopoiesis and exhibited features of early se-
nescence [28, 29, 49]. 
In our study, expanded MSCs of patients with ESRD complied with the phenotypic criteria 
for MSCs as defined by the International Society for Cellular Therapy (ISCT) [8], indicating 
that ESRD did not affect MSC phenotype. Also, the growth and differentiation characteristics 
were not impaired in expanded MSCs from patients with ESRD. These data are important 
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for our clinical protocols because they validated our ability to obtain sufficient numbers of 
autologous MSCs at a low passage within 4 weeks. 
We observed a clonal karyotypic aberration in the MSC product from one of the patients 
with ESRD. Because subsequent karyotype analysis on the patient’s peripheral blood did not 
show this aberration, we could not attribute these findings to patient chimerism. Theoretically, 
it would be possible that the generation of this aberration was caused by the MSC expansion 
process. However, we argue this to be very unlikely because clonal karyotypic aberrations 
were never detected in expanded MSC populations from healthy individuals and never found 
in any of 37 MSC preparations from healthy donors that we have manufactured for clinical 
applications under the same culture conditions. At the present time, we consider chimerism 
in the patient’s MSC compartment, possibly related to medication over a long period, the 
most plausible explanation for this observation, which warrants further investigations. 
mRNA expression of self-renewal genes was highly similar between ESRD patient groups 
and healthy controls with the exception of increased mRNA levels of Oct4 in the patient-
derived MSCs. The potential clinical significance of this difference is unclear. More recent 
studies have demonstrated increased Oct4 mRNA expression in MSCs after hypoxia [50]; 
however, the effect of uremia on the expression of self-renewal genes is unknown. We also 
focused on the mRNA profiles of inflammatory cytokines and angiogenic factors that have 
been associated with immune modulation and regenerative functions in acute kidney injury 
(AKI) and renal transplantation. mRNA levels of cytokines of cultured MSCs were highly simi-
lar between ESRD patient groups and healthy controls. In addition, we found similar expres-
sion levels of VEGF, Tie-2 and Ang-1 in both groups. The last-mentioned is of great relevance 
because Ang-1 is recognized as a crucial stromal cell derived factor that is indispensable for 
stabilization of the microcirculation, can preserve peritubular perfusion and can prevent 
renal failure in AKI [51]. Uremic BM-derived murine MSCs showed decreased expression of 
VEGF and stromal cell derived factor, decreased proliferative capacity, decreased in vitro tube 
formation and decreased angiogenesis in vivo [33]. This discrepancy could be attributed to 
species or culture conditions during MSC expansion. 
More recent studies have focused on the importance of miRNAs in MSC differentiation and 
function [36]. It was demonstrated that micro-vesicles released from MSCs may account for 
their paracrine mechanism of action by a horizontal transfer of mRNA and miRNA. In a rat 
model, micro-vesicles released from MSCs protected from AKI induced by ischemia-reperfu-
sion injury and from subsequent chronic renal damage [52]. miRNA expression and clearance 
may also be altered in renal failure. A more recent study demonstrated reduced circulating 
miRNA levels in chronic kidney disease [37]. Another study compared miRNA profiles of hu-
man proximal tubular cells (HK-2) cultured in control versus uremic dialysate and indicated 
that the uremic environment can alter miRNA expression [53]. In contrast, we found that 
miRNA expression signatures in MSCs from patients with ESRD were highly similar to miRNA 
expression signatures from healthy controls, contributing to their extensive phenotypic and 
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functional overlaps. Cell type and culture methods could be important factors accounting for 
these differences. 
In conclusion, MSCs are an interesting candidate for the induction of tolerance or the treat-
ment of allograft rejection because of their immunosuppressive properties. In our experi-
ments, we found that MSCs from patients with ESRD and healthy controls have similar immu-
nosuppressive capacities. Functionally, MSCs were shown to have a similar dose-dependent 
inhibition of PBMC proliferation, similar decrease in the production of pro-inflammatory 
cytokines TNF-α and IFN-γ and similarly increased production of tolerogenic cytokine IL-10. 
Taken together, our study demonstrates that ex vivo expanded BM-MSCs from patients with 
ESRD are both phenotypically and functionally similar to BM-MSCs from healthy controls. 
These findings are important for the potential clinical use of autologous MSCs in transplant 
recipients.
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ABSTRACT
Mesenchymal stem cells (MSCs) have potent immunosuppressive effects in vitro and are 
considered as a therapeutic option for autoimmune disease and organ transplantation. 
While MSCs show beneficial effects on immune disease progression and transplant survival 
in animal models, the immunomodulatory mechanisms involved are largely unknown. In the 
present study, we show that intravenously infused C57BL/6- green fluorescent protein (GFP) 
MSCs home to the lungs in C57BL/6 recipient mice and induce an inflammatory response. 
This response was characterized by increased mRNA expression of monocyte chemoattrac-
tant protein-1 (MCP1), IL1-β, and TNF-α and an increase in macrophages in lung tissue 2 h 
after MSC infusion. Simultaneously, serum levels of proinflammatory IL6, CXCL1, and MCP1 
protein increased, demonstrating systemic immune activation after MSC infusion. In liver 
tissue, no C57BL/6-GFP MSCs were detected, but MCP1 and TNF-α mRNA levels peaked 4 h 
after MSC infusion. The expression of the anti-inflammatory cytokines TGF-β, IL4, and IL10 
was only marginally affected. Nevertheless, 3 days after MSC infusion, animals developed a 
milder inflammatory response to lipopolysaccharides. Our results suggest that the in vivo 
immunomodulatory effects of MSCs originate from an inflammatory response that is induced 
by the infusion of MSCs, which is followed by a phase of reduced immune reactivity.
MSC induce an inflammatory response 129
INTRODUCTION
Mesenchymal stem cells (MSCs) are multipotent cells that reside in most, if not all, tissues [1]. 
They are capable of osteogenic, adipogenic and chondrogenic differentiation [2] and have 
particularly potent immunosuppressive properties [3, 4]. These characteristics have raised 
interest in the use of MSCs for the treatment of degenerative and immunological diseases 
such as graft versus host disease [5], multiple sclerosis [6], Crohn’s disease [7] and rejection 
of organ transplants [8]. 
The immunosuppressive capacity of MSCs has been a subject of extensive research over 
the last decade. In vitro experiments have demonstrated that MSCs inhibit the proliferation 
and cytokine secretion of T cells [9], B cells [10] and NK cells [11]. MSCs target lymphocytes via 
a variety of mechanisms, which depend on both the secretion of soluble anti-inflammatory 
factors, such as TGF-β, hepatocyte growth factor (HGF) [3], HLA-G [12], and on cell contact 
interactions via the inhibitory co-stimulatory programmed death ligand 1 (PD-L1) pathway 
[13]. The expression by human MSC of the tryptophan-depleting enzyme indolamine 2,3-di-
oxygenase (IDO) is crucial for the inhibition of lymphocyte proliferation [14]. The expression 
of IDO and other anti-inflammatory factors by MSCs is strongly induced under inflammatory 
conditions [15-17], suggesting that the immunomodulatory effects of MSC act as a feedback 
mechanism to control ongoing immune responses. 
Studies in animal models and early clinical trials have attempted to translate the potent in 
vitro immunosuppressive effects of MSCs in effective immune therapy. The most widely used 
route of administration of MSCs in these studies is via intravenous (IV) infusion. In contrast to 
the in vitro immunomodulatory effects of MSCs, however, little is known about the effects of 
MSCs after IV infusion. IV-infused MSCs home to the lungs [18-21] and it is believed that they 
migrate from there to sites of injury and inflammation [22, 23] and exert their immunosup-
pressive function. However, recent evidence suggests that this is not the case. It has been 
shown that living MSCs are only detectable in the lungs after IV infusion, and not in any other 
tissue or at sites of injury [24, 25]. Furthermore, the presence of living MSCs in the lungs 
is temporary and within 24 h, the majority of MSCs in the lungs die and their cell debris is 
distributed to other sites, in particular, the liver.
Even though MSCs appear to be short-lived after IV infusion, they induce potent immuno-
modulatory effects in various disease models. For instance, infusion of MSCs has been shown 
to alleviate experimental colitis [26], ameliorate experimental encephalomyelitis [27] and 
inhibit allograft rejection [28]. In these models, infused MSCs are unlikely to be present at the 
site of inflammation or live long enough to become activated by inflammatory conditions 
and exert their immunosuppressive effect. Therefore, it is unlikely that the in vitro established 
mechanisms of immunomodulation by MSCs are operational after infusion of MSCs. Other 
mechanisms are likely to mediate the effect of MSCs, probably involving other cell types. The 
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purpose of the present study was to map the type, origin, and duration of the immunomodu-
latory response that is induced upon IV infusion of the MSC.
MATERIALS AND METHODS
Isolation and culture of MSCs
MSCs were isolated from the adipose tissue of C57BL/6 mice expressing enhanced green 
fluorescent protein (GFP) under the human ubiquitin C promoter (The Jackson Laboratory). 
The adipose tissue was a kind gift from E. Koning en Dr. R. Mebius of the Free University 
Amsterdam. Animals were kept in accordance with the institutional guidelines. The adipose 
tissue of five animals was pooled, minced with a scalpel knife, and enzymatically digested 
with 0.5 mg/mL collagenase type IV (Life Technologies) in a minimal essential medium eagle-
alpha (MEM-α) supplemented with 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL 
streptomycin (1% p/s) (all Life Technologies) for 30 min at 37°C under continuous shaking. 
After centrifugation at 1,200 g for 10 min, the cell pellet was resuspended in a red blood 
cell lysis buffer (eBioscience) and incubated for 10 min at room temperature. The cells were 
then washed, resuspended in the MEM-α supplemented with 2 mM L-glutamine, 1% p/s, and 
15% fetal bovine serum (FBS; Lonza), and filtered through a 70-μm cell strainer (BD Biosci-
ences). The cells were then transferred to a 175-cm2 cell culture flask (Greiner Bio-One) and 
expanded in a humidified atmosphere with 5% CO2 at 37°C. Nonadherent cells were removed 
after 3–4 days. The culture medium was refreshed twice weekly. Cells were removed from 
culture flasks at subconfluency using 0.05% trypsin-EDTA (Life Technologies) and reseeded 
at 1,000 cells/cm2 to ensure optimal proliferation. MSCs were used for experiments between 
passages 4 to 10.
Characterization of MSCs
MSCs were examined for GFP expression by fluorescence microscopy. For immunopheno-
typing, MSCs were harvested, washed in FACSFlow (BD Biosciences), and stained with Sca-
1-PE-Cy7, CD11b-APC, CD44-PE, and CD45-PERCP (all BD Biosciences) and measured on a 
FACSCanto II flow cytometer (BD Biosciences) using FACSDiva software.
Adipogenic differentiation was induced by culturing confluent MSCs in the MEM-α 
supplemented with 2 mM L-glutamine, 1% p/s, 15% heat-inactivated FBS (FBS-HI), 50 μg/mL 
L-ascorbic acid (Sigma-Aldrich), 500 μM 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich), 
60 μM indomethacin, 2 μM insulin (Sigma-Aldrich), and 10 nM dexamethasone (Sigma-Al-
drich) for 14 days. Lipid-filled vesicles were detected by Oil Red O staining. Cells were washed 
with phosphate-buffered saline (PBS), fixed with 60% isopropanol for 1 min, and incubated 
with filtered 0.3% Oil Red O (Sigma-Aldrich; in 60% isopropanol) for 30 min. Following three 
washes with PBS, the cells were photographed.
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Osteogenic differentiation was induced by culturing confluent MSCs in the MEM-α supple-
mented with 2 mM L-glutamine, 1% p/s, 15% FBS-HI, 5 mM β-glycerophosphate (Sigma-
Aldrich), 50 μg/mL L-ascorbic acid, and 10 nM dexamethasone for 21 days. The deposition 
of calcified nodules was identified using von Kossa staining. Cells were washed with PBS 
and fixed with cold 4% paraformaldehyde for 5 min. Following an additional wash step with 
PBS and two wash steps with distilled water, cells were incubated with 1% silver nitrate (in 
water) on a light box until blackening occurred. Cells were washed three times with water, 
incubated with 2.5% sodium thiosulfate (in water) for 5 min, washed again twice with water, 
and photographed.
For examination of the immunosuppressive capacity of MSCs, Swiss mouse splenocytes 
were stimulated with 5 μg/mL Concanavalin A (ConA; Sigma Aldrich) and MSCs added at 
ratios of 1:5 to 1:640 in 96-well plates. After 3 days, proliferation was measured by incorpora-
tion of 3H-thymidine (0.25 μCi/well; PerkinElmer) during 8 h of incubation using a Wallac 1450 
MicroBeta TriLux Liquid Scintillation Counter & Luminometer (PerkinElmer).
Infusion of MSCs
Male C57BL/6 mice, 8–10 weeks old and weighing ~25 g, were obtained from Harlan. The 
experimental protocol was approved by the Animal Experiments Committee under the 
Dutch National Experiments on Animals Act and complied with the 1986 directive 86/609/
EC of the Council of Europe. MSCs were trypsinized, washed, and resuspended in PBS. Three 
hundred thousand MSCs in 200 μL PBS were infused via tail vein injections. Control mice re-
ceived 200 μL PBS only. After 2, 4, 20, 68, and 216 h, mice were sacrificed and blood collected 
in Minicollect serum separation tubes (Greiner Bio-One). Two experiments were carried out, 
totaling five animals per time point. Lungs, livers, and kidneys were removed and frozen at 
−80°C. Spleens were removed and cell suspensions prepared. After red blood cell lysis (RBC 
lysis buffer; eBioscience), splenocytes were frozen in 10% DMSO at −150°C.
Treatment with lipopolysaccharides
One day or 3 days after infusion of MSCs as described above, animals were injected with 
5 mg/kg body weight lipopolysaccharides (LPS; Sigma-Aldrich) dissolved in PBS via the tail 
vein. Animals were sacrificed 4 h later and blood collected in Minicollect serum separation 
tubes.
PCR analysis
Frozen lung, liver, and kidney tissue were sectioned in 20-μm slices and RNA isolated using the 
Trizol reagent (Life Technologies). cDNA was synthesized from 500 ng RNA with random prim-
ers (Promega). Quantitative gene expression was determined using TaqMan Gene Expression 
Master Mix (Life Technologies) and assays-on-demand for IL1-β (mm01336189.m1), IL10 
(mm00439614.m1), CCL2 [monocyte chemoattractant protein-1 (MCP1)] (mm00441242.m1), 
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CCL3 (MIP1-α) (mm00441258.m1), TNF-α (mm00443258.m1), IFN-γ (mm01168134.m1), TGF-β 
(mm01178820.m1), IL4 (mm00445259.m1), CD68 (mm03047340.m1), F4/80 (mm008002529.
m1), Ly6G6c (mm00458275.m1), and housekeeping gene HPRT (mm01545399.m1) (all Ap-
plied Biosystems) on a StepOnePlus (Applied Biosystems). GFP expression was determined 
by SYBR green-based (Applied Biosystems) RT-PCR. Primer sequences used for the detection 
of GFP were 5c-CCA CAT GAA GCA GCA GGA CTT-3c and 5c-GGT GCG CTC CTG GAC GTA-3c 
(BaseClear). Results were expressed as a ratio to HPRT.
Analysis of serum proteins by Milliplex
Serum concentrations of a broad panel of chemokines, cytokines, and acute-phase proteins 
were measured by Milliplex cytokine/chemokine panel I (Millipore) according to the manu-
facturer’s instructions. The panel existed of the following proteins: CRP, CXCL1, CXCL5 (LIX), 
CCL11 (Eotaxin), G-CSF, GM-CSF, IFN-γ, IL1-α, IL1-β, IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL10, IL12p40, 
IL12p70, IL13, IL15, IL17, IP10, LIF, CCL2 (MCP1), M-CSF, CCL3 (MIP1-α), MIP1-β, MIP2, MIG, 
Rantes, SAP, TNF-α, and VEGF.
Splenocyte analysis
Splenocytes were thawed and stimulated with 5 ng/mL PMA (Sigma-Aldrich) and 500 ng/
mL ionomycin (Sigma-Aldrich) for 4 h at 37°C in the presence of 1 μl Golgiplug (BD Biosci-
ences) per 1×1x106 cells. Controls were not stimulated with PMA/ionomycin. The cells were 
then washed and stained with CD3-PERCP, CD4-FITC, and CD25-PE-Cy7 antibodies (all BD 
Biosciences). Subsequently, cells were washed and incubated in a Fixation/Permeabilization 
solution (BD Biosciences) for 30 min at 4°C, followed by a wash in the Perm/Wash buffer (BD 
Biosciences), and stained with the IFN-γ-APC antibody (BD Biosciences). After washing, the 
cells were analyzed on a FACSCanto II flow cytometer using FACSDiva software.
To determine the effect of the MSC on the proliferative capacity of splenocytes after LPS 
treatment, splenocytes were collected 4 h after LPS treatment and seeded at 150,000 cells 
per well in a 96-well round-bottom plate and stimulated with 5 μg/mL ConA for 3 days. They 
were then incubated with 3H-thymidine (0.25 μCi/well) for 8 h. 3H-thymidine incorporation 
was measured using the Wallac 1450 MicroBeta TriLux Liquid Scintillation Counter & Lumi-
nometer.
RESULTS
Characterization of adipose tissue-derived MSCs
MSCs were isolated from the adipose tissue of C57BL/6 mice expressing GFP under the ubiq-
uitin promoter. In culture, MSCs displayed a characteristic fibroblast-like morphology (Figure 
1A) and showed strong GFP expression (Figure 1B). Flow cytometric analysis confirmed 
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Figure 1. Characterization of MSCs isolated from adipose tissue of C57BL/6 mice expressing GFP under 
the ubiquitin promoter. (A) Bright-field image of cultured MSCs showing characteristic MSC morphology. 
(B) Fluorescence (FITC) image of cultured MSCs showing GFP expression. Scale bars represent 100mm. 
(C) Expression of GFP, CD11b, CD44, CD45, and Sca-1 by MSCs. Representative experiment shown. Closed 
histograms: unstained cells, open histograms: stained cells. (D) MSCs cultured under control (upper panel) 
or osteogenic conditions (lower panel) for 21 days stained with von Kossa staining. Calcified nodules 
appear in brown/black. (E) MSCs cultured under control (upper panel) or adipogenic conditions (lower 
panel) for 14 days stained with Oil Red O. Lipid-filled vesicles appear in red. Scale bars represent 100mm. 
(F) Dose-dependent inhibition of ConA stimulated splenocyte proliferation, measured by 3H-thymidine 
in- corporation assay (n=3). *P<0.01 compared to white bar. MSC, mesenchymal stem cells; GFP, green 
fluorescent protein; ConA, concanavalin A. 
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Figure 2. Gene expression changes in lung tissue in response to IV infusion of MSCs. Lungs were removed 
at various time points after administration of MSCs and mRNA isolated. Expression of GFP, CCL2 (MCP1), 
CCL3 (MIP1-a), IL1-β, TNF-α and TGF- β is depicted as a ratio to HPRT. (A–F) show single measurements of 
five animals per time point (control group contains 10 animals) with medians. *P<0.01.
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GFP expression in close to 100% of MSCs and demonstrated positive expression of the MSC 
markers CD44 and Sca-1 (Figure 1C). None of the cells expressed the hematopoietic markers, 
CD11b and CD45, indicating the absence of macrophages and dendritic cells in the cultures. 
Culture under osteogenic and adipogenic differentiation-inducing conditions stimulated 
the production of calcified nodules (Figure 1D) and lipid-filled vesicles (Figure 1E) by MSCs. 
Finally, MSCs were capable of inhibiting the proliferation of ConA-stimulated splenocytes in 
a dose-dependent manner (Figure 1F). These results demonstrate that the MSCs used in this 
study were fully functional.
Effects of IV infusion of MSCs on lung tissue
Three hundred thousand GFP-MSCs were infused via the tail vein in syngeneic C57BL/6 
mice. At 2, 4, 20, 68, and 216 h after infusion, five mice were sacrificed and lungs removed 
for analysis. MSCs could be detected in the lungs 2 h after infusion by means of GFP mRNA 
expression (Figure 2A). GFP expression in the lungs subsequently decreased. The presence 
of MSCs in the lungs was accompanied by an inflammatory response, which peaked at 2 h2h 
after infusion of MSCs and was characterized by increased mRNA levels of the proinflamma-
tory chemokines and cytokines CCL2 (MCP1; 32-fold), CCL3 (MIP1-α; 2-fold), IL1-β (5-fold), 
and TNF-α (2-fold) (Figure 2B-E). Simultaneously, there was a twofold increased expression of 
anti-inflammatory TGF-β (Figure 2F). All gene expression levels returned to basal levels at 4 
to 20 h after MSC infusion. The expression of IL4, IL10, and IFN-γ did not significantly change 
upon administration of MSCs (data not shown). 
MSCs increase the number of macrophages in the lungs
To investigate whether the inflammatory response in the lungs induced by the infusion 
of MSCs resulted in increased numbers of macrophages and neutrophils in the lungs, PCR 
analysis for the macrophage markers CD68 and F4/80 and for the neutrophil marker Ly6G6c 
was performed. There was an increase in CD68 and F4/80 expression in the lungs 2 h after 
infusion of MSCs (Figure 3A,B). At 20 h, expression levels had returned to basal levels. There 
was no significant change in Ly6G6c, although at 2 h, there was a trend for increased expres-
sion (Figure 3C). 
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Systemic effects of IV infusion of MSCs
To analyze whether the inflammatory response in the lungs evoked by MSC infusion was also 
detectable systemically, levels of 34 cytokines, chemokines, and acute-phase proteins were 
measured in serum at the various time points after administration of MSCs. Two hours after 
infusion of MSCs, there were increases in the concentrations of the neutrophil stimulator G-
CSF (4-fold), proinflammatory IL6 (18-fold), the neutrophil chemoattractant CXCL1 (10-fold) 
and CCL2 (MCP1, 4-fold) (Figure 4A-D). Concentrations of the proteins returned to basal levels 
at 20 h after administration of MSCs. In contrast, levels of the neutrophil chemoattractant, 
CXCL5, dropped significantly 2 h up to 20 h after infusion of MSCs, while the eosinophil 
chemoattractant, CCL11, was decreased at 20h (Figure 4E-F). No significant changes in serum 
concentrations of CRP, GM-CSF, IFN-γ, IL1-α, IL1-β, IL2, IL3, IL4, IL5, IL7, IL9, IL10, IL12p40, 
IL12p70, IL13, IL15, IL17, IP10, LIF, M-CSF, CCL3 (MIP1-α), MIP1-β, MIP2, MIG, Rantes, SAP, 
TNF-α, and VEGF were detected (data not shown).
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Figure 3. Expression of macrophage and neutrophil markers in lung tissue in response to IV infusion of 
MSCs. (A–C) Expression of CD68 and F4/80 for macro- phages and Ly6G6c for neutrophils is shown as a 
ratio to HPRT. Single measurements of 5 animals per time point (control group 10 animals) with medians 
shown. *P<0.01.
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Effects of IV infusion of MSCs on liver and kidney tissue
Earlier, we found that the MSC label, but no viable MSCs, accumulated in liver tissue 1 day 
after infusion of MSC [29]. To examine whether this would leave an immunological footprint 
in liver tissue, livers were removed for analysis 2, 4, 20, 68, and 216 h after MSC infusion and 
mRNA expression of a number of cytokines and chemokines analyzed. No expression of GFP 
was detected in the liver at any time after MSC infusion, confirming that no viable MSCs 
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Figure 4. Serum concentrations of cytokines/chemokines after IV infusion of MSCs. Serum was collected 
at various time points after administration of MSCs. Protein concentrations of G-CSF, IL6, CXCL1, CCL2 
(MCP1), CXCL5, and CCL11 (Eotaxin) were determined by Milliplex assay. (A–F) show single measurements 
of 5 animals per time point (control group 10 animals) with medians. *P<0.01.
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localized to the liver (data not shown). Expression of TNF-α, CCL2 (MCP1), and CCL3 (MIP1-α) 
increased 2 h and peaked 4 h after infusion of MSCs, showing twofold, fourfold, and twofold 
increases, respectively (Figure 5A-C). IFN-γ and IL1-β levels also peaked, but at 68 and 216 h 
after MSC infusion, respectively (Figure 5D-E). TGF-β showed a 1.5-fold increase after 4h 
(Figure 5F), while no changes in IL10 expression were observed (data not shown). In kidney 
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Figure 5. Gene expression changes in liver tissue in response to IV infusion of MSCs. Livers were removed 
at various time points after administration of MSCs and mRNA isolated. Expression of IFN-γ, CCL2 (MCP1), 
CCL3 (MIP1-a), IL1- β, TNF-α, and TGF- β is depicted as a ratio to HPRT. (A–F) show single measurements of 
5 animals per time point (con- trol group 10 animals) with medians. *P<0.01.
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tissue, no significant changes in cytokine and chemokine gene expression were detected at 
any time point after infusion of MSCs and no expression of GFP was found (data not shown).
Effect of IV infusion of MSCs on splenocytes
The effect of MSC infusion on the responsiveness of splenocytes was determined by in vitro 
stimulation of splenocytes with PMA/ionomycin and measurement of their IFN-γ production. 
PMA/ionomycin induced an IFN-γ response in ~6% of CD3+ and CD3− splenocytes of control 
animals. The IFN-γ response in CD3+ splenocytes was not significantly different in animals 
that received MSCs, although there was a trend for a reduced IFN-γ response at 2, 4, 20, and 
68 h after administration of MSCs (Figure 6A). The IFN-γ response in CD3− splenocytes was 
not affected by MSC treatment (Figure 6B).Infusion of MSCs dampens the immune response 
to LPS
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Figure 6. In vitro IFN- γ response of splenocytes isolated at various time points after IV infusion of MSCs. 
Splenocytes were stimulated for 4h with PMA/ionomycin and intracellular IFN- γ production measured by 
flow cytometry. The percentage of IFN- γ producing cells of CD3+ (A) and CD3- (B) splenocytes is depicted.
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Figure 7.  Effect of MSC infusion on the response to LPS. Mice received 5mg/kg LPS 3 days after IV 
infusion of 300,000 MSCs or phosphate- buffered saline. Four hours later, mice were sacrificed and serum 
and splenocytes collected. (A-F) Protein concentrations of G-CSF, IL6, CXCL1, CCL2 (MCP1), IP10, and 
IL12p40 in serum were determined by Milliplex assay. Means with 95% percentiles of 4 measurements 
with SD shown. (G) Proliferative response to ConA of splenocytes from animals injected with LPS with and 
without prior treatment with MSCs (24 or 72h). *P<0.01.
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To examine whether the early immune activation induced by the infusion of MSCs would 
lead to an immunomodulatory effect in vivo later on, animals received 5 mg/kg LPS at day 
1 or 3 after administration of MSCs or PBS and were sacrificed after 4 h. LPS induced major 
increases in serum concentrations of multiple cytokines and chemokines, including G-CSF, 
IL6, CXCL1, MCP1, IP10, and IL12p40. Infusion of MSCs 1 day before administration of LPS had 
no effect on the serum levels of these factors (data not shown). However, infusion of MSCs 3 
days before LPS significantly reduced the increases in G-CSF, IL6, CXCL1, IP10, and IL12p40, 
suggesting a dampened immune response to LPS (Figure 7A–F).
To examine their proliferative response, splenocytes were stimulated with ConA. Spleno-
cytes from animals that were treated with MSCs 24 h before LPS tended to show an increased 
proliferative capacity, whereas splenocytes from animals that were treated with LPS 72 h 
earlier tended to show reduced proliferation, although the differences were not significant 
(Figure 7G).
DISCUSSION
There is increasing interest in the use of MSC therapy for immunomodulatory purposes. 
In contrast to pharmacological immunosuppressants, which need to be taken lifelong and 
which suppress specific molecular pathways, MSC therapy is thought to be able to achieve 
long-term effects by modulating the function of various cells of the immune system. Although 
beneficial effects of MSCs have been demonstrated in inflammatory disease and transplant 
models, the mechanisms of immune modulation by MSCs after in vivo administration remain 
obscured. Understanding of these mechanisms is essential for the development of efficient 
MSC therapy.
Surprisingly, in the present study, we found that infusion of syngeneic MSCs induced 
an inflammatory response, which was detectable systemically and in lung and liver tissue. 
No inflammatory response was evident in the kidneys. The response in lung tissue was 
characterized by increased expression of monocyte and neutrophil chemoattractants and 
proinflammatory cytokines. In addition, we observed an increase in the expression of the 
macrophage markers, CD68 and F4/80, suggesting that intravenous infusion of MSCs causes 
an influx of macrophages in the lungs. We and others have described that MSCs interact 
with macrophages and induce macrophages with an immunomodulatory phenotype [30]. 
Whether macrophages that are recruited to the lungs upon infusion of MSCs are adapting a 
regulatory function will need further investigation.
The question rises whether the administered MSCs themselves were the source of the 
proinflammatory cytokine response. Gene expression changes in lung tissue coincided with 
the presence of MSCs and the genes that showed significant upregulation in the lung encode 
proteins that are expressed by MSCs. Nevertheless, a more likely possibility is that MSCs trig-
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ger the expression of proinflammatory factors in resident cells of the lungs. MSCs are shown 
to accumulate in the microvasculature after infusion due to space restriction [31], where they 
mechanically interact with endothelial cells and leukocytes. The encounter of MSCs with lung 
endothelial cells and cells of the immune system may evoke the inflammatory response.
Our results strongly suggest that the increased expression of proinflammatory factors in 
liver tissue did not directly derive from MSCs. At the time the increases were observed, 4 h up 
to 216 h after MSC infusion, no MSCs were detected in the liver, indicating that liver resident 
cells are responsible for the gene expression changes. It is possible that the initial inflam-
matory response in the lungs is transferred via circulating chemokines and cytokines, which 
trigger a response in the liver. Another possibility is that mobile cell types like macrophages 
are activated by MSCs and transfer the signal from the lung to the liver via the blood stream. 
Some of the systemic changes in the levels of chemokines and cytokines are also unlikely to 
be a direct effect of MSCs. We observed a significant increase in G-CSF levels in serum after 
MSC infusion, but MSCs do not produce G-CSF [32]. Furthermore, MSCs decreased serum 
levels of CXCL5 and CCL11, showing that MSCs inhibit the production of these chemokines 
by other cells.
Although it seems that MSCs elicit a response of the immune system after infusion, at the 
moment, we can only speculate about the trigger that induces this response. As we used 
syngeneic MSCs, an alloresponse can be excluded. The infused MSCs, however, expressed 
GFP, whereas the recipients did not, but as GFP is an intracellular protein, it is unlikely to 
evoke an immune response as rapidly as was observed. It is possible that the immune system 
responds to infused MSCs as the cells are culture generated and differ in size and protein 
expression pattern from non-cultured MSCs [33]. In addition, under normal conditions, MSCs 
are present in the circulation at extreme low numbers [34, 35] and the high numbers present 
after MSC administration may activate a clearance response. It is thus likely that the immune 
reaction induced after infusion of MSCs is a response to cells that are seen as foreign and/or 
are present at an unusual location, rather than a MSC-specific response. Other cell types may 
well induce a similar response. We have not set out to test this in the present study.
How the immunoactivating effects of MSC administration lead to beneficial immuno-
modulatory effects in disease models remain unclear. The immune responses, which are 
evoked by MSCs, may result in an immunosuppressed status. In line with this hypothesis, we 
observed that the systemic inflammatory response to LPS was reduced 3 days after infusion 
of MSCs. We were not able to demonstrate reduced in vitro responsiveness of splenocytes 
from animals that received MSCs 3 days before LPS. In fact, splenocytes from animals that 
received LPS did not respond more potently to in vitro ConA stimulation than splenocytes 
from PBS control animals. This observation could relate to the fact that the ConA stimulation 
assay takes 3 days, after which the effect of LPS treatment of the animals may have been 
washed out.
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In line with our data, organ transplant models have demonstrated that infusion of MSCs 
7 to 4 days before transplantation was effective in prolonging transplant survival, whereas 
administration at later time points was not [28, 36]. In contrast, in models for arthritis [37] 
and colitis [38], administration of MSCs after inflammatory disease onset was shown to be ef-
fective. There may be differences in the effect of MSCs under inflammatory and homeostatic 
conditions. First, cytokine footprints are different under these conditions and MSCs will have 
a different modulating effect, and, second, MSCs, which are exposed to inflammatory condi-
tions, become more immunosuppressive in vitro [15, 16] and in vivo [39] and may induce 
a different response upon infusion. Further research should clarify which conditions are 
optimal for effective MSC therapy for various applications.
In summary, intravenous infusion of syngeneic MSCs in mice triggers a systemic inflamma-
tory response, which originates in the lungs and proceeds systemically. This response may 
lead to an immunosuppressed status in a few days via feedback mechanisms. Even though 
MSCs are present for only a few hours, their effects last for much longer and this offers pos-
sibilities to use MSCs for immunomodulatory therapy.
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SUMMARY
Mesenchymal Stem or Stromal Cells (MSC) are multipotent cells with the ability to modulate 
immune responses in vitro and in vivo. These properties make them appealing for application 
as a cell therapeutic agent in the field of solid organ transplantation (SOT) (chapter 1). How-
ever, there are many queries considering the clinical application of MSC in SOT. These queries 
include MSC efficacy and mechanism of action, the optimal MSC preparation and safety and 
immunogenicity of MSC. The current thesis aimed to provide answers to these questions.
In chapter 2, the immunomodulatory effect of bone marrow-derived MSC (BM-MSC) and 
adipose tissue derived MSC (ASC) was evaluated in vitro and in vivo. BM-MSC and ASC were 
immunosuppressive in vitro and inhibited alloreactivity, as marked by decreased CD45+ leu-
kocyte infiltration and IFNγ expression, in a humanized skin transplant model in the mouse. 
These results underline the potential of BM-MSC as well as ASC in the field of transplantation. 
For MSC therapy, safety is crucial. Genetic stability of culture expanded ASC is an important 
safety aspect and was studied in chapter 3. It was found that ASC cultures contain on aver-
age 3.4% of aneuploid cells. This percentage increased with extended culture expansion and 
was highest in senescent ASC.  Freshly isolated ASC did not contain aneuploid cells indicating 
that aneuploidy in ASC is a culture induced phenomenon. Importantly, aneuploid ASC did 
not transform in vitro nor did they cause tumour formation when injected in immunocom-
promised mice, indicating that aneuploidy in low passage ASC does not endanger safety of 
ASC therapy. 
Culture conditions may provide opportunities to improve the cell therapeutic agent. There 
are indications that oxygen tension affects the differentiation capacity of MSC. The effect of 
oxygen tension on the immunosuppressive capacities of ASC was studied in chapter 4.  It 
was found that the immunosuppressive potential of ASC is preserved under hypoxic condi-
tions in vitro indicating that ASC can be used under conditions involving low oxygen tension 
such as in ischemic tissues. 
In chapter 5, the allogenicity of BM-MSC and ASC was studied. When exposed to al-
logeneic PBMC, BM-MSC induced CD8+ T cells capable of HLA-class I specific cytotoxicity. 
ASC were also capable of inducing HLA-class I specific lysis, yet this lysis was significantly 
lower than the lysis induced by BM-MSC. IFNγ stimulation caused up-regulation of HLA-class 
I expression on BM-MSC and ASC and increased the lysis induced by BM-MSC and ASC. These 
results indicate that allogeneic BM-MSC and ASC can be immunogenic and advocate the use 
of autologous MSC in clinical organ transplantation to avoid sensitization.
It is questionable whether autologous MSC therapy in kidney transplantation is feasible 
as it implies using cells from patients with (end stage) renal disease. In this thesis, the effect 
of (end stage) renal disease on ASC (chapter 6) and BM-MSC (chapter 7) was investigated. 
ASC and BM-MSC derived from patients with (end stage) renal disease displayed a normal 
MSC immunophenotype and proliferation capacity. The immunosuppressive effects of 
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ASC and BM-MSC derived from renal disease patients were comparable to those from ASC 
and BM-MSC derived from healthy controls. Further, when ASC derived from renal disease 
patients were exposed to uremic conditions in vitro, ASC maintained their characteristics, 
including their anti-proliferative effect on immune cells. Together, these results indicate that 
it is feasible to isolate and use ASC and BM-MSC from renal disease patients and suggest that 
ASC remain functional when infused in a uremic patient.
Finally, while MSC are currently entering the clinical arena, little is known about how MSC 
exert their immunomodulatory potential after administration. In chapter 8 it was aimed to 
untwine the effect of MSC infusion in mice. Infusion of syngeneic MSC resulted in a rapid 
accumulation of MSC in the lungs 2 hours after infusion. This was accompanied with a local 
and systemic inflammatory response which vanished within a day. When mice were chal-
lenged with LPS 3 days after infusion of MSC, the LPS induced inflammation was significantly 
decreased. Together, these results show that infusion of MSC induces a phase of immunosup-
pression after an initial phase of immune activation.
DISCUSSION
The current thesis describes the results of research aimed to get insight in the applicability 
of MSC therapy in clinical SOT, and in particular in kidney transplantation. In accordance with 
other studies [1-3], the potential of MSC as an immunosuppressive agent in transplantation 
was underlined in this thesis as it was demonstrated that MSC of both adipose and bone 
marrow origin are capable of inhibition of alloreactivity in vitro and in vivo. As a result of 
these immunomodulating capacities, MSC have already made their entrance in the clinical 
arena. While initial clinical studies were performed in osteogeneis imperfecta [4] and graft 
versus host disease (GvHD) patients [5], the indications for clinical MSC therapy expanded 
and include now a wide range of mainly immunological conditions including Crohn’s disease 
[6], rheumatoid arthritis [7] and clinical organ transplantation. Recently, the first clinical tri-
als using MSC in clinical kidney transplantation have been effectuated [8-13]. These studies 
mainly focussed on safety and feasibility of MSC therapy in kidney transplantation (table 1). 
The main conclusion of these studies is that MSC therapy in kidney transplantation is feasible 
and safe, and in addition, indications of immunosuppression were reported [8, 11]. 
These results are in accordance with studies performed in other medical fields showing 
safety and feasibility of clinical MSC therapy [6, 14]. However, substantial efficacy data is still 
lacking and an industry supported phase III trial in GvHD did not live up to expectations [15]. 
The absence of efficacy data from MSC trials might be explained by the great diversity in study 
design and the mainly small study sizes. Thus, to obtain reproducible and consistent efficacy 
data on the therapeutic effect of MSC, profound studies should be initiated including ap-
propriate endpoints and standardized immune monitoring assays [16]. Yet, when designing 
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such studies, researchers will face multiple queries. These queries involve the optimal MSC 
preparation for clinical application and the mechanism of action and safety of MSC therapy.
Considering the optimal MSC preparation, culture expansion of MSC is an important topic. 
Culture expansion might involve a risk for contamination or transformation. Therefore, to 
ensure safety of MSC therapy, the MSC therapeutic product is subject to strict release criteria. 
There is a consensus on comprehensive testing of MSC for microbiological contamination, 
yet the genetic stability of MSC [17-22], and subsequently, the way to test MSC for genetic 
stability [23, 24] is under debate. When using FISH analysis, as described in this thesis, an-
euploidy in culture expanded ASC was detected. Importantly, aneuploidy amongst ASC 
remained stable in low passage MSC and did not result in transformation in vitro or tumour 
formation in vivo. These results indicate that aneuploidy in MSC does not comprise a risk 
when low passage MSC are used. 
Interestingly, it is unknown how aneuploidy in ASC develops and evolves. Aneuploidy in 
ASC might reflect aging and subsequently senescence of ASC in culture. This theory is sup-
ported by the increased percentage of aneuploidy in ASC with extended culture expansion as 
discussed in this thesis. However, while aneuploidy in ASC appears to be induced by culture 
expansion, aneuploidy ASC in vivo might also be undetectable as they are immunological 
cleared. Nonetheless, genetic stability of MSC for clinical application deserves continued 
attention; MSC cultures should be monitored for morphological changes and conventional 
karyotyping should be combined with other techniques such as CGH/SNP array or FISH[23, 
24]. Additionally, though there are currently no indications for a clinical risk for MSC induced 
malignancies [25], the occurrence of de novo malignancies should be closely monitored after 
clinical MSC treatment.
Next to a potential risk, culture expansion may also provide a window of opportunity to 
improve the MSC preparation. For survival, MSC require growth factors and nutrients which 
are typically provided by supplemented fetal bovine serum (FBS) in the media. Adding IFNγ 
to the media has shown to increase the immunosuppressive potential of MSC [26] and the 
use of platelet lysate containing media increases the proliferation rate of MSC [27, 28]. More-
over, the use of platelet lysate (or human serum) containing medium provides an animal-free 
culture expansion protocol which is desirable to avoid potential xeno-reactivity. 
Next to the culture medium, the environment in which MSC are expanded might affect 
MSC functionality. Culturing under hypoxic conditions has shown to affect the differentia-
tion capacity of MSC [29]. As oxygen levels in tissues are substantially lower than the oxygen 
levels in incubators [30], hypoxic culture conditions might be more physiological for MSC. 
In the current thesis, it was described that hypoxia did not abolish the immunomodulatory 
effect of MSC in vitro. This implies that MSC can maintain their immunosuppressive effect 
when they are applied in ischemic conditions.
An alternative to the use of culture expanded MSC is the use of freshly isolated MSC. 
However, as described in the current thesis and by others [31, 32], freshly isolated MSC have 
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different characteristics compared to their cultured counterparts. The immunosuppressive 
potential of freshly isolated MSC is unknown and needs to be evaluated before these freshly 
isolated cells might be applicable in clinic.
Next to the question how and if MSC should be expanded, the choice of MSC preparation 
includes two other important questions: is there a favourable tissue to isolate MSC from? And 
should MSC from autologous or allogeneic origin be used?  While MSC are originally isolated 
from bone marrow [33] and bone marrow derived MSC (BM-MSC) are still the most commonly 
used MSC, MSC can be isolated from multiple tissues[34]. Currently, based on MSC function-
ality, no superior source of MSC has been identified. In this thesis, it was demonstrated that 
BM-MSC and adipose tissue derived MSC (ASC) were equally effective in inhibiting PBMC 
proliferation in vitro and alloreactivity in a humanized mouse model. This indicates that, in 
accordance with others [35, 36], ASC provide a good alternative for BM-MSC. 
Next, the choice arises whether to use ASC or BM-MSC from autologous or allogeneic tissues. 
Allogeneic MSC have the benefit that they can be isolated from healthy individuals, culture 
expanded and tested and stored in advance. Yet, as described in the current thesis, BM-MSC 
and ASC can induce HLA-class I specific cytotoxicity when exposed to allogeneic PBMC. Sur-
prisingly, BM-MSC induced more lysis than ASC. The underlying mechanism explaining this 
difference between BM-MSC and ASC is unknown and it is up to now undetermined whether 
the induction of HLA-class I cytotoxicity will also take place in vivo. Nonetheless, the induc-
tion of HLA-class I specific cytotoxic T cells by allogeneic BM-MSC and ASC in vitro contradicts 
the old paradigm that MSC are low immunogenic. Furthermore, although contradicting data 
is published, MSC induced antibody production seems possible[37]. Hence, allogeneic MSC 
administration might induce T and B immune responses. Such immune activation could 
impair the effect of repeated MSC administration and even future organ transplantations if 
the transplanted organ shares HLA typing with MSC. Studies using allogeneic MSC for indica-
tions such as Crohn’s disease and rheumatoid arthritis might be able to provide valuable 
data on the risk of sensitization by allogeneic MSC therapy.  At this stage however, usage of 
autologous MSC in transplant patients seems the safest option to avoid any risk of sensitiza-
tion. However, in situations when allogeneic MSC therapy is preferential, or the only feasible 
option, mismatching of MSC donor and organ donor can provide in a low-risk regimen to 
exclude the possibility of T and B cell activation against the allograft. Finally, screening for 
signs of sensitization after MSC therapy, such as MSC-HLA specific antibodies, should be part 
of studies using allogeneic MSC.
While the use of autologous MSC might be preferential in the field of SOT, feasibility 
of this strategy was unknown as several diseases [38, 39] have been shown to affect MSC 
functionality. In this thesis, it was documented that BM-MSC and ASC were not affected by 
renal disease. Their proliferation rate was unaffected which enables expansion of sufficient 
numbers of MSC, and importantly, the in vitro immunosuppressive potential of BM-MSC and 
ASC was not affected by the renal disease. So as renal disease is known to affect several other 
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cell types [40], the current thesis shows that it does not affect MSC functionality and that 
autologous MSC therapy in kidney transplantation is thus feasible.
Taken together, the results presented in the current thesis support the use of culture 
expanded autologous BM-MSC or ASC for clinical application in kidney transplantation. 
Still, besides MSC preparation, multiple other aspects of clinical MSC therapy need further 
elucidation. An important topic is the timing of MSC therapy. To date, MSC have been ap-
plied, pre-[9], shortly after [10] and late after [8] kidney transplantation. MSC infusion shortly 
after transplantation in the present of (ATG) induction therapy caused increases in serum 
creatinine in two patients, which was not the case when MSCs were administrated pre trans-
plantation. These data indicate, in accordance with findings in animal studies [2, 10] that 
pre-transplantation infusion might be the preferred time of administration of MSC. Yet, the 
optimal timing is closely related to the mechanism of action of MSC therapy and this requires 
further evaluation.
It has been suggested that MSC migrate in vivo to sites of injury and or inflammation after 
infusion [41, 42]. However, multiple studies, including a study described in this thesis, indicate 
that MSC do not migrate beyond the lungs after infusion [43, 44]. The contradiction of these 
results with other tracing studies can be explained by the fact that most studies trace MSC 
label and cannot discriminate between label and MSC. It furthermore raises the question 
how MSC therapy works if MSC are only shortly present after infusion.
The last aim of this thesis was therefore to study the effect of MSC infusion in mice. It was 
found that after intravenous administration, MSC accumulated in the lungs. This was accom-
panied with a rapid pulmonary, and slightly later, a systemic inflammatory response.  Within 
hours, the MSC in the lungs as well as the inflammatory response vanished. After 3 days, MSC 
infusion resulted in immune suppression. Hence, as MSC are presumably not present any-
more at this time, it can be hypothesized that MSC might act via an initial phase of immune 
activation. During this phase of inflammation, MSC might be able to interact with immune 
cells such as macrophages resulting in immunosuppression at a later stage. Nevertheless, 
this hypothesized mechanism of action can probably only account for part of the effect of 
MSC as locally administrated MSC can also be effective as described in this thesis. Therefore, 
the importance of the MSC induced immune activation needs further study. Additionally, the 
optimal dosing of MSC therapy needs investigation. Currently, most studies used a treatment 
regimen including 1 or 2 dosages of approximately 1 – 2 X 106 MSCs/kg body weight. How-
ever, dose escalating studies, such as designed for liver transplant recipients[45], and studies 
evaluating frequency and interval of MSC infusion will be informative of the best treatment 
regimen. Evaluation of repeated MSC infusion is of particular importance in studies using 
allogeneic MSC as they might evoke alloreactivity which could affect study outcome. 
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CONCLUSION
Taken together, in this thesis it was aimed to eliminate some of the preclinical issues which 
come across when applying MSC in clinical (kidney) transplantation. It was concluded that 
both MSC derived from bone marrow and adipose tissue are immunosuppressive in a pre-
clinical transplant model; that low passage culture expanded MSC do not transform and form 
no oncogenic risk; but that the use of allogeneic MSC might involve the risk for anti-HLA 
sensitization which argues for the use of autologous MSC for clinical application. The feasibil-
ity of using autologous MSC treatment in kidney transplantation was confirmed by showing 
that bone marrow and adipose tissue derived MSC are not affected by renal disease. Finally, 
in search for the mechanism of action of MSC therapy, MSC were found capable of immune 
suppression after an initial phase of immune activation. 
The results discussed in this thesis are of relevance for the clinical application of MSC in 
solid organ transplantation and in particular for the application of MSC in kidney transplanta-
tion. 
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Dutch summary
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Vitale organen zoals het hart, de longen, lever en nieren zijn essentieel voor overleving. Wan-
neer organen falen als gevolg van ziekte of schade is orgaantransplantatie de enige gene-
zende behandeling. Ieder individu heeft unieke ‘transplantatie moleculen’ (HLA-moleculen) 
op zijn of haar organen. Lichaamsvreemde (allogene) HLA-moleculen op getransplanteerde 
organen zullen herkend worden door het immuunsysteem van de ontvanger van dit orgaan. 
Deze herkenning initieert een afstotingsreactie (alloreactiviteit). Deze afstotingsreactie dient 
geremd te worden met afweer-onderdrukkende medicijnen om het orgaan te behouden. 
Ontwikkelingen op het gebied van deze afweer-onderdrukkende medicijnen hebben de af-
gelopen decennia gezorgd voor indrukwekkende verbetering van de korte termijn uitkomst 
van orgaantransplantatie. Deze medicijnen hebben echter ook bijwerkingen die vooral de 
lange termijn uitkomst na transplantatie beïnvloeden. Om de lange termijn uitkomst na 
transplantatie te verbeteren is er behoefte aan nieuwe behandelmogelijkheden. Celtherapie, 
waarbij specifieke therapeutische cellen worden toegediend, kan mogelijk voorzien in deze 
behoefte.
Mesenchymale Stam- of Stromale Cellen (MSC) zijn voorloper cellen die kunnen differen-
tiëren in onder andere bot- en vetcellen. Verder zijn deze MSC in staat om een afweerreactie 
te remmen. Deze eigenschappen maken MSC interessant voor toepassing als celtherapie 
in orgaantransplantatie patiënten (hoofdstuk 1).In transplantatie patiënten zouden MSC 
gebruikt kunnen worden om afstotingsreacties te remmen en beschadigde organen te repa-
reren. Er zijn echter nog veel onzekerheden omtrent de klinische toepassing van MSC. Deze 
vragen betreffen de effectiviteit, werkingsmechanismen en veiligheid van MSC en de opti-
male MSC preparatie. Het doel van dit proefschrift was het beantwoorden van deze vragen.
In hoofdstuk 2 werd het immuun modulerend effect van beenmerg MSC (BM-MSC) en 
vetweefsel MSC (ASC) bestudeerd. BM-MSC en ASC waren allebei in staat om de proliferatie 
van imuuncellen te remmen. Vervolgens werd het effect van BM-MSC en ASC bestudeerd in 
een diermodel. In dit model werd menselijke huid getransplanteerd op de rug van een muis. 
Toediening van menselijke allogene imuuncellen veroorzaakte vervolgens afstoting van de 
huid wat gekenmerkt werd door toename van de imuuncellen en het ontstekingseiwit IFNγ 
in de huid. Deze afstotingsreactie werd geremd door therapie met BM-MSC en ASC. Deze 
resultaten ondersteunen het toedienen van BM-MSC en ASC als celtherapie in orgaantrans-
plantatie patiënten.
Veiligheid is cruciaal voor MSC therapie. De genetische stabiliteit van de cellen is daarbij 
van groot belang en werd bestudeerd in hoofdstuk 3. Er werd aangetoond dat een percen-
tage van de gekweekte ASC een abnormaal aantal kopieën van de chromosomen had (aneu-
ploidie). Dit percentage nam toe wanneer ASC langer gekweekt werden. Ongekweekte ASC 
bevatten geen aneuploide cellen wat impliceert dat aneuploidie wordt geïnduceerd door het 
kweken van ASC. Van belang is dat geen van ASC kweken kwaadaardig transformeerden of 
resulteerden in tumor groei wanneer de ASC werden geïnjecteerd in muizen zonder afweer. 
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Het kweken van MSC biedt de mogelijkheid tot optimalisatie van het MSC celproduct. Het 
gebruik van lage zuurstof condities (hypoxia) bevorderde de differentiatie capaciteit van 
MSC. Het effect van hypoxia op de immuunmodulerende eigenschappen van MSC is echter 
niet bekend en werd bestudeerd in hoofdstuk 4. Wanneer ASC werden blootgesteld aan 
hypoxia behielden ze hun immuun onderdrukkende eigenschappen. Dit betekent dat ASC 
kunnen worden toegediend in situaties met lage zuurstof spanning zoals getransplanteerde 
organen.
In hoofdstuk 5 werd onderzocht of HLA-moleculen op allogene BM-MSC en ASC zelf een 
immuunreactie kunnen opwekken. Blootstelling van BM-MSC aan allogene imuuncellen re-
sulteerde in de inductie van cytotoxische immuuncellen die in staat waren tot HLA specifieke 
lysis. ASC waren ook in staat tot het induceren van HLA specifieke lysis door cytotoxische 
immuuncellen. Echter, deze lysis was significant lager dan de lysis geïnduceerd door BM-
MSC. Stimulatie van BM-MSC en ASC met het ontstekingseiwit IFNγ zorgde voor verhoging 
van het HLA op BM-MSC en ASC en de geïnduceerde lysis. Deze resultaten tonen aan dat 
allogene BM-MSC en ASC immunogeen kunnen zijn. Dus, om alloreactiviteit te voorkomen 
heeft het gebruik van patiënt eigen (autologe) MSC in orgaantransplantatie patiënten de 
voorkeur boven het gebruik van allogene MSC.
Het is echter de vraag of autologe MSC therapie in niertransplantatie patiënten mogelijk is 
omdat dit het gebruik betekent van cellen van nierziekte patiënten. In dit proefschrift werd 
het effect van nierziekte op BM-MSC (hoofdstuk 6) en ASC (hoofdstuk 7) onderzocht. ASC 
en BM-MSC afkomstig van patiënten met nierziekte vertoonden een normaal MSC uiterlijk 
en deling capaciteit. De anti-proliferatieve effecten van ASC en BM-MSC afkomstig van 
nierziekte patiënten waren vergelijkbaar met die van gezonde donoren. Ten slotte waren 
de karakteristieken van ASC, inclusief het immuun onderdrukkende effect, niet aangedaan 
wanneer ASC werden blootgesteld aan bloedserum van nierziekte patiënten. Deze resultaten 
tonen aan dat het mogelijk is om functionele BM-MSC en ASC te isoleren van patiënten met 
nierziekte en suggereren bovendien dat ASC hun functionaliteit behouden wanneer ze 
toegediend zouden worden in een patiënt met nierziekte.
Ten slotte, terwijl MSC momenteel al in de kliniek gebruikt worden is er nog weinig bekend 
over hoe MSC werken. In hoofdstuk 8 werd het effect van MSC infusie in muizen bestudeerd. 
Infusie van MSC in muizen resulteerde in een snelle ophoping van de MSC in de longen. Tege-
lijkertijd was er in de longen een lokaal en in het bloedserum een systemische ontstekingsre-
actie te detecteren. Deze reactie verdween binnen een dag. Drie dagen na het toedienen van 
MSC was het immuunsysteem van de muizen echter onderdrukt.
Samenvattend tonen de resultaten besproken in dit proefschrift aan dat BM-MSC en ASC in 
staat zijn om een afweerreactie te onderdrukken, dat het kweken van MSC veilig is maar dat 
allogene MSC zelf wel een alloreactie kunnen veroorzaken. Om deze alloreactie te voorko-
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men heeft het gebruik van autologe therapie de voorkeur. Dit is ook mogelijk aangezien de 
BM-MSC en ASC van patiënten met nierziekte niet aangetast zijn in hun functie. Ten slotte 
werd geconcludeerd dat infusie van MSC in muizen een ontstekingsreactie veroorzaakte 
waarna een fase van onderdrukking van het immuunsysteem volgde.

Appendix

167Acknowledgements / Dankwoord
ACKNOWLEDGEMENTS / DANKWOORD
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bewonderenswaardig hoe jij me mijn eigen weg hebt laten zoeken. Je stuurde me alleen 
sporadisch (en dan ook nog subtiel) bij en je had eigenlijk altijd tijd voor overleg! Je steunde 
me in drukke en lastige periodes en onze samenwerking was niet alleen constructief en 
productief maar ook gewoon heel gezellig. Ik hoop dan ook dat deze met het voltooien van 
dit boekje niet eindigt! Bedankt voor alles! Ook al staat mijn naam boven dit boekje, het voelt 
toch echt als ons boek.
Beste prof. dr. Jan NM IJzermans, u kent mij al sinds mijn keuze co-schap transplantatiechi-
rurgie in het Erasmus MC. Sinds die periode heb ik mij niet alleen in mijn werk en onderzoek, 
maar ook in mijn privé leven door u gesteund gevoeld. U zei ooit; ‘Marieke, altijd als ik jou 
zie, moet ik aan vet denken’. U vulde dan ook vele potjes met vet voor me en maakte in 
uw drukke bestaan altijd even tijd vrij om bij te praten over de stamcellen uit dat vet. Uw 
immunologische kennis is on-chirurgische en u hebt me met vragen vaak aan het denken 
gezet. Bedankt voor uw steun en dat u in mijn leescommissie plaats wilt nemen.
Beste prof. dr. Herold J Metselaar, van alle commissie leden kent u mij het langste en wel-
licht ook het beste. U hebt mij zien groeien van een studente die met uw steun het eerste 
(spannende!) stapje deed op een internationaal podium, tot arts, onderzoeker, moeder en nu 
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bijna doctor. Ik voel me bevoorrecht dat ik bij alle beslissende momenten van de afgelopen 
(en soms wat turbulente) jaren op u kon rekenen. U hebt mij doen inzien dat het aloude ‘wie 
niet waagt wie niet wint’ ook betekent dat je jezelf de kans moet geven om fouten te maken. 
Maar bovenal gaf u mij de ruimte om mijn hart te volgen, te worden wie ik nu ben en te weten 
wat ik wil. Ik zie er heel erg naar uit om, al is het op afstand, vakgenoten te worden. Dank voor 
uw geduld en steun. Ik ben heel blij dat u in mijn leescommissie plaats wilt nemen.
Beste prof. dr. AJ Ton Rabelink, in de afgelopen jaren heb ik u vooral via Marlies en de 
transplantatie- en MSC-congressen leren kennen. De Leids-Rotterdamse samenwerking is 
naar mijn mening niet alleen productief maar ook erg efficiënt, leerzaam en leuk geweest. 
Dank voor uw directe en indirecte steun hierbij en dank dat ook u in mijn leescommissie 
plaats wilt nemen.
Ik wil alle overige commissieleden ook bedanken voor het plaats willen nemen in mijn pro-
motiecommissie:
Beste dr. Carla C Baan, bedankt daarnaast dat ik de afgelopen jaren, net als vele voorgan-
gers, mijn plek mocht vinden in het transplantatielaboratorium. De ruimte die ik ook van jou 
kreeg om de vele technieken te leren, zeer gevarieerd onderzoek te doen en daarnaast veel 
kennis en contacten op te doen op vele bijeenkomsten en congressen waardeer ik enorm.
Dear dr. Marc H Dalhke, it’s a great pleasure that you are willing to take place in this com-
mittee. Your involvement in the MiSOT collaboration and the field of basic transplantation 
and MSC research is inspiring, particularly as you combine it with your busy clinical work.
Beste prof. dr. Robert J Porte, zoals ik inmiddels ook weet, er gaat niets boven Groningen. 
Toch ben ik blij dat ik u voor mijn promotie in Rotterdam mag treffen. Het is indrukwekkend 
hoe u vele organisatorische en bestuurlijke taken combineert met zowel kliniek als weten-
schap en ik zie uit naar een eventuele toekomstige samenwerking.
Beste dr. Michiel GH Betjes, vanaf mijn start als beginnende onderzoeker was je geïnteres-
seerd, dacht je mee en kon ik domme nefrologische vragen aan je stellen. Ik heb bewondering 
voor hoe jij je klinisch werk combineert met basaal onderzoek en nu ook het leiden van de 
afdeling. Bedankt voor al je betrokkenheid.
Verder wil ik in het bijzonder de Rotterdamse (nier)transplantatie chirurgen bedanken. Al tij-
dens mijn keuze co-schap voorzagen jullie mij van vele potjes met vet. Gauw na de OK rende 
ik daar dan mee naar het lab om het te verwerken. Toen ik daarna ‘echt’ onderzoek ging doen 
kon ik ook altijd bellen of langs komen voor mijn potjes met vet. Turkan Terkivatan, Khe Tran, 
Diederik Kiemenai, Frank Dor en alle anderen die vet voor mij afnamen: allemaal heel veel 
dank! Frank, ik wil jou daarnaast ook bedanken voor de samenwerking en al het meedenken.
Uiteraard ook veel dank voor alle anderen van het Rotterdamse niertransplantatie team; 
de research verpleegkundigen, poli dames, en natuurlijk de nefrologen, bedankt voor alles! 
Saïda, jij ook bedankt voor alle hulp de afgelopen jaren. Je bent een goede bewaker van de 
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agenda van de baas (‘en nu is het tijd’) maar dat betekende ook dat je me er vaak ‘nog even 
tussen kon proppen’. Wellicht komen we elkaar in de toekomst nog tegen in het transplan-
tatie wereldje!
Marlies, de door jou en Martin opgezette Leids-Rotterdamse samenwerking is een mooi 
voorbeeld van hoe samenwerken ook kan: productief en leuk! Ik ben heel blij dat ik onder-
deel was van deze samenwerking. Bedankt voor je altijd constructieve (en bijzonder snelle) 
feedback en betrokkenheid!
Verder wil ik Annelies de Klein en Hannie Douben bedanken voor de prettige samenwer-
king en alle hulp bij voor mij vaak ingewikkelde genetische thema’s.
Abdullah, Luc en Ron, dank voor alle hulp met ‘de muizen’!
Andere collega onderzoekers: het leuke van onderzoek doen op het gebied van transplan-
tatie en stamcellen is dat je samenwerkt met andere vak- en onderzoeksgroepen. Dus ook 
alle collega onderzoekers van de chirurgie/MDL/endo en zelfs orthopedie, bedankt voor alle 
gezelligheid tijdens besprekingen, cursussen en congressen en uiteraard ook voor input, 
hulp en vriendschappen die soms uit deze samenwerkingen ontstonden.
Nienke en Karel; bedankt voor het veiligstellen van vele potjes met vet en gezelligheid 
op congressen. Anneke; bedankt voor de prettige samenwerking met de ‘vetjes’, Maarten; 
bedankt voor de hulp bij de L-kynu assay.
Soms ontstaan er uit samenwerkingen zelfs dierbare vriendschappen: Viviana; thanks for 
all the support, coffee/tea’s and sharing, I wish you and your family all the best in Greece! 
Emmeloes, we kunnen inmiddels een hoop met elkaar delen: het onderzoek, het moeder-
schap en ook onze toekomst binnen de MDL! Succes met alles en ik hoop dat we elkaar op 
de hoogte blijven houden!
En dan natuurlijk het transplantatielab!
Allereerst alle analisten: dank voor jullie hulp en steun, dank voor het (leren) ficollen, 
facsen, de prettige samenwerking maar ook gezelligheid, altijd inspirerende besprekingen, 
kopjes koffie en lekkere taartjes! Ik ga jullie missen! En uiteraard een speciaal bedankt voor 
Sander. Ik denk dat we in de afgelopen jaren een heel goed team zijn geworden, met jouw 
precisie en mijn (te?) volle schema’s hebben we mooie resultaten geboekt. Bedankt voor al je 
hulp, bedankt voor al het killen en voor de gezelligheid!
Beste Nicolle, de afgelopen jaren heb ik met jou ook veel gedeeld, veel koffie, grote en 
kleine frustraties en nadat je een kamer ging delen met Martin ook vele ‘heb je even…’ mo-
mentjes. Daarnaast was je net als voor vele anderen ook voor mij een FACS en immunologie 
vraagbaak. Bedankt voor alles!
Beste Karin, al hoorde jij als echte post doc natuurlijk ook niet meer bij de aio’s, toch voelde 
dat wel een beetje zo! Het was fijn de ditjes en de datjes maar ook de belangrijkere dingen 
te kunnen delen!
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En dan de ‘aio hok alumni’! Best klein dat hok, best muffig ook aan het einde van de dag. 
Maar stiekem ook heel gezellig en leuk om te zien hoe we de afgelopen jaren zij aan zij ons 
ontwikkelden als onderzoekers. Een voor een zwaaien we nu af en de jonge garde vult onze 
plekjes.
Meindert, het was erg leuk om je op te volgen, alles liep en ik kon gelijk al gebruik maken 
van de vele door jou ingevroren MSC(-tjes…). Dank voor het enthousiaste inwerken en alles 
wat je me geleerd hebt over MSCs en onderzoek.
Anne, al waren onze projecten en levens de afgelopen jaren erg verschillend, toch maakten 
we in grote lijnen dezelfde fasen door en ook starten we allebei in 2014 weer in de kliniek, jij 
op weg om nefroloog te worden, ik om MDL arts te worden. Ik zie er naar uit om jouw boek 
te zien, het wordt vast heel mooi. Succes met de laatste loodjes en tot op onderwijs dagen/
congressen/ aio BBQ’s!
Martijn, de afgelopen jaren waren het TEC’s voor jou en MSC’s voor mij. De probleempjes 
die we tegenkwamen met kweken en testen waren echter vergelijkbaar en ondanks dat onze 
levens erg verschilden had je veel begrip en steun voor mijn ietwat chaotische leven in het 
afgelopen jaar, bedankt! Even een cappuccino is nu lastig nu we beiden zijn gestart met onze 
nieuwe carrières in twee uithoeken van Nederland, hopelijk is ook jouw boek gauw af, ik ben 
heel benieuwd, succes met de laatste loodjes!
Ruud(je), (of hoofd-aio?), voor jou is jouw promotie traject een bewogen periode. Toch 
maak je een indrukwekkende bliksemstart en ik heb er vertrouwen in dat je een heel mooi 
boek af gaat leveren, succes!
Gretchen, jij kwam het aio hok binnen vliegen en spontaan was het roze! Met hetzelfde 
enthousiasme vloog je ook het onderzoek in. Je weet wat je wilt en je weet je enthousiasme 
goed op anderen over te brengen, veel succes!
Beste Franka, leuk om nog even samen te werken met de nieuwe MSC-onderzoeker! Jouw 
enthousiasme en ideeën maken het heel leuk om ‘het stamcel stokje’ aan je over te dragen, 
heel veel succes en plezier!
 
Dear Anja and Marcella, working together with you two in our MSC team was a perfect 
combination of fun and functional!
Dear Marcella, I know the weather did not always make you happy about the choice to 
come to the Netherlands, yet I am very happy you did! Your positive and enthusiastic per-
sonality in combination with your knowledge and sharp analytical skills made it very nice to 
work with you! I’m very excited about the new Catalan-Dutch baby and I hope that soon we 
will have an AIO-hok/MSC and baby reunion!
Dear Anja, it was really nice to have you as a colleague and friend literally next to me 
last years. I’m very grateful for all your help and support. I enjoyed our collaboration, trips, 
chitchats and all other things we shared. It was a great pleasure to join you at (one of ) your 
great day(s) and I know that I will feel your support wherever you will be during my defense! 
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I’m very excited that your next big day is approaching soon and I’m looking forward to meet 
the new Engela!
 
Vriendschap vergroot het geluk en vermindert ellende, door onze vreugden te verdubbelen en 
ons verdriet te delen (Joseph Addison).
 
Lieve Liza, Marieke, Wouter, Karlijn, Judith, Marieke en roeidames; jullie hebben mij allemaal 
op jullie eigen manier gesteund de afgelopen jaren. Bedankt voor die steun, vriendschap en 
betrokkenheid!!
Nienke, de klik was er al in 2002 maar het duurde een studie geneeskunde voor ons contact 
werd zoals het nu is. Het was super fijn om alle grote en kleine dingen met je te delen. Ik mis 
onze soja lattes, maar vooral ons intense contact. Jij waakte afgelopen jaar echt een beetje 
over mij, dank je wel!! Ons leven is de afgelopen jaren erg veranderd, inmiddels allebei mama, 
(bijna) klaar met promotieonderzoek en een start in de kliniek. We zullen elkaar niet meer zo 
vaak kunnen zien maar ik hoop dat we ook in deze nieuwe fase onze levens blijven delen. Ik 
ben heel blij dat je mijn paranimf wilt zijn!
Lieve Marte, Pallieter, Mees, Frouke en Jaap; het is heel leuk om me als ‘koude kant’ bij jullie 
te voegen. Een dag/avond/BBQ/vakantie met ‘de Roemelingen’ staat altijd garant voor een 
leuke en ontspannen tijd, dat er nog maar vele van zulke mooie momenten mogen volgen! 
Lieve Hans en Kurien, heel veel dank voor alle steun die wij als gezin en dus ook ik van jullie 
krijgen. Jullie staan altijd voor ons klaar en jullie sprongen al veelvuldig in. Hierdoor werden 
uitdagende schema’s van afgelopen jaar niet alleen een stuk makkelijker, ook een stuk leu-
ker! Lieve Hans, 10 jaar voor mijn geboorte hield jij je bezig met renale alloreactiviteit in het 
Erasmus en nu ligt mijn boekje hier…toeval bestaat niet!
Lieve Renske, Patrick, Hannah, Jelle en Mila, wat is het mooi dat er zoveel geluk is in de familie 
en dat wij dit met onze gezinnen kunnen delen.
Lieve Renske, ik vind het heel fijn om jou als zus achter me te hebben staan! We hebben al 
een hoop gedeeld samen en gelukkig de laatste jaren vooral heel veel moois samen met onze 
mannen en bende boefjes. Ik vind het heel stoer dat je met je nieuwe studie bent begonnen 
en ik voel me vereerd dat ik jou vandaag naast me mag hebben, bedankt voor al je steun, 
bedankt dat je mijn paranimf wilt zijn!
Papa, ook al hebben we al lang geleden afscheid moeten nemen, ook jouw liefde, doorzet-
tingsvermogen, genen en helaas ook het verdriet om jouw gemis hebben mij gevormd. Dit 
is ook jouw boekje.
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Lieve mama, ik heb verschrikkelijk veel respect voor jou als mens, moeder en oma. Dank voor 
de stevige basis die je me in soms ook roerige tijden mee hebt gegeven, dank voor al je steun 
en je liefde! Dank dat we dit jaar bij je in mochten trekken. Zo werd afgelopen jaar niet alleen 
meer een jaar van rennen en vliegen maar kwam er rust en tijd om te genieten. Dick, samen 
met mijn moeder vormen jullie een prachtig team. Je brengt niet alleen heel veel moois in 
haar leven, ook in dat van ons (en dan heb ik het niet alleen over de whisky)! De rol van opa, 
die je zomaar bij de liefde cadeau kreeg, gaat je fantastisch af. Jij ook bedankt voor alle hulp, 
al het faciliteren en alle steun!
Lieve Pieter en Hendrik, wat een cadeau om jullie moeder te zijn. Mijn onderzoek heeft ook 
best wat invloed gehad op jullie jonge leven. Zo hebben jullie al bijzonder vaak wat over 
stamcellen gehoord, vraag jij (Pieter) je af wanneer dat boekje nou eindelijk af is, (en of er 
dan ook iets leuks in staat?!), zijn jullie in en buiten mijn buik al vaak mee geweest naar een 
congres maar hebben jullie me af en toe ook moeten missen (en ik jullie!). Ik geniet van jullie 
positiviteit en onbevangenheid, moeder zijn van jullie heeft me meer dan al het andere leren 
relativeren. Ik zie enorm uit naar ons nieuwe leven in Eelde en hoop dat jullie altijd zulke blije 
heren blijven! Logica brengt je van a naar b, verbeelding brengt je overal (Albert Einstein). Ik 
hoop nog lang met jullie mee te mogen reizen!
Lieve Stijn, t is zoals het is, en dat is met jou verdraaid leuk! Dank voor je grenzeloze ver-
trouwen en steun! Je hebt mij niet alleen veelvuldig gefaciliteerd (oa congres-campertje te 
Amsterdam/Leuven/Glasgow), maar ook vele frustraties voor mij gerelativeerd. Het was altijd 
verfrissend om door jou bril naar mijn dillema’s te kijken (maar, nee FACSen is niet iets met 
eerst een ‘0’ draaien:-)). Het leven met jou en onze jongens maakt mij super blij, gelukkig en 
trots. Dat latten van afgelopen jaar is zeg maar niet echt m’n ding dus ik ben dan ook heel 
gelukkig dat we weer samenwonen. ‘Borte bra, hjemme best’. En dat is, waar wij samen zijn.
Enne, binnenkort weer samen naar het werk fietsen?
Marieke
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